Nanomaterials for Drug Delivery and Multi-Modal Imaging by Lamb, Jennifer








Nanomaterials for Drug Delivery and Multi-Modal Imaging
Lamb, Jennifer
Abstract: Molecular imaging uses techniques to visualise, characterise and measure biological processes
at the cellular and molecular level. These techniques can be incredibly sensitive, allowing the detection
of small abnormalities at the tissue or cellular level based on molecular differences, and thus providing
accurate diagnosis and monitoring of disease, especially in the field of oncology. Image acquisition relies
on the use of molecular imaging agents which target and accumulate at biomarker sites, allowing visu-
alisation of the target in comparison to background tissue. Nanomedicine is a field which refers to the
use of nanomaterials in a therapeutic or diagnostic setting. Nanomaterials often display unique char-
acteristics, offer structural versatility and act as scaffolds; providing platforms that have the potential
to be truly multi-functional. In this thesis, we take advantage of these properties by synthesising and
developing tumour-targeted nanomaterial constructs for multi-modal imaging and therapy. Iron oxide
nanoparticles provide MRI contrast, therefore, following radiolabelling with a diagnostic radionuclide,
the nanoparticles can be used as multi-modal imaging agents in techniques such as PET/MRI. Chapter
2 in this thesis focuses on the synthesis, characterisation and development of iron oxide nanoparticles for
further experiments and applications. Preliminary radiolabelling methods explore classical radiolabeling
techniques, where chelates are deployed to bind radionuclides. Subsequent radiolabelling techniques focus
on non-classical, chelate-free methods which offer fast and efficient synthesis, superior yields, and have
minimal impact to the nanoparticle structure. We explore the versatility of chelate-free radiolabelling on
different nanoparticles and also perform kinetic studies to gain an insight into the mechanism by which
this process occurs. Using chemistries established in Chapter 2, Chapter 3 focuses on developing the
nanoparticle systems for PET/MR imaging. Nanoparticle constructs are targeted toward an established
cancer biomarker, and tested in vitro and in vivo by using small-animal PET imaging. Chapters 4 and
5 use graphene nanomaterials as scaffolds to create multi-modal agents. Graphene nanoflakes (GNFs)
consist of a graphene sheet approximately 30 nm in diameter with a pristine aromatic system and an edge
terminated with carboxylic acid groups. Their high water solubility and relative ease of functionalization
by using carboxylate chemistry means that GNFs are potential scaffolds for the design of multi-modality
nanomedicines. Chapter 4 establishes the chemistry and provides a first indication on the flexibility of
GNFs as potential theranostic agents. GNFs are multi-functionalised with drug molecules, chelates to
bind PET active radionuclides, small-molecule biological targeting vectors and pharmacokinetic modify-
ing groups. Further experiments in vitro and in vivo were used to evaluate the performance of GNFs in
theranostic drug design. Building from our experience with GNFs functionalised with small-molecule tar-
geting agents, Chapter 5 further utilises GNFs to create targeted constructs for application in PET/MRI.
GNFs are multi-functionalised with, chelates to bind PET radionuclides as well as gadolinium complexes
for MRI contrast, they are then functionalised with an antibody that is known to bind a specific cancer
biomarker. Again, constructs are evaluated in vitro and in vivo to evaluated their pharmacokinetics and
tumour-targeting and to test their potential as PET/MRI agents.
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Molecular imaging uses techniques to visualise, characterise and measure biological processes at the cellular 
and molecular level. These techniques can be incredibly sensitive, allowing the detection of small 
abnormalities at the tissue or cellular level based on molecular differences, and thus providing accurate 
diagnosis and monitoring of disease, especially in the field of oncology. Image acquisition relies on the use of 
molecular imaging agents which target and accumulate at biomarker sites, allowing visualisation of the target 
in comparison to background tissue. Nanomedicine is a field which refers to the use of nanomaterials in a 
therapeutic or diagnostic setting. Nanomaterials often display unique characteristics, offer structural 
versatility and act as scaffolds; providing platforms that have the potential to be truly multi-functional. In this 
thesis, we take advantage of these properties by synthesising and developing tumour-targeted nanomaterial 
constructs for multi-modal imaging and therapy.  
  
Iron oxide nanoparticles provide MRI contrast, therefore, following radiolabelling with a diagnostic 
radionuclide, the nanoparticles can be used as multi-modal imaging agents in techniques such as PET/MRI. 
Chapter 2 in this thesis focuses on the synthesis, characterisation and development of iron oxide nanoparticles 
for further experiments and applications. Preliminary radiolabelling methods explore classical radiolabelling 
techniques, where chelates are deployed to bind radionuclides. Subsequent radiolabelling techniques focus 
on non-classical, chelate-free methods which offer fast and efficient synthesis, superior yields, and have 
minimal impact to the nanoparticle structure. We explore the versatility of chelate-free radiolabelling on 
different nanoparticles and also perform kinetic studies to gain an insight into the mechanism by which this 
process occurs. 
  
Using chemistries established in Chapter 2, Chapter 3 focuses on developing the nanoparticle systems for 
PET/MR imaging. Nanoparticle constructs are targeted toward an established cancer biomarker, and tested in 
vitro and in vivo by using small-animal PET imaging.  
  
Chapters 4 and 5 use graphene nanomaterials as scaffolds to create multi-modal agents. Graphene nanoflakes 
(GNFs) consist of a graphene sheet approximately 30 nm in diameter with a pristine aromatic system and an 
edge terminated with carboxylic acid groups. Their high water solubility and relative ease of functionalisation 
by using carboxylate chemistry means that GNFs are potential scaffolds for the design of multi-modality 
nanomedicines.  Chapter 4 establishes the chemistry and provides a first indication on the flexibility of GNFs 
as potential theranostic agents. GNFs are multi-functionalised with drug molecules, chelates to bind PET active 
radionuclides, small-molecule biological targeting vectors and pharmacokinetic modifying groups. Further 
experiments in vitro and in vivo were used to evaluate the performance of GNFs in theranostic drug design.  
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Building from our experience with GNFs functionalised with small-molecule targeting agents, Chapter 5 further 
utilises GNFs to create targeted constructs for application in PET/MRI. GNFs are multi-functionalised with, 
chelates to bind PET radionuclides as well as gadolinium complexes for MRI contrast, they are then 
functionalised with an antibody that is known to bind a specific cancer biomarker. Again, constructs are 
evaluated in vitro and in vivo to evaluated their pharmacokinetics and tumour-targeting and to test their 





Die molekulare Bildgebung verwendet Techniken zur Visualisierung, Charakterisierung und Messung 
biologischer Prozesse auf zellulärer und molekularer Ebene. Diese Techniken können unglaublich empfindlich 
sein und ermöglichen, basierend auf molekularen Unterschieden, den Nachweis kleinster Anomalien in 
Geweben oder Zellen. Ein solcher Ansatz schafft die Möglichkeit einer präzisen Diagnose und Überwachung 
von Krankheiten, insbesondere im Bereich der Onkologie.  
 
Diese Bilderfassung beruht auf dem Einsatz von molekularen Bildgebungsmitteln, welche sich an 
Biomarkerstellen anreichern, wodurch das Ziel- im Vergleich zum Hintergrundgewebe sichtbar gemacht 
werden kann. Die Nanomedizin ist ein Forschungsgebiet, welcher sich auf die Verwendung von 
Nanomaterialien mit einem therapeutischen oder diagnostischen Zweck bezieht. Nanomaterialien weisen oft 
einzigartige Eigenschaften auf, sie bieten strukturelle Vielseitigkeit und fungieren als Gerüst. So bilden sie 
Plattformen, welche das Potenzial haben multifunktional zu sein. In dieser Arbeit machen wir uns diese 
Eigenschaften zunutze, indem wir tumorgerichtete Nanomaterialien für die multimodale Bildgebung und 
Therapie entwickeln und synthetisieren.  
 
Eisenoxid-Nanopartikel bieten MRT-Kontrast, weshalb die Nanopartikel nach der Radiomarkierung mit einem 
diagnostischen Radionuklid als multimodale Bildgebungsmittel in Techniken wie PET/MRI eingesetzt werden 
können. Kapitel 2 dieser Arbeit konzentriert sich auf die Synthese, Charakterisierung und Entwicklung von 
Eisenoxid-Nanopartikeln. Vorläufige Radiomarkierungsmethoden untersuchen klassische 
Radiomarkierungstechniken, bei welchen Chelate zur Bindung von Radionukliden eingesetzt werden. 
Nachfolgende Radiomarkierungstechniken konzentrieren sich auf nicht-klassische, chelat-freie Methoden, 
welche eine schnelle und effiziente Synthese, überlegene Ausbeuten und minimale Auswirkungen auf die 
Struktur der Nanopartikel bieten. Wir untersuchen die Vielseitigkeit der chelat-freien Radiomarkierung von 
verschiedenen Nanopartikeln und führen kinetische Studien durch, um einen Einblick in den Mechanismus des 
Prozesses zu erhalten. 
 
Kapitel 3 konzentriert sich auf die Entwicklung von Nanopartikelsystemen für die PET/MR-Bildgebung unter 
Verwendung der in Kapitel 2 festgelegten chemischen Verfahren. Nanopartikel-Konstrukte werden auf einen 
etablierten Krebs-Biomarker ausgerichtet und in vitro und in vivo mit Hilfe der PET-Bildgebung an Kleintieren 
getestet. 
 
In den Kapiteln 4 und 5 werden Graphen-Nanomaterialien als Gerüst für die Herstellung multimodaler 
Wirkstoffe verwendet. Graphen-Nanoflocken (GNFs) bestehen aus einer Graphenfolie von etwa 30 nm 
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Durchmesser mit einem rein aromatischen System und einem Rand, der mit Carbonsäuregruppen 
umschlossen ist. Ihre hohe Wasserlöslichkeit und die relativ einfache Funktionalisierung durch die 
Verwendung von Carboxylatchemie bedeutet, dass GNFs potenzielle Gerüste für das Design von multimodalen 
Nanomedizinprodukten sind.  Kapitel 4 schafft die Grundlage für die Chemie und gibt einen ersten Hinweis auf 
die Flexibilität der GNFs als potentielle Theranostika. GNFs sind multifunktional mit Arzneimittelmolekülen, 
Chelaten zur Bindung von PET-aktiven Radionukliden, niedermolekularen biologischen Zielvektoren und 
pharmakokinetisch modifizierenden Gruppen ausgestattet. Weitere in vitro- und in vivo-Experimente wurden 
durchgeführt, um die Leistung der GNFs beim Design von Theranostika zu bewerten.  
 
Aufbauend auf unseren Erfahrungen mit GNFs, die mit niedermolekularen Vektoren funktionalisiert wurden, 
werden in Kapitel 5 GNFs weiter genutzt, um zielgerichtete Konstrukte für die Anwendung in PET/MRT zu 
designen. GNFs werden multifunktionalisiert mit Chelaten zur Bindung von PET-Radionukliden sowie 
Gadolinium-Komplexen für den MRT-Kontrast. Anschließend werden sie mit einem Antikörper 
funktionalisiert, von dem bekannt ist, dass er einen spezifischen Krebs-Biomarker bindet. Auch hier werden 
die Konstrukte in vitro und in vivo evaluiert, um ihre Pharmakokinetik und Tumor-Targeting zu bewerten und 






[18F]FDG [18F]-2-fluoro-2-deoxy-D-glucose  
APD Avalanche photodiode 
APTES (3-aminopropyl)triethoxysilane  
ATSM Diacetyl-2,3-bis(N4-methyl-3-thiosemicarbazone)  
c-MET Human hepatocyte growth-factor receptor 
CSF Cerebrospinal fluid 
CT Computed tomography  
CVD Chemical vapour deposition  
DFO Desferrioxamine B 
DLS Dynamic light scattering  
DOTA 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
DTPA Diethylenetriaminepentaacetic acid  
EC Electron Capture  
EMA European Medicines Agency  
EPR Enhanced permeability and retention  
Fab Antigen-binding fragment 
FACS Fluorescence-activated cell sorting 
FDA Food and Drug administration  
FH Feraheme (FH) 
FOV Field of view 
GCPII Glutamate carboxypeptidase II 
GNFs Graphene Nanoflakes  
GO Graphene oxide 
HER2/neu Human epidermal growth factor receptor 2 
HGF Hepatocyte growth-factor (HGF) 
HPLC High-performance liquid chromatography  
IARC International Agency for Research on Cancer 
IC Internal conversion 
IT Isomeric transition 
I.V. Intravenous  
KSP Kinesin spindle protein  
logD Distribution coefficient 
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mAb Monoclonal antibody  
MRI Magnetic resonance imaging  
NAAG N-acetyl-L-aspartyl-L-glutamate 
NCI National Cancer Institute 
NMR Nuclear magnetic resonance 
NOTA 1,4,7-triazacyclononane-1,4,7-triacetic acid  
PASP Polyaspartic acid 
PD10 SephadexTM desalting columns  
PDT Photodynamic therapy 
PEG Polyethylene glycol 
PEI Polyethyleneimine 
PET  Positron emission tomography  
PHA Pulse height analyser  
PMT Photomultiplier tube  
PSA Prostate specific antigen 
PSMA Prostate specific membrane antigen 
PTT Photothermal therapy 
rGO Reduced graphene oxide 
RTK Receptor tyrosine kinase 
SAM Self-assembled monolayer 
SCX Small cation exchange resin  
SEC Size exclusion chromatography  
SF Scatter factor 
SPECT Single-photon emission computed tomography  
SPIONs Superparamagnetic iron oxide nanoparticles  
SPPS Solid-phase peptide synthesis 
SPR Surface Plasmon Resonance  
STM Scanning tunnelling microscopy  
TEM Transmission electron microscopy  
TS Transition state 
US ultrasound  
XPS X-ray photoelectron spectroscopy 
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Chapter 1: Introduction  
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1.1 Aims of Chapter 
This chapter introduces the main themes and basic concepts used in this thesis as well as providing a brief 
overview of recent literature.  
 
1.2 Cancer  
1.2.1 Statistics  
In 2018, 18.1 million new cancer cases (and 9.6 million cancer deaths) were reported worldwide.1 The 
International Agency for Research on Cancer (IARC) predicted that the incidence rate will increase to 29.5 
million by 2040, demonstrating the ever-growing burden cancer will have on future global society.2 Despite 
recent medical advances, cancer remains the leading cause of death in 30-69 year olds in a number of 
developed countries including both Switzerland and the United States of America (USA).3 However, early and 
thorough diagnosis provides patients with the best prognosis possible. Whilst the detection of cancer 
biomarkers during in vitro diagnostics is a valuable tool, it must be combined with companion diagnostic 
methods to determine the development of the disease and potential spread of the cancer to secondary 
metastatic sites. These companion techniques include molecular imaging which often target biomarkers in 
vivo. 
1.2.2 Cancer biomarkers 
The National Cancer Institute (NCI) in the USA defines a biomarker as “a biological molecule found in blood, 
other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease.”4 
Therefore, a cancer biomarker acts as an indicator that cancer is present in the body, and when combined 
with other diagnostics tools, can aid the initial diagnosis.5  However, biomarkers are used throughout all stages 
of a patients cancer treatment and can be categorised into different types based on their potential use (Table 
1).6,7 Biomarker identification allows clinicians to offer patients an accurate and effective treatment plan which 
is personalised to the individual.  
 
Table 1.1. Summary of the categories of biomarkers used during cancer diagnosis and treatment.6 Note: 
some biomarkers fall into more than one category. 
 
Category Potential use 
Diagnostic Elevated levels of biomarkers can be indicative of tumour presence 
Prognostic Predicts the disease risk and progression for the patient 
Predictive Indicates the likelihood of a patient responding to a given drug 
Pharmacodynamic Determines an effective drug dose  
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1.2.3 Examples of biomarkers 
In this thesis, biomarkers will be targeted in the development of radiotracers for in vivo imaging. Below are 
examples of biomarkers which are relevant to the research found in later chapters.  
 
Prostate specific membrane antigen (PSMA) 
Prostate cancer is the most commonly occurring cancer in European men.8 For many years, the prostate 
specific antigen (PSA) played a major role in the diagnosis of prostate cancer. A serum PSA level above 4.0 
ng/mL is often considered a sign of prostate cancer, however this is not always the case. Some prostate 
cancers do not cause an increase in PSA serum concentrations, resulting in a false negative which can 
potentially lead to the patient not receiving the required treatment. On the contrary, other factors, including 
aging, can cause an increase in PSA levels, and this can produce a false positive result which could lead to 
unnecessary biopsies. It would, therefore, be logical that whilst PSA can act as an indication of disease, it 
should not be used solely when evaluating disease progression. Additional diagnostic methods are required 
which should ideally monitor alternative biomarkers. Other biomarkers can offer the potential for in vivo 
imaging allowing tumour size to be assessed and metastases to be located, assisting clinicians in prescribing 
the correct treatment.9 
 
Glutamate carboxypeptidase II (GCPII; also known as or N-acetyl-L-aspartyl- L-glutamate peptidase I [NAALADase I] 
or folate hydrolase I) is a membrane-bound glycoprotein enzyme which is predominantly located in the extracellular 
space.10 GCPII is found in a number of different tissues including the central nervous system where it known to 
catalyse the hydrolysis of N-acetyl-L-aspartyl-L-glutamate (NAAG) to produce glutamate and N-acetyl-L-aspartate 
(NAA).11,12 It is also found in the intestine where it catalyses the hydrolysis of folylpoly-γ-L-glutamate ultimately 
producing folate whilst releasing glutamate in the process.13,14 GCPII is found in the prostate and this has led to the 
protein being more commonly known as the prostate specific membrane antigen, PSMA.  In this thesis, the term 
PSMA will be used, however it is important to state that the terms GCPII and PSMA refer to the same, structurally 
identical protein. Although PSMA is expressed in normal prostate epithelium and tissues including those mentioned 
above, it is more highly expressed in several prostate cancers and resulting metastatic lesions. Therefore, PSMA can 
be used a potential biomarker in the diagnosis and monitoring of disease. 15–18 
 
PSMA is a type II transmembrane protein comprised of 750 amino acids.19 The first X-ray crystal structures of PSMA 
were determined in 2005 by Davis et al. who elucidated the structure of the extracellular domain (residues 44-750) 
(Figure 1.1).20 PSMA is a symmetrical dimer with each polypeptide chain containing a protease, an apical and a helical 
domain. A large cavity lies between the domains where substrate binding can occur. The cavity is a funnel shape 
which leads down 20 Å from the protein surface. The active site lies at the point in the cavity where two zinc ions 
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(Zn2+) are present and two binding sites are found; S1 and S1’. As introduced above, the active site of PSMA is 
responsible for the hydrolysis of substrates to release glutamate. The S1’ site binds to the glutamic acid residue of a 
compound with very high affinity, whilst the S1 pocket allows the binding of several different structures with a lower 
affinity.19–22 
 
Figure 1.1. The X-ray diffraction crystal structures of an inactive mutant of PSMA (human glutamate 
carboxypeptidase II) in complex with N-acetyl-L-aspartyl-L-glutamate (NAAG) (Data extracted from RCSB PDB. 
Code: 3BXM).23 
 
Binding to PSMA can be accomplished via two methods: using small, low molecular weight compounds or antibodies. 
Due to the high affinity of which the S1’ pocket binds glutamate residues, small-molecule inhibitors of PSMA often 
contain a glutamic acid moiety. Another region of the molecule should bind to the zinc ions and either mimic the 
transition state (TS) of the hydrolysis reaction or mimic the natural ligand without being susceptible to hydrolysis.24,25 
2-phosphonomethyl pentanedioic acid (2-PMPA) was the first potent and selective inhibitor of PSMA with an 
inhibition constant (Ki) of 0.3 nM.26 The glutarate (pentanedioic acid) portion of the compound is tightly bound to 
the S1’ pocket, whilst the phosphonate group forms strong dative covalent bonds with the zinc ions (Figure 1.2B). 
The nature of the bonding in the S1’ pocket favours the binding of the (S)-enantiomer, this is logical given that this 
configuration is comparable to L-glutamate.27 Urea-based compounds are a second class of small-molecules that 
exhibit PSMA binding. A large number of these compounds are glutamate-urea-lysine (Glu-NH-CO-NH-Lys) 
analogues, and as with 2-PMPA, the glutarate portion of the molecule binds tightly to the S1’ pocket. The urea mimics 
the peptide bond found in the natural ligands such as NAAG and the carboxyl group coordinates to a zinc ion.25 The 
lysine residue acts as a handle for chemical functionalisation (R-group in Figure 1.2C) to attach, for example, a 
fluorophore for optical imaging, a chelator of Gd3+ for MRI imaging and radionuclides for nuclear imaging. 28–31 When 
an aromatic 125I group (R = 1-carboxy-(4-[125I]iodo-benzoylamino) is present the compound has a Ki value of 0.01 nM 
which results in significant binding to PSMA expressing tumours. During preclinical SPECT/CT studies an uptake of 








The murine monoclonal antibody (mAb) 7E11-C5.3 was used for early imaging of PSMA, however, it binds an 
intracellular epitope of the protein creating issues when imaging viable cells that have intact cell membranes.33 To 
overcome this issue, humanised or fully human mAbs that bind to the extracellular region were developed.34–36 J591 
is a notable example of a PSMA binding mAb, and derivatives have been used in both imaging and treatment of 
PSMA expressing tumours. A number of radioimmunoconjugates were developed including 225Ac-J591, 213Bi-J591 
and 90Y-J591 for therapeutic applications and 177Lu-J591 and 89Zr-J591 for medical imaging.37–41 Despite promising 
results small-molecules are considered a superior option for developing diagnostic imaging agents since antibodies 
exhibit long circulation times and poor tumour penetrability, especially for bone metastases.42 
 
Figure 1.2. (A) Chemical structure of 2-PMPA with PSMA binding sites highlighted and (B) 2-PMPA in complexation 
with the PSMA active site (Data extracted from RCSB PDB. Code:2PVW).21 (C) Chemical structure of Glu-NH-CO-
NH-Lys derivative with the PSMA binding sites highlighted and (D) Glu-NH-CO-NH-Lys-NH-1-carboxy-(4-[125I]iodo-
benzoylamino in complexation with the PSMA active site (Data extracted from RCSB PDB. Code:3D7H).43 Note: 
Hydrogen bonds are represented using blue bonds, whilst bonding to Zn2+ (purple) are represented via dashed purple 
bonds. 
 
Human epidermal growth factor receptor 2 (HER2/neu) 
Human epidermal growth factor receptor 2 (HER2/neu; also known as ErbB-2) is overexpressed in 
approximately 20-30% of breast cancers.44 Although the protein is expressed during embryonic development 
it is almost undetectable in normal adult tissue. In effected cancer lines, expression of the HER2/neu oncogene 
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is significantly amplified which leads to the overexpression of the associated protein; thus making it an ideal 
target for therapeutics and for imaging.45 The protein itself is a receptor tyrosine kinase (RTK), a category of 
proteins which play a critical role in cell proliferation, differentiation and survival. There are over 20 different 
classes of RTK proteins and HER2/neu falls into the ErbB family.46,47 The ErbB family of proteins reside in the 
cell surface membrane. Whilst there is no known ligand for HER2/neu, other ErbBs respond to polypeptide 
growth factors in the local environment which cause homo- and heterodimerisation with other ErbB proteins, 
including HER2/neu.48,49 The dimers then cross-phosphorylate, a process where each protein phosphorylates 
tyrosine residues on the other. The result is a cascade of downstream signalling which has the potential to 
alter nucleus transcription events. Alterations in RTK expression and activation can lead to dysregulation of 
normal cell prosesses.50,51  
 
Harari et al. stated that, “ErbB-2 (HER2/neu) overexpression hotwires the cell cycle.”50  An overexpression of 
HER2/neu causes an increase in downstream signalling, which accelerates cell proliferation, and provides 
resistance to apoptosis. Overexpression of HER2/neu is also thought to increase the motility of cells (the ability 
of cells to migrate to other tissues) as well as the releasing signals which cause angiogenesis (the development 
of new blood vessels). Overall, HER2/neu overexpression results in a cancer which is incredibly progressive 
and, before recent advances in medicine, resulted in a very poor prognosis for the patient.52  
 
Nowadays, HER2/neu positive (+ve) tumours can be treated by using various mAbs including trastuzumab, 
pertuzumab and margetuximab.53–55 Trastuzumab is the most commonly used and the formulated drug  is 
known in the clinic as Herceptin®.55 HER2/neu is a transmembrane protein with an extracellular region 
consisting of approximately 630 amino acids that make up four domains (I-IV Figure 1.3A). The antigen-binding 
fragment (Fab) of trastuzumab binds to the C-terminal portion of domain IV (Figure 1.3B).56 The anti-tumour 
properties are well-known and documented, however, the process by which it occurs is a little less understood 
and several mechanisms are proposed. The binding of the trastuzumab may cause:  
1) Antibody-dependent cellular cytotoxicity (ADCC), a mechanism where an immune effector cell 
recognises and induces cell lysis; 
2) Inhibition of the homo- or heterodimerisation, preventing the initial cross-phosphorylation and 
downstream signalling from occurring; 
3) Blocking the cleavage of the extracellular domain of HER2/neu, which inhibits the signalling pathway; 




Figure 1.3. The X-ray diffraction crystal structures of the extracellular domains of (A) rat HER2 which is 
analogous to human sHER2 (Data extracted from RCSB PDB. Code: 1N8Y) and (B) human HER2 complexed with 




Traditionally, to determine if a patient has a HER2/neu +ve tumour, a biopsy must be taken. An 
immunohistochemistry (IHC) test then detects the HER2 protein and samples are scored by a pathologist, or a 
fluorescence in situ hybridisation (FISH) test detects an upregulation of the HER2 gene in the biopsied lesion. 
The process of taking the biopsy from a lesion may cause movement of cancer cells to other tissues when 
extracting the tissue with the needle, inducing tumour metastasis. The biopsy also only removes a small 
amount of tissue from the primary lesion. Since cancerous lesions are often heterogeneous, the portion of 
biopsied tissue may not contain HER2/neu levels which are representative of all sites of disease. Molecular 
imaging targets biomarkers in vivo, and so can act as a non-invasive method which informs the clinician of 
biomarker expression throughout all areas of the primary tumour and metastatic lesions.59 Since trastuzumab 
is known to bind to HER2/neu, it can be modified to create a molecular imaging agent. Conjugating a diagnostic 
radionuclide to the mAb and administering the radiotracer at microdose levels allows imaging HER2/neu 
expression using techniques such as PET and SPECT. There are multiple reports of zirconium-89 conjugates of 
trastuzumab, an ideal radioisotope as the long half-life is compatible with the long circulation times of the 
mAb.60–64 A number of 89Zr-trastuzumab conjugates have been trailed in the clinic; for example, a 2010 study 
focussed on the quantification of HER2/neu +ve lesions following administration of 89Zr-trastuzumab.65–67  
 
Human hepatocyte growth-factor receptor (c-MET) 
Similar to HER2/neu, the human hepatocyte growth-factor receptor (c-MET) is a RTK protein. It is expressed 
on the cell surface of normal epithelial cells and is also known to be overexpressed in a number of cancers 
including colon, gastric, bladder, breast, ovarian, liver, lung, and thyroid.68 The only known natural ligand for 










of the ligand causes dimerisation of the receptor resulting in tyrosine phosphorylation and the consequential 
activation of downstream signalling. These signalling events control cellular responses such as proliferation, 
motility and morphogenesis which are important in facilitating a wide range of biological processes including 
embryological development, wound healing, tissue regeneration, angiogenesis and growth. As with HER2/neu, 
due to the myriad of cellular responses that c-MET controls, upregulation of this RTK in cancer cells usually 
results in an aggressive disease which is likely to metastasise.70 
 
There are several inhibitors of c-MET which have been developed for therapeutic and imaging purposes.71 For 
example, crizotinib (Xalkori®, Pfizer, New York, USA) exhibited an IC50 of 8.4 nM in vitro using gastric carcinoma 
cells. Following subsequent successful clinical trials, crizotinib became an European Medicines Agency (EMA) 
approved drug.72 HGF itself has also been radiolabelled with 64Cu to produce a potential PET imaging agent.73 
However, due to ability of HGF to accelerate unfavourable cellular responses, other protein-based imaging 
agents have proved more attractive.73 As bivalent antibodies can also cause dimerisation and internalisation, 
and induce downstream signalling, the one-armed antibody onartuzumab (Genentech Inc., South San 
Francisco, CA) was developed. The monovalent antibody has been studied for the treatment of non-small-cell 
lung cancer in phase III clinical trials and radiolabelling with zirconium-89 has proved promising in pre-clinical 
studies.74,75  
 
1.3 Molecular Imaging 
1.3.1 Medical imaging and biomarkers  
Traditional medical imaging methods including X-ray computed tomography (CT), magnetic resonance imaging 
(MRI), and ultrasound (US) have provided clinicians with detailed anatomical information.  These techniques 
allow the location of tumours to be determined, as well as their size and structure. Molecular imaging uses 
techniques such as positron emission tomography (PET), single-photon emission computed tomography 
(SPECT) and optical imaging to visualise, characterise and measure biological processes at the cellular and 
molecular level.76,77 This is often achieved via the use of molecular imaging agents that target biomarkers. 
Molecular imaging agents accumulate at biomarker sites and allow visualisation of the target in comparison 
to background tissue. Providing an effective imaging agent is used, molecular imaging techniques have the 
potential to be incredibly sensitive techniques by detecting small abnormalities based molecular differences. 
For example, PET imaging with [18F]FDG (see below for details) can visualise tumours with a volume as small 
as 80 mm3.78 Comparatively, anatomical imaging techniques, such as CT, can only visualise tumours once they 
are a centimetre in diameter and are unable to characterise the biochemistry of the disease.79 Therefore, by 
targeting a specific biomarker, molecular imaging can allow for earlier diagnosis in comparison to traditional 
imaging techniques.76,80  
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Moreover, molecular imaging can provide benefits when combined with in vitro diagnostic assays. Whilst in 
vitro assays are able to aid the diagnostic process, the simple detection of a biomarker in the blood becomes 
less useful during the treatment of the patient. During the course of treatment, biomarker concentrations may 
fluctuate in ways that are not representative of the patient response. Therefore, molecular imaging must be 
used to investigate if treatment is effective on a lesion-by-lesion basis. For example, a patient undergoing 
treatment can exhibit a partial response to treatment which may result in a decrease in biomarker 
concentrations in the blood. However, a simple, in vitro test cannot determine whether all lesions have 
decreased in size or whether a heterogeneous response has occurred with some lesions increasing in size 
whilst others diminish. In this case, molecular imaging can act as a non-invasive method to determine the 
heterogeneity of response to therapeutics.81    
 
1.3.2 Imaging techniques 
Positron emission tomography 
PET is a nuclear imaging technique which detects and locates radioactive decay events in vivo, providing 
quantitative tomographic images. The steps involved in the acquisition and data processing of a PET image are 
summarised in Figure 1.4A.82   
 
Figure 1.4. (A) The steps of image acquisition in PET: 1) Positron (ß+) decay event which results in the eventual 
emission of two γ-photons at ~180o. 2) Photons travel along the line of response (LOR) before reaching 
detector. 3) Scintillation events converts γ-rays to visible light. 4) Visible light is converted to electrical pulses 
by a photomultiplier tube (PMT). 5) If the energy of detection is in the correct widow, a coincidence event is 
registered. 6) Coincident events are stored in the form of a sinogram. 7) Images in real space are reconstructed 
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The technology relies on ß+ decay which is explained in detail in section 3.3.1. Briefly, following the 
administration of a radiotracer containing a positron-emitting radionuclide, it accumulates in tissues. The 
radionuclide emits a positron which travels through the surrounding tissues losing enough kinetic energy by 
interaction with the medium. When the positron has lost the majority of its kinetic energy it slows down and 
interacts which an electron causing both particles (ß+ and e-) to annihilate. Annihilation produces two gamma 
(γ) photons of 511 keV that propagate at ~180o and their coincident detection is the mechanistic basis of PET.83 
 
Detection of the 511 keV photons is facilitated by using a scintillator; a material which when excited by ionising 
radiation (e.g. X-rays, γ-rays) emits visible or UV photons. Scintillators vary greatly in composition, however, 
inorganic single-crystal scintillators are most commonly used in PET imaging as their high density and high 
effective atomic number leads to efficient detection of γ-rays.84 Lutetium oxyorthosilicates (Lu2SiO5[Ce] or 
LSO) are commonly used scintillation crystals and are considered superior to other inorganic scintillators for a 
number of reasons. As well as a high density and effective atomic number, they exhibit high light output which 
optimises resolution. LSO crystals also have a short decay time (40 ns) allowing the detector to run at a high 
efficiency at higher count rates.83–85 However, images in this thesis were acquired using a G4 PET/X-ray camera 
which uses bismuth germanate (Bi4Ge3O12 or BGO) scintillator crystals. Whilst BGO may not hold some of the 
advantages of other scintillator crystals, for small animal PET imaging it is ideal. BGO is a lower cost scintillator, 
has a high stopping power and can be easily fabricated. It also exhibits reduced inter-crystal scatter, improving 
spatial resolution, and has low intrinsic radioactivity which improves the minimum detectable activity.86  
 
The visible light that is emitted from scintillators is converted into an electrical pulse and amplified by 
photomultiplier tubes (PMTs). The PMT itself is a vacuum tube with a photocathode which releases electrons 
following the absorption of light. The electrons are accelerated through a series of dynodes which multiply 
the number of electrons before the electron pulse reaches the anode to which it is attracted. Further 
amplification occurs until the pulse is detectable by a pulse height analyser (PHA). The PHA facilitates energy 
discrimination of the signal and ensures that only photons of the correct energy are used for the image 
construction, removing any data which may have arisen from scattered photons.83,87 Early PET cameras 
required one PMT per scintillation crystal, which made production expensive and limited the number of 
crystals that could be used, in turn limiting the spatial resolution. Nowadays, to overcome these issues, block 
detection is used. A block detector is a large crystal that is divided into an array of sub-elements by partial cuts 
and is connected to multiple PMTs. Geometric calculations from the resulting pulses allows the location of the 
scintillation event within the crystal to be determined and assigned to a particular crystal element.88  
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With the two photons emitted by the annihilation event propagating at ~180o from each other, it is possible 
to locate their source along a straight line of coincidence known as the line of response (LOR). Put simply, a 
LOR is the volume of space between opposite detectors. The number of LORs is a function of the PET camera 
design.89 Detectors can be arranged in several geometries but state-of-the-art cameras usually use a full ring 
of detectors in a circular arrangement.  This increases the number of LORs and hence improves the field of 
view (FOV) (Figure 1.4B).90,91 Each detected photon (in the correct energy window) is time stamped (±1 ns) 
and pairs of photons are considered coincident if they fall into the ‘coincidence timing window’ (often between 
6-12 ns).92  The data obtained from coincident events are stored in the form of a sinogram for image 
reconstruction. 
 
The acquisition of the image is reliant on the administration of the radiotracer. [18F]-2-fluoro-2-deoxy-D-
glucose ([18F]FDG) is currently the most commonly used radiopharmaceutical for oncological PET studies.93 
The first 18F-labelled FDG for human studies was synthesised in 1976 via electrophilic fluorination of 3,4,6-tri-
O-acetyl-D-glucal with [18F]F2.94 Due to low yields, long reaction times and the development of [18F]F- 
production, a new synthetic route was reported in 1986 using nucleophilic substitution (Figure 1.5A).95 This 
allowed [18F]FDG to be synthesised in high yields with a high purity and in the subsequent years automated 
synthesis modules were made commercially available.96 
 
Figure 1.5. (A) Chemical synthesis of [18F]FDG. (B) PET images of a patient recorded 70-90 min. post-injection 
(left) and 0-90 min post-injection of [18F]FDG. Image reproduced with permission from Rahmim et al., Eur. J. 
Nucl. Med. Mol. Imaging, 2018, 46, 501–518, Copyright 2018 Springer nature.97 
 
 
With the structure of [18F]FDG being analogous to glucose it is transported into cells by glucose transporters, 
however, with no -OH group at the C2 position normal metabolism cannot take place and FDG remains in the 
cell. Cancer cells are known to exhibit an increased rate of glycolysis and therefore an increased accumulation 
of [18F]FDG can be observed in tumours providing contrast to background tissue.98 The biochemical similarities 
of [18F]FDG with glucose allow it to cross the blood brain barrier, meaning this versatile radiotracer can also 























Magnetic resonance imaging (MRI)  
MRI is an imaging technology based on nuclear magnetic resonance (NMR) which produces three dimensional 
anatomical images of the body. The NMR phenomenon was first discovered by Isidor Isaac Rabi in 1938 which 
later led to the development of MRI which used NMR technology to create images. For this work Lauterbur 
and Mansfield shared the 2003 Nobel Prize in Physiology/Medicine. The first human MR images were reported 
in 1977 and following this, the technology became available in the clinic from the early 1980s.99,100   
 
MRI usually images hydrogen nuclei as they are the most common nuclei in biological tissue.  An adult human 
is around 60% water and there is also an abundance of protons in fat, carbohydrates, etc. The spins of each 
proton (I = 1/2) are randomly orientated when no magnetic field is applied. When a magnetic field B0 is applied 
across the subject or sample, most spins align with the external magnetic field, whilst a minority of high energy 
spins align in the antiparallel direction. The result is a net magnetisation in the Mz (longitudinal) direction 
(Figure 1.6A). The rotation of the spin is known as precession and the rate of precession is given by the Larmor 
frequency (v) seen in Equation 1.1. Here, B0 is the strength of the applied magnetic field and ! is the gyrometric 
ratio which for a proton is equal to 42.58 MHz/T. 
 
Equation 1.1. The Larmor equation  
" = ! ∙ %& 
 
 
A radiofrequency (RF) pulse is then applied (Figure 1.6B) at the Larmor frequency so that resonance can occur 
allowing the energy to be transferred from the RF pulse to the protons. The pulse causes a portion of spins to 
flip to the opposite state diminishing the longitudinal magnetisation (Figure 1.6D) and causes the spins to 
synchronise resulting in a growth of magnetisation in the Mxy (transverse) direction (Figure 1.6C). As the net 
magnetisation is flipped from the longitudinal to the transverse plane we denote this as a 90o RF pulse. When 
the RF pulse is removed, there is a rapid loss of transverse magnetisation, this is known as T2 or ‘spin-spin’ 
relaxation (Figure 1.6C to 1.6D). Following this the high-energy protons in the opposite direction to the applied 
magnetic field fall back to the low energy state and the longitudinal magnetisation grows again (Figure 1.6E 
to 1.6F). The energy released during the transition is absorbed by the surrounding tissue as heat energy and 
therefore this T1 relaxation is also referred to as ‘spin-lattice’ relaxation. The T1 time is the time it takes for the 
longitudinal magnetisation to return to 63% its original state, whilst the T2 time is the time it takes for the 




Figure 1.6. Representation of the orientation of proton spins and resulting net magnetisation during MRI 
acquisition steps. (A) An external field, B0, causes alignment of the majority of spins. (B) A 90o RF pulse then 
causes (C) spins to align the xy plane resulting in the growth of the transverse magnetisation and (D) Spins 
then dephase via T2 relaxation (C →D).  The 90o RF pulse also causes (E) some spins to flip resulting in a 
diminishing of the longitudinal magnetisation and (F) longitudinal magnetisation regrows via T1 relaxation (E 
→F).   
 
   
 














































The observed relaxation following a 90o RF pulse is actually denoted as T2*. Here, T2* is defined as the spin-
spin dephasing (“true” T2 relaxation) plus relaxation that occurs from inhomogeneities in the local magnetic 
field, ∆Binhom (Equation 1.2). These inhomogeneities arise due to the differences in magnetic susceptibility of 
various tissues, a distribution in chemical shifts and inhomogeneities in the applied magnetic field itself.102  
The result is the observed T2* relaxation is significantly faster than T2. 
 






        where        
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To eliminate the dephasing caused by inhomogeneities, a 180o pulse can be used alongside the 90o pulse in a 
process known as a spin echo. Following the initial 90o pulse, the protons begin to dephase via T2* relaxation 
generating a free induction decay (FID) signal. A 180o RF pulse is then applied which causes the spins to flip to 
the opposite axis and rephase which causes a second signal peak known as the spin echo. The time between 
the initial RF pulse and the spin echo is referred to as TE. To determine the true T2, multiple 180o pulses are 
used in a sequence and T2 is found as the time it takes for the echo amplitudes to decay to 37% (Figure 1.8). 
Following the sequence, time TR passes before the new 90o pulse is applied.103–105 
 
Different tissues exhibit variations in T1 and T2 relaxation times due to the different environments of the 
protons. In general, fluids have longer relaxation times than denser tissues; for example, cerebrospinal fluid 
(CSF) has  T1 and T2 times of approximately 4500 ms and 2200 ms respectively, whilst for fat these values are 
lower at 250 ms and 60 ms.106 To provide sufficient contrast between tissues the differences can be 
accentuated by altering the pulse sequence. In a T1-weighted image, energy is transferred more easily in 
tissues, such as fat, as heat deposited in the surrounding tissue. This increases the speed spins flip during 
longitudinal relaxation which decreases T1 times and is assigned the greyscale colour of white on an image. To 
accentuate this characteristic, short TE and TR times are used as the longitudinal magnetisation recovers more 
quickly in fat and can be detected. The longitudinal magnetisation in fluids does not recover on this timescale 
and the regrowth in longitudinal magnetisation is not as observable. This is assigned the greyscale colour of 
grey/black. In a T2-weighted image, the protons in tissues such as fat de-phase faster, resulting in a decreased 
T2 time which is assigned a greyscale colour of black on the MRI image. On the contrary, protons in substances 
such as water remain in phase for a longer time and have longer T2 relaxation times which is assigned a 
greyscale colour of white. To accentuate these differences, long TE and TR times are used, this gives spins ample 
time to dephase to a position where a greater variance in transverse magnetisation can be observed.107,108  
Despite the inherent differences in T1 and T2 relaxation times of certain tissues, contrast agents are often used 
to further accentuate the differences.  
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Figure 1.8. (A) Formation of multiple spin echoes from a string of 180o RF pulses. The initial faster decay 
observed after the 90° RF pulse is due to T2* effects and the true T2 decay can be determined from the 




MRI contrast agents  
T1 contrast agents  
T1 contrast agents (also known as positive contrast agents), as the name suggests, catalytically shorten the 
longitudinal relaxation times of nearby protons and hence increase signal intensity on T1-weighted images. 
Gd3+ is by far the most commonly used T1 contrast agent and will therefore be discussed further.109–111 With 
seven unpaired electrons in the 4f shell, Gd3+ is paramagnetic with a high magnetic moment (7.9 µB). It is also 
in a totally symmetric electronic state (ground state term symbol: 8S7/2) which provides a slower electronic 
relaxation allowing sufficient time for the magnetic state to be transferred to the surrounding bulk water.112 
However, the free, non-complexed Gd3+ (found as the aquated  [Gd(H2O)9]3+) is highly toxic and must be bound 
to chelating ligands. The earliest example is Gd-diethylenetriaminepentaacetic acid [Gd(DTPA)H2O]2– which 
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The ability of contrast agents to increase the rate of longitudinal relaxation of surrounding water molecules is 
known as the relaxivity (r1). r1 is described by Equation 3 where (1/T1)0 refers to the contrast agent-free 
solution and [CA] refers to the concentration of the contrast agent.114 To measure and predict the relaxivity of 
potential Gd3+ based chelators, Solomon–Bloembergen–Morgan (SBM) theory is used. Factors which increase 
the relaxivity value are (i) a greater number of inner sphere water molecules (q), (ii) an optimal, but short, 
water residence time (τm), (iii) a slow tumbling rate (1/τR), (iv) interactions with the complex and water 
molecules in the outer spheres (a), and (v) sufficient coordination distance (r) (Figure 1.9).112,114,115 
 
T2 contrast agents  
T2 contrast agents catalytically shorten the transverse relaxation times of nearby protons which decreases 
signal intensity on T2-weighted images (known as negative contrast agents) (Figure 1.10). Iron oxide 
nanoparticles are the most commonly used T2 and T2* contrast agents. They consist of γ-Fe2O3 (maghemite), 
Fe3O4 (magnetite) or α-Fe2O3 (hematite), however, magnetite and maghemites are the most commonly used 
in MR imaging. Magnetite consists of iron (II,III) oxide with 1/3rd of the iron sites are filled with Fe2+ ions, and 
2/3rd filled with Fe3+ (described as Fe2+Fe3+2O4(2−)). In aqueous conditions, magnetite slowly oxidises to 
maghemite which consists solely of iron in the 3+ oxidation state. Both magnetite and maghemite bulk 
materials are ferrimagnetic but once the nanoparticles reach the size of a single domain they exhibit 
superparamagnetism. Iron oxide nanoparticles begin to exhibit superparamagnetism at sizes below 20 nm, 
































magnetic field, SPIONs exhibit strong magnetism which causes inhomogeneities in the local magnetic field. 
This accelerates the dephasing of the surrounding protons causing an accelerated loss in transverse 
magnetisation which decrease T2 signal intensity.116,117 Whilst concentration still impacts the relaxivity (r2) of 
the nanoparticles, their size, shape and coating is also important. 
 
Figure 1.10. T2-weighted MR images. (A) Conventional MRI versus (B) MRI 24 h post-administration of SPIONs. 
The arrow highlights the accumulation of the nanoparticles in the lymph node. Image reproduced with 




Although nanoparticles must be sufficiently small to qualify as SPIONs (core size <20 nm), larger particles 
within this range exhibit larger mass magnetisation values, and therefore, produce shorter T2 relaxation times. 
For example, this can be seen in the work by Jun et al. who observed a darker contrast in T2-weighted images 
as the size of SPION is increased (4-12 nm).119 The effect is due to spin canting and is also known as the 
inclination effect.120,121 The magnetic moments of SPIONs arise from the unpaired 3d electrons in the Fe2+ and 
Fe3+ atoms. The spins at the octahedral sites and the spins at the anti-parallel tetrahedral sites couple via 
oxygen atoms. Due to the incomplete coordination shells for surface atoms and general disordering of the 
lattice at the nanoparticle surface, sufficient coupling cannot take place, and the spins are said to be canted. 
As size decreases the surface area to volume ratio increases and more spins are canted, which decreases the 
overall magnetic moment of the SPION.120 Kim et al. reported that 93.6% of spins in 3 nm-sized iron oxide 
nanoparticles are canted, whereas only 38.6% of spins in 12 nm-sized nanoparticles are canted. This results in 
an increase in magnetic moments with values of 273 and 24800  µB for 3 and 12 nm particles respectively.122 
Once a size is reached where canting effects no longer cause a significant difference, T2 relaxation times 
decreases with increasing size. As surface area to volume ratio decreases with increasing size there is a 
reduction in the surface accessibility to water molecules, therefore a decrease in proton exchange rate. SPIONs 
with a diameter of 22 nm are reported to have faster T2 relaxation times in comparison to those with a 
diameter of 30 nm.123 
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The shape of the nanoparticles can also influence the T2 relaxivity by altering the core size and surface area. A 
study by Alipour et al. indicated that cubic iron oxide nanoparticles exhibit increased relaxivities.124 Particle 
coatings can also have an effect on the relaxivity of the nanoparticle. Park et al. explored the effect of coating 
the SPION with PEG chains of varying length. They found that the relaxivity of the SPION decreases as the 
molecular weight of the PEG increases. The coating both decreases the diffusion rate of the water molecules 
due the hydrophilicity of PEG and increases the distance between the iron core and the water molecules.125  
PET/MR imaging  
As with all imaging techniques, both PET and MRI have unique advantages and disadvantages. Nuclear imaging 
techniques such as PET provide functional information and are exceptionally sensitive, requiring just 
picomoles of radiotracer. However, PET images do not provide anatomical information and offer limited 
resolution. Vice versa, MRI provides high soft-tissue contrast and anatomical information at high resolution 
but if contrast agents are required, they must be administered at a relatively high concentration. To 
circumvent some of these issues and to employ the advantages of each imaging moiety, hybrid imaging can 
be used.126 PET/MRI multimodal imaging  is a relatively new technology which was first introduced to the clinic 
in 2010 with one of the earliest scanners being installed at the University Hospital Zurich (2011, Discovery 
PET/CT + MR combo, installed by GE Healthcare).127 Integrating PET and MRI scanners is particularly 
challenging as the strong magnetic field can degrade the PMTs on the PET detector and can affect the positron 
range and spatial resolution. Therefore, early scanners relied on tandem scans where PET and MRI images are 
acquired sequentially. Nowadays, these issues can be overcome and simultaneous scanners have been 
developed. The Siemens mMR system was the first commercially available whole-body PET/MRI scanner. 
PMTs are replaced with solid-state silicon photo sensors known as avalanche photodiodes (APDs) which are 
not sensitive to the magnetic field.128  
 
Figure 1.11. (A) The full body MRI, (B) PET image following the injection of 68Ga-DOTA-TOC, and (C) the overlaid 
PET/MRI. Image reproduced with permission from S. A. Esfahani et al., Am J Nucl Med Mol Imaging, 2017, 7, 




PET/MR imaging agents 
In theory, in acquiring a PET/MR image a clinician has three options when deciding how to use potential 
imaging agents. The first option is to inject a patient with the PET tracer alone and rely on the natural contrast 
of different tissues in MRI imaging. Whilst this is routinely practiced, it is a non-ideal solution as the addition 
of a contrast agent would add clarity to the MR image and may, for example, highlight lesions that would not 
be seen on a normal MRI scan.130 Secondly, two separate imaging agents could be injected simultaneously into 
the patient, a T1 or T2 contrast agent plus a radiotracer.131 This can be problematic as the compounds may 
have different pharmacodynamic and pharmacokinetic profiles 
which can complicate data obtained from the scan. Potential 
drug interactions can also not be excluded. Finally, a single 
dual-modality molecular imaging probe could be injected into 
the patient. By designing a compound that contains a MRI 
contrast agent, a radionuclide and a biological targeting vector 
(Figure 1.12), a single biomarker can be imaged with multiple 
techniques using just one entity. With the introduction of 
PET/MRI technology research began to focus on the development of hybrid imaging agents. For example, 
Frullano et. al. developed a Gd3+ based contrast agent radiolabelled with 18F which targeted the acidic nature 
of tumours.132 Shen et al. used superparamagnetic manganese ferrite (MnFe2O4) nanoparticles as the MRI 
detection unit which also act as a scaffold to conjugate the targeting vector arginine-glycine-aspartic acid 
(RGD)-peptide and a 64Cu complex.133 Despite the increased research into the development of dual PET/MRI 
probes, there has been little progress in solving concentration-related issues in the design if the multimodal 
imaging agents. Whilst PET requires only picomoles of radiotracer, MRI contrast agents often require the 
administration of millimoles of material. Small-molecule probes offer little solution to this issue with their 
limited loading capacity. However, nanotechnology may offer a solution to this problem as nanoparticles, and 
similar materials, offer a large surface or volume for functionalisation.134 Using nanotechnology to overcome 
these issues forms a large basis of this thesis and will be discussed in more detail in Section 1.5. 
 
1.4 Radionuclides in nuclear medicine 
1.4.1 Laws of radioactive decay 
Radionuclides are unstable due to an excess of nuclear energy. The transition to a stable state involves the 
emission of ionising radiation in a process known as radioactive decay. The rate at which radioactive decay 
progresses follows classic first-order kinetics where the decay rate (-dN/dt) is proportional to number of 
radioactive atoms (N) multiplied by the decay constant (λ) of the radioactive species (Equation 1.4A). When 
A = A& at t = 0, we can integrate to obtain Equation 1.4B.135 Half-life (t1/2) is frequently used to describe the 
MRI detection unit PET imaging agent
Targeting vector
Linking unit
Figure 1.12. Design of multi-modal 
PET/MR imaging agent. 
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time required for half the radioactive atoms to decay (ABC/* = A&/2).  Hence, when E = 	 E(/F Equation 1.4C 
applies.  During practical measurements of radioactivity, the measured quantity of G ∙ A is referred to as the 
activity (A).  Therefore, Equation 1.4A holds and A can be described by Equation 1.4D. The SI unit for activity 
(A) is the Becquerel, where 1 Bq = 1 decay s-1.136      
 
Equation 1.4. (A) Decay rate and (B) the corresponding integrated rate law. Definitions of (C) half-life and (D) 
activity.  
A.     − IJIB = 	G ∙ A          B.      A = A& ∙ K
LMB         C.    E(/F =	 NOFM          D.    ; = ;& ∙ K
LMB  
 
1.4.2 Radiopharmaceuticals   
There are a large number of radionuclides used in nuclear medicine and a selection of these are highlighted in 
Table 1.2. Therapeutic radiopharmaceuticals deliver cytotoxic ionising radiation to tumour sites, resulting in 
the death of local cells. Radionuclides used in α-therapy decay via the emission of a high-energy helium 
nucleus known as a α-particle. Radionuclides used in ß-therapy are neutron rich and undergo isobaric (ß-) 
decay. Here, a neutron is converted into a proton, a ß- particle (e-) and an anti-neutrino.137 Diagnostic 
radiopharmaceuticals depend on the use of radionuclides at very low concentrations (nM to pM) to perform 
non-invasive imaging.138  
 
Table 1.2. A selection of common radionuclides used as radiopharmaceutics.139–143 
  
Radionuclide  Half-life Decay mode Application  
177Lu 6.7 d ß- (100%) ß-therapy 
225Ac 10.0 d α (100%) α-therapy 
67Ga 3.3 d EC SPECT 
68Ga 67.7 min ß+ PET 
111In  2.8 d  EC (100%) SPECT 
89Zr 78.4 h EC (77%), ß+ (23%) PET 
18F 110 min ß+ (97%), EC (3%) PET 
11C 20.4 min ß+ (99.8%), EC (0.2%) PET 
64Cu 12.7 h  EC (44%), ß+ (17%), ß- (39%) PET, SPECT 
99mTc 6.01 h  IT SPECT 
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1.4.3 Decay modes related to diagnostic radiopharmaceuticals used in PET and SPECT 
ß+ decay 
PET imaging relies on ß+ decay. Here, a proton rich radionuclide decays when a proton is converted into a 
neutron (n), a positron (ß+) and a neutrino (P) (Equation 1.5). The equation shows that the products are 
heavier by 2 electron masses. The energy which is equivalent to this mass balance is 1.022 MeV, therefore, for 
positron decay to occur, the radionuclide must have a transition energy (known as the Q-value) greater than 
this value. Additional energy is transferred as kinetic energy to the positron, the neutrino, and to the daughter 
nuclide. The positron travels a random walk path length before it loses enough energy that it can interact with 
an electron (511 keV). This matter-antimatter interaction causes annihilation of both particles and releases 
two γ-photons of 511 keV at ~180o.83,136 
 
Equation 1.5. Scheme of ß+ decay. 
Q → R +	ST + 	P 
 
Electron capture  
Similar to ß+ decay, electron capture (EC) occurs when a radionuclide is proton rich. However, when the 
transition energy (Q-value) is less than 1.022 MeV, ß+ decay cannot take place. In this case, an electron from 
the inner shell of the radionuclide is captured by the nucleus and the proton decays to a neutron releasing a 
neutrino in the process. The empty position from the inner shell is then filled by electrons from higher shells 
and this causing the emission of X-rays. Some nuclides which undergo EC produce a daughter nuclide which is 
in an excited state. When this falls to its ground state it releases γ-rays which can be detected in SPECT imaging. 
Other nuclides emit an electron, this process is known as Auger electron emission and can be used in 
therapeutic applications.144 
 
Equation 1.6. Scheme of electron capture. 
Q + KL → R + 	P 
 
Isomeric transition (IT) 
Isomeric transition occurs when an radionuclide in an excited (nuclear) state de-excites to a metastable or 
ground state without change in the number of neutrons or protons. Transitions are facilitated via γ-ray 
emission or internal conversion (IC). IC is a process where an orbital electron enters the nucleus and absorbs 
the energy from the excited state before being emitted from the atom.144 
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1.4.4 Radionuclides used as diagnostic radiopharmaceuticals 
Gallium-68  
Gallium-68 decays primarily via ß+ emission, allowing it to be an ideal candidate for PET imaging. The half-life 
of 68Ga is 67.71 min which provides sufficient time for production of the tracer and performing the PET imaging 
whilst minimising the radiation exposure to the patient. Following a 68Ga PET scan a patient must wait a 
minimal time to be activity free and can typically be released from hospital on the day of the procedure. As 
can be seen from the decay diagram (Figure 1.13), 68Ga decays through 89% positron emission. This high 
positron abundance allows for a reduction in the administered dose and shorter scan times. However, 
positrons produced from the largest branch of the positron emission (amounting to 87.7%) have a maximum 
energy of 1.9 MeV. This energy is considerably higher than the energy of positrons emitted from many other 
clinically relevant PET radionuclides, which explains the relatively low resolution of 68Ga PET as positrons travel 
a longer range before annihilation occurs (Table 1.3).145,146 Despite this draw back, 68Ga still remains a desirable 
nuclide for PET imaging because of its easy accessibility and relatively low cost due to the development of the 
68Ge/68Ga generator. In the generator-based production of 68Ga, the parent nuclide 68Ge decays to 68Ga 
through electron capture with a half-life of 270.9 days. Germanium-68 is produced by using a cyclotron and 
then is absorbed onto a stationary solid-phase, which in modern commercial generators is often composed of 
titanium(IV) oxide or tin(IV) oxide. The ionic differences between 68Ge(IV) and 68Ga(III) are then exploited to 
achieve separation of the daughter radionuclide from the parent, and the 68Ga3+ ions are eluted with a 
hydrochloric acid solution (typically 0.1-1 M). The breakthrough of 68Ge(IV) in modern generators is usually 
very low.147,148 However, removal of 68Ge along with other contaminants including 68Zn(II) (the final decay 
product) and Fe(III) (a general chemical impurity and radiochemical ‘poison’) remains important. There are 
several established methods for the removal of these impurities; in our facility, we use a small cation exchange 
resin (SCX) and a highly ionic (of ~5 M NaCl in 0.1 M HCl) solution to elute purified 68GaCl3(aq.).148–150  
 
Finally, the chemistry of 68Ga is versatile with Ga3+ behaving similar to high-spin Fe3+ and readily forming 6-
coordinate octahedral complexes. As Ga3+ acts as a hard Lewis acid, chelates are designed to contain hard 
Lewis bases to produce thermodynamically stable complexes. High thermodynamic stability is essential to 
prevent ligand exchange in the blood serum as gallium can transchelate to the iron transport protein 
transferrin.151 Also, due to the short half-life of 68Ga, fast formation kinetics are necessary for a successful 
chelator.152–154 For example, the commonly used desferrioxamine-B (DFO) coordinates via the oxygen atoms 
in its hydroxamate groups binding the Ga3+ ion with high affinity (formation constant, log ß = 28.2) with 
reaction times less than 5 minutes.152,155 However, chemistry performed with Ga3+ is often limited due its 
strong tendency to hydrolyse in aqueous conditions. The precipitation of Ga(OH)3 is reported to occur at a pH 
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as low as 3.3.156   Such a low pH is often not necessary when producing radiotracers due to the nanomolar 
concentrations, however,  until the Ga3+ is coordinated, reactions must remain under acidic conditions.156  
 





Compared with 68Ga, the positron emitting radionuclide 89Zr has a long half-life of 78.4 h. Whilst this may 
expose the patient to a prolonged radiation dose, it does allow for PET images to be taken at later time points, 
allowing larger biomolecules such as antibodies to circulate and accumulate in target tissue. The decay of 89Zr 
results in a positron energy of 0.9 MeV. This relatively low energy improves image resolution compared with 
nuclides that emit higher energy positrons. As can be seen in the decay scheme in Figure 1.14A, 23% of decay 
is via ß+ emission, whilst 77% is via electron capture. This decay is initially to a short-lived 89mY (t1/2 = 15.6 s) 
species, before IT produces the 89Y ground state releasing a γ-ray of 909 keV.157 Due to release of the high 
energy, highly penetrating γ-rays in almost 100% of the decay pathways, increased shielding for transport and 
handling is required to work with 89Zr safely. It may also limit the dose which can be given to patients. As only 
23% of decay events result in positron emission this may cause problems as higher doses may be required, 
however, this could potentially be overcome by using longer scan acquisition times.158 89Zr is produced by 
using a cyclotron, coupled with either a 89Y(p,n)89Zr or 89Y(d,2n)89Zr reaction. Fortunately, the metal target 89Y 
is 100% naturally abundant, is commercially available and is inexpensive when compared with other target 
materials such as enriched 64Ni (used in the production of 64Cu, vide infra). Typically, 89Y(p,n)89Zr produces 















of 83.4 days.  Purification is usually achieved by using a hydroxamate resin column with oxalic acid as the 
eluent where the suspected isolated species is [89Zr][Zr(oxalate)4]4-. The oxalate can then be converted to the 
chloride by using an anion exchange column to produce ZrCl4.159,160 
 
Figure 1.14. (A) The decay scheme of 89Zr, data extracted from the Laboratoire National Henri Becquerel.157 




Due to the long half-life of 89Zr, its main application in imaging is immuno-PET. As Zr4+ displays low affinity for 
non-specific binding to protein, chelates are conjugated to the antibody (or protein targeting vectors) prior to 
89Zr labelling. The chelate must provide high thermodynamic and kinetic stability in vivo whilst also facilitating 
high radiochemical yields. Similar to Ga3+, Zr4+ is a hard Lewis acid, and therefore, the chemistry is dominated 
by the binding of oxygen, nitrogen and anionic ligands. With its relatively large ionic radius (87 pm) and empty 
d-orbitals ([Kr]d0), Zr4+ exhibits coordination numbers from 6 through to 8.161,162 DFO is a common chelate for 
Zr4+.163 DFT calculations show the most stable mode of binding is coordination through the hydroxamate 
groups with one H2O molecule coordinating in an axial position to form a 7-coordinate complex (Figure 14B).161  
 
Copper-64 
PET imaging with 64Cu provides high resolution images due to the low energy of the emitted positrons (Emax = 
0.65 MeV). Its half-life of 12.7 h means that it may decay substantially before an antibody clears sufficiently 
from the blood pool and accumulates at its target. However, this half-life is ideal for smaller molecules such 
as peptides. 64Cu is an interesting nuclide because of its multiple decay modes (Figure 1.15).  64Cu can be 
described as a potential theranostic radionuclide; ß+ decay provides PET capabilities whilst ß- decay and EC 
(and associated emission of Augur electrons) offer therapeutic potential.164 Similarly to 89Zr, 64Cu is also 
cyclotron produced, most often by the 64Ni(p,n)64Cu transmutation reaction. Unlike other radionuclides 



































and can form complexes with chelates bearing softer N and S donor atoms. To make use of the versatile 
properties of 64Cu, diacetyl-2,3-bis(N4-methyl-3-thiosemicarbazone) (ATSM) is often used as a chelate to 
deploy the nuclides potential theranostic properties.165 It is a tetradentate ligand binding to the 64Cu(II) centre 
via the thiosemicarbazide groups.166 On entry into a hypoxic cancer cell (acidic conditions) the 64Cu(II) centre 
is reduced to 64Cu(I). The [64Cu(I)-ATSM]- complex is not stable in the cell and dissociates by a proton-mediated 
pathway, trapping the 64Cu(I) in the cell and allowing potential imaging and therapeutic action.167,168 
 





111In decays 100% by EC to a 111mCd excited state level (417 keV), this then decays via a two-step γ-emission 
(E1 =171 keV, E2 =245 keV).170 As there is no positron emission, 111In cannot be used in PET imaging. However, 
after 99mTc it is the second most commonly used radioisotope in SPECT imaging. Unlike 99mTc, 111In must be 
produced by using a cyclotron, nevertheless it is popular in the clinic due to its long half-life (t1/2 = 67.32 h). 
This half-life makes 111In ideal to conjugate to antibodies for use in immuno-SPECT. 
 
111In is stable in aqueous conditions in a +3 oxidation state. As a hard metal ion, chelates that contain hard 
donor atoms show greater stability. 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and 
diethylenetriaminepentaacetic acid (DTPA) are commonly used to complex 111In3+ ions. Whilst the macrocycle 
DOTA may provide improved thermodynamic stability, heat is required to form the complex which may be 
problematic when working with heat sensitive constructs, such as mAbs. Therefore, DTPA is often used 
preferentially. Also, similar to 68Ga3+, 111In3+ ions are prone to hydrolysis and radiolabelling reaction must be 












Figure 1.16. The decay scheme of 111In, data extracted from the Laboratoire National Henri Becquerel.170 
 
Selection of radionuclide  
Table 1.3 shows the properties of commonly used PET radionuclides. Here, the listed properties are key when 
determining which nuclide should be incorporated into the radiotracer. Firstly, the half-life should be 
appropriate for the circulation time of the radiotracer, whilst minimising exposure of the patient to 
radioactivity. Therefore, longer circulating constructs such as radiolabelled antibodies require longer-lived 
nuclides such as 89Zr (t1/2 = 78.4 h), whilst agents with faster PK profiles such as many small-molecules or 
peptides should ideally be radiolabelled with radionuclides such as 11C (t1/2 = 20.4 min), 18F or 68Ga. Second, it 
is important to consider the abundance of ß+ decay. High branching ratios of ß+ decay allow a lower effective 
dose to be administered and reduce the exposure of patient to other forms of decay. Third, it is important to 
consider the energy associated with emitted ß+. High energy ß+ travel a further distance before annihilation. 
Therefore, those radionuclides with a larger ß+ range generally result in low resolution PET images. Finally, the 
chemistries of the radionuclide must be considered. Metalloradionuclides can be beneficial because they can 
usually form metal-chelate complexes quickly and in mild conditions. That said, radionuclides such as 11C form 
covalent bonds with the radiotracer providing stability, however, they may require a more complicated 
synthesis with harsher conditions. Overall, a radionuclide should be selected based on the ease of radiotracer 
synthesis, compatibility of decay properties and availability.  
 
Table 1.3. Radionuclides commonly used in PET imaging and their characteristics (Rmax and Rmin refer to the ß+ 
range in water). Data extracted from Conti et al.173 
 
Radionuclide Half-life / 
min 
Major ß+  
Branch / % 
Emax / MeV Emean / 
MeV 
Rmax / mm Rmin / mm Production 
68Ga 67.8 87.7 1.90 0.84 9.2 3.3 Generator  
89Zr 4704 22.7 0.90 0.40 3.8 1.3 Cyclotron 
64Cu 762 17.5 0.65 0.28 2.5 0.7 Cyclotron 
11C 20.4 99.8 0.96 0.39 4.2 1.2 Cyclotron 








1.5 Nanotechnology in medicine  
In 1959, Richard Feynman delivered a lecture titled, ‘There’s Plenty of Room at the Bottom’ which was an 
introduction to what we now call nanotechnology.174 Whilst there is no unique universally accepted definition 
of nanotechnology, it can be broadly defined as, ‘the manipulation and study of materials at the molecular 
and atomic level between the dimensions of 1-100 nm’.175 At this scale, the properties of matter can differ 
from both the bulk materials and single atoms or molecules.175 Nanotechnology is truly an interdisciplinary 
field; from materials science and physics, to mechanical engineering and chemistry.176  The materials produced 
are incredibly versatile with unique characteristics such as interesting optical, magnetic and electrical 
properties. This versatility results in nanotechnology being used in several different applications across a wide 
range of industries, including medicine. Here, we use the term nanomedicine which refers to the use of 
nanomaterials in therapeutic or diagnostic applications.177 A large proportion of these applications are based 
in the field of oncology and include the use of nanomaterials as tumour targeted drug delivery vehicles, 
imaging agents and heat therapy vectors.178,179 
 
Nanoparticles possess a variety of intrinsic properties which make them suitable for potential use in the 
diagnosis or therapy of cancer. For example, some iron oxide nanoparticles are superparamagnetic and can 
alter T2 relaxation times in MR imaging.180 Gold nanoparticles exhibit surface plasmon resonance allowing 
photothemal therapy.181 Nanoparticles can also act as scaffolds for drug molecules, targeting vectors or 
imaging moieties. For example, nanoparticles can be radiolabelled with 89Zr for PET imaging, or loaded with 
cisplatin for chemotherapy treatment.182,183 However, nanomaterials are challenging materials to work with.  
The complexity of constructs often leads to problems with complete and thorough characterisation, batch-to-
batch reproducibility and stability. That said, overall, nanomaterials are versatile, adaptable materials with a 
range of intrinsic properties and functionalisation options. This allows scientists to create multi-modal 
nanomaterials which can be used simultaneously in multiple applications. This thesis will focus on 
nanomaterials as multi-modal PET imaging agents; specifically, PET/MR imaging agents and theranostic agents 







1.5.1 Design of nanomaterials as multi-modal PET imaging agents 
Properties influencing circulation times in vivo 
Figure 1.17. Summary of properties which effect the biocompatibility and circulation abilities of 




A major challenge in the development of nanomedicines is the delivery of the nanomaterial to the tumour. A 
nanoparticle may exhibit favourable properties in vitro but this is redundant if the particles are unable to 
circulate in vivo. The circulation time of a nanoparticle is largely determined by: (i) the size, (ii) the surface 
charge of the particle, also known as the zeta-(z-)potential, and (iii) the hydrophobicity (or solubility).184 
 
The size of nanomaterials is fundamental to their use in nanomedicine. Particles at the nanoscale exhibit a 
surface area which is orders of magnitude larger than the bulk material. Not only does this give some 
nanoparticles interesting magnetic and electronic properties, but it also provides more sites for 
functionalisation. It follows that the smaller the nanoparticle, the greater the nanoparticle surface area and 
the greater the loading capacity of the particle. However, if particles are too small they are unable to circulate 
for a significant length of time as particles smaller than 8 nm are excreted rapidly via the renal system.185 On 
the other hand, larger particles are sequestered and excreted by the hepatic system. Splenic filtration removes 
particles larger than 200 nm whilst Kupffer cells located in the liver rapidly take up nanoparticles greater then 
150 nm in diameter. Smaller particles escape uptake by Kupffer cells by diffusion out of the sinusoids through 
the fenestrae. Here, the smaller nanoparticles then reach the hepatocytes, which rapidly phagocytise particles 
















































with a diameter between 10-20 nm.186,187 This complex filtration system of the liver has a detrimental effect 
on nanoparticle circulation. It tends to be unavoidable with 30-99% of injected nanoparticles sequestering in 
the liver.188  By careful control of nanoparticle size this sequestering effect can be minimised.  
 
The thin layer of aqueous ions surrounding a charged nanoparticle is referred to as the electrical double layer 
(EDL) (Figure 1.18). As the name implies, the EDL comprises of two layers, with the first being known as the 
Stern layer. Here, nanoparticles with a net charge will have a layer of ions of the opposite charge tightly bound 
to the surface. The second, more diffuse layer is then found. This has the same charge as the nanoparticle 
surface and is known as the slipping layer where exchange with the bulk takes place. The z-potential is the 
electrostatic potential of the slipping plane. For nanoparticles to be stable in solution, z-potential values 
should be greater than ±30 mV. At these values the electrostatic repulsion is high enough to prevent 
aggregation.189,190 However, the surface charge of the nanoparticles is not only significant for particle stability, 
but also affects the fate of the nanoparticles in vivo. Particles with a positive z-potential are more likely to 
induce aggregation of platelets and cause haemolysis.191 To avoid these cytotoxic effects, anionic 
nanoparticles with a z-potential >30 mV should be used, which promotes circulation and prevents 
aggregation.184,185  
 
Figure 1.18. Depiction of the EDL solvating nanoparticles.192 
 
The final characteristic which is important to biocompatibility and circulation is the hydrophobicity of the 
nanoparticles. Hydrophobic nanoparticles are rapidly removed from the bloodstream by cellular components 
of the reticuloendothelial system (RES) (i.e. ingested by the macrophage system).193 However, uptake into 
tumour sites relies on prolonged circulation times, therefore, hydrophilic coatings, such as polyethylene glycol 






























































ζ-potential decreasing the cytotoxicity of the nanoparticle.184,185 Figure 1.17 (vide supra) summaries how the 
properties above influence the circulation of the nanoparticles in vivo. Overall, the system is complicated and 
it is difficult to obtain nanoparticles that possess sufficient circulation times. However, if nanoparticles are 
anionic, hydrophilic and between the sizes of 20 to 150 nm there is an increased possibility of an extended 
blood pool half-life. This longer circulation time may allow a nanoparticle to accumulate in a tumour via non-
specific or specific uptake.   
 
Tumour uptake of nanoparticles 
Often nanoparticles exhibit tumour uptake because of the enhanced permeability and retention (EPR) 
effect.194 Due to the rapid proliferation of cancer cells, blood vessels in tumours are irregular. They lack the 
detailed branching that leads from large vessels to smaller capillaries which results in abnormal vessel 
structure with large pores. The growth of the cancer cells also compresses lymphatic vessels, consequently, 
the only functional lymphatic drainage occurs at the periphery of the tumour. Nanoparticles can extravasate 
through the large vessel pores into the tumour and the lack of lymphatic drainage leads to their increased 
retention, which is the basis of the EPR effect.195 Whilst nanoparticles can be designed to achieve EPR driven 
uptake, this phenomenon does not target a specific biomarker. By incorporating a biological targeting vector 
into the nanoparticle structure, nanoparticles can be specifically targeted towards a biomarker, giving 
nanoparticles the potential to be used in molecular imaging. 
 
Radiolabelling methods 
There are a number of restrictions and requirements that should be considered when radiolabelling 
nanomaterials for PET imaging. Due to the short-lived nature of several radionuclides used in nuclear 
medicine, radiolabelling will ideally be fast and carried out in the final step of the synthesis. This ensures an 
optimal amount of radioactivity is present for administration into the patient. The radiolabelling should also 
minimise changes to the physical, chemical, or biologic properties of the nanoparticles to prevent changes in 
stability of the nanoparticles which could result in aggregation. Radiolabelling should also avoid alterations in 
the specific binding to the biological target and changes in the pharmacokinetics of the nanoparticles in vivo. 
Reaction conditions will also ideally be mild and at physiological pH. This will avoid exposing nanomaterials to 
conditions which may cause aggregation or a change in the oxidation state of metal ions. Finally, the 
radiolabelling method should provide a stable product to avoid loss of activity from the construct in vivo, which 
may produce false images which would be detrimental to the diagnosis of disease.192,196 
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Currently, there are a number of different methods used for radiolabelling of nanomaterials. In 2018, we 
published a review detailing current radiolabelling methods for multimodal nuclear imaging agents.192 Here, 
we divided radiolabelling methods into two categories; classical and non-classical methods (Table 1.4).  
 
Classical radiolabelling methods use a chelate or prosthetic group to radiolabel the nanoparticle. The surface 
of the particle is modified directly. Figure 1.19A shows examples of this type of radiolabelling using thiol-
mediated binding to gold nanoparticles, silylation of surface hydroxyls, and bisphosphonate binding to iron 
oxide particles.192,197,198 Similarly, the coating of the nanoparticle can be modified to attach a chelate or 
prosthetic group to the coating of the nanoparticle by a covalent bond. For example, the carboxymethyl 
dextran coating of the Food and Drug Administration (FDA) approved iron oxide nanoparticle Feraheme can 
be modified with DFO for 89Zr labelling (Figure 1.19B).199 The advantages and disadvantages of classical 
radiolabelling are summarised in Table 1.4. 
 
Figure 1.19. Classical radiolabelling methods. (A) Particle surface modification (B) Particle coating 






































































































Table 1.4. Non-classical and classical nanoparticle radiolabelling methods.
Radiolabelling method Advantages Disadvantages 
Classical radiolabelling methods 
O Particle surface modification 
O Particle coating modification 
o Covalent attachment of anchoring groups to the 
nanoparticle provides kinetic and thermodynamic stability. 
o The radionuclide is either covalently bound to a prosthetic 
group or tightly bound in a multi-dentate ligand, this 
providing further stability. 
o High stability ensures activity remains associated with 
nanomaterial in vivo. 
o Radiolabelling of chelate can be achieved prior to 
nanoparticle conjugation, this can minimise the exposure 
of the nanoparticles to harsh reaction conditions.  
o Can often require a multi-step radiolabelling reaction 
producing lower specific activities and radiochemical 
yields. 
o Addition of a lipophilic prosthetic groups or chelate can 
have adverse effects on toxicity and/or the 
pharmacokinetic profile by altering the surface charge of 
the nanoparticles. 
o May reduce the specific binding of the nanoparticle to its 
biological target. 
Non-classical radiolabelling methods o Generally, does not affect the physical and biochemical 
properties of the nanoparticles.  Avoiding the use of bulky 
groups during radiolabelling has minimal effects on the 
stability of nanoparticles, preventing aggregation.  It also 
prevents the change in the pharmacokinetic properties in 
vivo. 
o Methods are versatile. For example, they are not reliant 
on the coordination chemistry of the radionuclide. 
o Often only requires a single step, radiolabelling reaction.  
This provides increased radiochemical yields and specific 
activities.  
o Lack of chelate/covalent bonds may result in lower kinetic 
and thermodynamic stability. 
o The exact chemical nature of many intrinsic radiolabelling 
methods are not fully understood. 
O Radiochemical doping  
O Physisorption 
O Direct chemisorption 
O Isotope exchange  
O Cation exchange  
O Particle beam/reactor activation 




Non-classical radiolabelling methods do not require a chelate or prosthetic group. This is often referred to as 
the intrinsic radiolabelling of a nanomaterial. Non-classical radiolabelling methods are illustrated in Figure 
1.20 with the general advantages and disadvantages summarised in Table 1.4 (vide supra). Earlier methods of 
intrinsic radiolabelling of nanoparticles often relied on radiochemical doping. This involved the addition of 
‘hot-plus-cold’ precursors, where small amounts of radionuclide are added during particle fabrication.200 The 
method is based on protocols defined in the Fajans-Paneth-Hahm law of radioactive coprecipitation (as 
described in Otto Hahn’s 1936 work, Applied Radiochemistry).201 The law describes the coprecipitation of a 
radioactive element in the presence of larger amounts of carrier metal, producing nanoparticles where the 
radionuclide resides either within the crystal lattice or on the surface of the nanoparticle. This method has 
been widely established producing doped nanoparticles using a number of radiotracers including, 64Cu, 65Zn, 
68Ga, 111In, 141Ce, 153Sm and 198Au.202–212  
 
More recently, a new method for nanoparticle radiolabelling has emerged.213–217 It involves the direct 
chemisorption of the radionuclide onto the nanoparticle surface.  This phenomenon was first reported in 2013. 
Following early reports of the uptake of arsenic ions onto iron oxide surfaces, Chen et al. studied the uptake 
of As3+ and As5+ onto the surface of magnetite (Fe3O4) to produce *As-SPIONs (where * = 71, 72, 74, 76).
213,223 
Since this initial report, the chemisorption technique has been used with a number of different radionuclides 
and nanoparticles.214–222 A detailed description of the literature and the chemical nature of the chemisorption 
of radionuclides will be presented Chapter 2.  
 




1.6 Nanomaterials as PET/MRI agents  
 
As discussed in section 2.2.3, the introduction of PET/MRI technology led to an increased research focus on 
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that the same target is being imaged as opposed to simultaneously administering two tracers that exhibit 
differential PK profiles. Nanomaterials are good candidates when designing PET/MRI agents as they offer a 
platform to create, multifunctional, multi-component structures.  
 
1.6.1 Inorganic nanoparticles as PET/MRI agents 
A large number of different nanomaterials are used to create PET/MRI agents; however, the field is largely 
dominated by inorganic nanoparticles. Inorganic nanoparticles used as PET/MR agents are usually inherently 
MR active and they are then radiolabelled with a positron-emitting radionuclide.   
SPIONs 
Superparamagnetic iron oxide nanoparticles (SPIONs) are the most commonly used materials used in the 
construction of PET/MR imaging agents. As introduced in Section 1.3.2, SPION coatings can have adverse 
effects on the T2 relaxation properties on the nanoparticles. However, coatings are often necessary to ensure 
biocompatibility of the nanoparticle. To avoid biocompatibility problems, some research has focused on 
modifying clinically approved particles. This limits any cytotoxic effects and simplifies the process of good 
manufacturing practice (GMP) quality control tests. Feraheme (also known as Ferumoxytol) is a clinically 
approved drug for the treatment of anaemia, and is comprised of an iron oxide core with a polyglucose sorbitol 
carboxymethylether coating (a modified dextran). Thorek et al. modified these nanoparticles with DFO to 
chelate 89Zr (Figure 1.19B), creating a radiolabelled tracer to target lymph node metastasis. Metastases in the 
lymph nodes are usually the initial indication of the spread of many cancers, and particularly prostate cancer. 
Current technology to obtain specimens from the lymph nodes relies on using SPECT imaging with 99mTc 
colloids, however, this does not provide anatomical information. By combining PET and MR capabilities 89Zr-
ferumoxytol overcomes the soft-tissue contrast problems and precisely delineates nodes in the axillary 
drainage models.199 In a similar example, de Rosales et al. functionalised Endorem, a dextran coated SPION. 
Here, two dithiocarbamate bisphosphate ligands (dtcbp) were used, where the bisphosphonate anchors bind 
to the nanoparticle iron oxide surface and whilst two dithiocarbamate chelate 64Cu. The [64Cu][Cu(dtcbp)2-
Endorem] accumulates in the popliteal lymph nodes and this can then be imaged, the PET/MR provides spatial 
and anatomical information and also indicated that the construct is stable in vivo.224 
 
Although using clinically approved nanoparticles as a starting point for constructing multi-modal imaging 
agents offers some advantages, synthesis of the particles provides enhanced freedom and control in the 
design. Table 1.5 shows various synthetic methods used to produced SPIONs.  In general, SPIONs should be 
designed in a way to provide a maximum magnetic moment to shorten T2 relaxation times, whilst using a 
coating and size that provides biocompatibility and adequate circulation times. Previously highlighted 
examples (vide supra) rely on the non-specific delivery lymph nodes which allows biopsies to be taken to 
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determine the presence of disease. However, they do not provide specific uptake directly into tumour sites. 
One of the earliest works to overcome these problems was published by Lee et al. in 2008.225 Here they 
synthesised iron oxide nanoparticles with a core size of 5 nm which when coated with polyaspartic acid (PASP) 
obtained particles with a hydrodynamic diameter of 45 ± 10 nm. The resulting nanoparticles gave T2 relaxation 
times comparable to Feridex, a clinical drug similar to Feraheme.226 The PASP coating gave the nanoparticles 
a desirable z-potential of -50 mV and provided both carboxylate and amino groups to functionalise the 
nanoparticles. The chelate DOTA was conjugated to allow for 64Cu labelling, along with cyclic arginine-glycine-
aspartic (RGD) peptide which targets integrin αVß3 positive tumours. The nanoparticle conjugates are reported 
to specifically bind to αVß3 positive cell lines in vitro. During in vivo PET and MR imaging, non-targeted 
nanoparticles were found to accumulate in the αVß3 positive tumour xenografts via the EPR effect. However, 
this uptake could be increased with the addition to the RGD targeting group. In small-animal PET imaging 
(Figure 1.21), an increased tumour uptake was observed when the targeting peptide is present on the 
nanoparticle surface. These results provide an encouraging precedent for the use of nanomaterials in PET/MR 
molecular imaging.225 
 
Figure 1.21. Decay-corrected whole-body coronal PET images of nude mouse bearing human U87MG tumour 
at 21 h after injection of 3.7 MBq of (A) 64Cu-DOTA-IO and (B) 64Cu-DOTA-IO-RGD. This research was originally 
published in JNM. Lee et al., J Nucl Med, 2008, 49, 1371-1379, copyright SNMMI .225 
 
Following this early example, several SPIONS decorated with biological vectors and chelators were developed 
as potential PET/MRI agents.227–231 A notable example from 2016 uses a Glu-NH-CO-NH-Lys derivative to target 
SPIONs towards tumour lines which overexpress PSMA. Radiolabelling with 68Ga was achieved by conjugating a 
DOTA derivative to the nanoparticle coating which allowed PET imaging. PET and MR imaging in mouse models 
showed favourable uptake in 22Rv1 (PSMA +ve) cell line versus the PC-3 (PSMA -ve) cell line xenografts.227   
 
Despite advances in the use of nanoparticles in PET/MR imaging, these examples all require the use of a chelate or 
prosthetic group to radiolabel. Although this provides thermodynamic and kinetic stability, the use of these 
classical radiolabelling methods often has disadvantages outlined in Table 1.4. Due to these disadvantages, it 





intrinsic labelling. The intrinsic radiolabelling of SPIONs has been demonstrated by our group, here we 
reported  the heat-induced chemisorption of 64Cu, 111In, and 89Zr onto Feraheme.183 Also, Burke et al. 
intrinsically radiolabelled iron oxide nanorods with 68Ga to produce intrinsically radiolabelled potential 
PET/MRI agents.232 However, to our knowledge, an intrinsic radiolabelled SPION bearing specific biological 
targeting vectors have not been reported. With the desire for molecular imaging to be used regularly during 
diagnosis and treatment of cancers, the development of such constructs will be advantageous to the field. 
Therefore, one of the aims of the thesis is to develop an intrinsic radiolabelled targeted SPION.  
Manganese nanoparticles 
Manganese is an interesting element when considering the design of PET/MR agents as it itself can be both 
PET and MR active. The isotopes 51Mn, 52mMn and 52gMn all emit positrons during their decay hence can be 
used as PET agents. Whilst, Mn(II) is paramagnetic and enhances the longitudinal relaxation of surrounding 
protons, hence it is a T1 contrast agent.
233 Therefore, Mn isotopes can be used directly for PET/MR 
applications. For example, Lewis et al. produce 52MnCl2 which they co-inject alongside 
natMnCl2 to reach the 
higher concentrations required for MR imaging.234  Manganese nanoparticles are typically defined as MnO, 
MnO2 or Mn3O4 and example of synthesis methods can be found in Table 1.5. Zhan et al. synthesised Mn3O4 
particles coated with polyethyleneimine (PEI) and the chelate NOTA is conjugated to bind 64Cu for PET 
functionality.235 Mn3O4@PEG nanoparticles can also be intrinsically radiolabelled via the chemisorption of 
89Zr 
onto the nanoparticle surface.236 This demonstrates the versatility of the chemisorption method of 
radiolabelling and indicates that an intrinsically radiolabelled, targeted manganese nanoparticle would be a 
viable option in the design of PET/MR imaging agents. 
Gadolinium nanoparticles 
Gadolinium oxide (Gd2O3) nanoparticles offer a platform in which to deliver high molecular weight compounds 
whilst offering a high concentration of Gd(III). However, due to the toxicity of the Gd(III), particles must remain 
stable to prevent leaching of the ions. Gd2O3 particles with a PEG coating have shown stability in physiological 
conditions and (when the diameter = 2.2 nm) exhibited longitudinal relaxivities over 2-fold that of Gd-DOTA.237 
Despite these favourable properties there are few examples of Gd2O3 used as potential PET/MR agents. 
However, Ai et al. attempted to create a multi-modal radiotracer by using intrinsically labelled Gd2O2S:Eu. The 
nanoparticles where synthesised and coated with PEG to improve biocompatibility. Radiolabelling then 
occurred via a chelate-free route with 89Zr where a RCY ~75% was achieved. Whilst the particles are not 
specifically targeted, [89Zr]Zr-Gd2O2S:Eu-PEG exhibits gamma ray-induced radioluminescence whilst the Gd(III) 
acts as a T1-weighted MRI agent. Therefore, this particle is PET and MRI active whilst also having the potential 






Synthesis method Size of bare 
nanoparticle / nm 
Nanoparticle coating Size of coated 
particle / nm 
Iron oxide – 
magnetite 
(Fe3O4) 
Co-precipitation239 12 - - 
Microwave assisted synthesis (aqueous 
conditions)240 
12 ± 2 Poly(sodium 4-styrenesulfonate) (PSSS) 
Sodium polyphosphate (SPP) 
13.4 ± 1.5 
10.1 ± 1.5 
Microwave assisted, high pressure, sol-gel 
(organic conditions)241 
5.5 ± 0.9 - - 
 High-temperature242 - Oleic acid and oleylamine 4 
 Electrochemistry.243 7.6 Poly(vinylpyrrolidone) (PVP) and polyethyleneimine 
(PEI) 
9.2 
 Sono-precipitation244 - 3-aminopropyl-triethoxysilane (APTES) 11.6 
Manganese 
oxide - MnO 
High-temperature, sol-gel 245 37 PET  
Thermal decomposition246 - PET  
 Microwave, polyol247 - Poly(acrylic acid) (PAA) and PVP 10 
Gadolinium 
oxide - Gd2O3 
Colloidal precipitation248 2-5 - - 
Colloidal precipitation followed by mediated 
seed growth237 
4.6 Polysiloxane shell 6 
Table 1.5. Examples of synthesis methods of inorganic oxide nanoparticles used in the construction of PET/MR imaging agents. 
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1.6.2 Organic nanoparticles as PET/MR imaging agents  
Whilst organic based nanomaterials used as potential PET/MRI agents are not intrinsically MR active, they 
facilitate the combination of radionuclides and MR active structures.  
Liposomes 
Liposomes are spherical-like structures constructed from phospholipids that self-assemble to form bilayers. 
Liposomes are versatile structures, and by altering the lipids used in the synthesis they can range in size (30 
nm to 2.5 µm), surface charge, fluidity of bilayer, and assembly conditions. They are biocompatible and can 
both encapsulate materials or incorporate compounds onto the surface by the modification of the 
phospholipids.249 For this reason they have become a focal point in the design of multi-modal PET/MR imaging 
constructs. Previous work has seen the encapsulation of maghemite SPIONs with the phospholipid heads 
modified with a NODAGA chelate for 68Ga radiolabelling and FDG for cancer cell targeting.250 However, this 
approach produced liposomes with a diameter of 100-300 nm and although PEG was used to try to avoid liver 
uptake, in vivo images showed high accumulation in the hepatic system with little tumour uptake.250 Abou et 
al. offered a different approach which allowed the intrinsic radiolabelling of the liposomes. 89Zr was added 
during the formation of the liposomes, this caused the 89Zr4+ to coordinate to the phosphate groups on the 
phospholipid heads in the bilayer whilst the constructs were targeted towards neuroendocrine tumours via 
human somatostatin receptor subtype 2 (SSTr2).251 
Dendrimers 
Dendrimers are macromolecules at the nanometre scale. They tend to be comprised of an organic framework 
that consists of a number of structures branching out from a central core. The elaborate branching structure 
provides a platform for chemically modification in a variety of ways. Therefore, dendrimers can be multi-
functionalised to form multi-modal nanomedicines.252 Li et al. produce a porphyrin based dendrimer to 
produce a multi-functional material. The nanoporphyrin combines PET and MRI functionalities, and can also 
be used to integrate a number of different functions including, near-infrared fluorescent imaging, 
photothermal therapy (PTT), photodynamic therapy (PDT) and targeted drug delivery. The PET/MRI 
capabilities originated from the structures intrinsic ability to bind 64Cu(II) and Gd(III). The metals ions bind 
within the structure which consists of linear polyethylene glycol (PEG) and dendritic oligomers of a porphyrin 
analogue and cholic acid. Whilst no targeting vector is present, a significant amount of tumour uptake was 
observed for dendrimers which were cross linked with additional cysteine groups. This brought the size of the 




Nano-sized carbon allotropes  
Graphene  
Graphene based nanomaterials have become increasingly popular in recent years in the field of nanomedicine. 
Aside from pristine graphene, graphene oxides (GO) and reduced graphene oxides (rGO) are commonly used 
in the design of a multi-modal agent. Covalent modification of pristine graphene is often chemically 
challenging; disrupting the delocalised network is highly thermodynamically unfavourable whilst steric 
hindrance arises from the lattice deformation that occurs following hybridisation of a carbon atom from sp2 
to sp3.254  Therefore, the presence of oxygen containing groups in rGO and GO offers sites for modification, 
and also improve the hydrophilicity of the constructs. Shi et al. took advantage of this method to modify rGO 
with polyethylene glycol (PEG), a tumour targeting antibody (anti-CD105 antibody TRC105) and the 64Cu 
chelator NOTA, creating a potential positron emission tomography (PET) imaging agent.255 Similarly, an elegant 
example of chelate-free labelling saw the direct radiolabelling on the GO surface with 18F replacing oxygen 
atoms via a cyclotron induced 18O(p,n)18F reaction.256 In spite of significant tumour uptake, these examples do 
not demonstrate multimodal PET/MRI capabilities. In a rare example, Xu et al., synthesised an iron oxide 
nanoparticles-rGO conjugate. This was then modified with NOTA (which was radiolabelled with 64Cu) on the 
perimeter of the first PEG shell, which was further modified with the addition of a second PEG shell. This 
second PEG shell helped to prevent non-specific interactions between graphene nanostructures and proteins.  
This allowed longer circulation times in vivo. An elimination half-life of 27.7 h provided adequate time for 
tumour uptake via the EPR effect. This can be observed in both the PET and MRI images (Figure 1.22).257 
Despite successful tumour uptake, this binding is not specific. During this thesis, work was carried out on 













Figure 1.22. (A) Serial coronal PET images of 4T1 tumour-bearing mice at different time points post-injection 
of 64Cu-NOTA–RGO–IONP–1stPEG–2ndPEG. Tumours are indicated by yellow arrowheads. (B) T2-mapped MR 
images acquired pre-injection at 3 h and 24 h time points following intravenous injection of NOTA-RGO-IONP-
1stPEG-2ndPEG. Image reproduced from Xu et al., Nanoscale, 2016, 8, 12683–12692, with permission from The 
Royal Society of Chemistry.257 
 
Carbon nanotubes  
In a different approach, Cisneros et. al. used carbon nanotubes to synthesise potential PET/MRI agents.258 
Nanotubes have the ability to encapsulate materials within the tube cavity, hence the experiment focused on 
the encapsulation of Gd(III) and 64Cu into ultra-short single-walled carbon nanotubes (US-SWCNTs). Gd(III) and 
64Cu where loaded into US-SWCNTs via sonication and dispersed in solution using a surfactant. Stability tests 
indicated no significant leakage of Gd(III) or 64Cu over 7 days. PET images in mice indicated uptake in the liver 
and lungs, and it was speculated that this accumulation arises due to interactions with surfactant peptides in 
the lungs. T1 studies of non-radioactive Cu-Gd-US-SWCNT gave relaxivity values of 52.7 mM
-1 s-1 which is 
greater than the r1 value of the clinically used Magnevist proving the real potential of the nanotubes. The 
undesirable property of these nanotubes is their poor aqueous solubility so it is not possible to administer the 
drug in vivo at a concentration sufficient to obtain a MRI contrast image. Future research in this area should 
focus on the dispersion of the compounds into water to exploit their full potential as PET/MRI agents. 
Nanodiamonds 
Despite the flexibility that comes with the use of carbon nanotubes as multi-modal imaging agents some 
research has suggested significant cytotoxicity of the materials due to their ability to accelerate oxidative 
stress and alter the morphology of cells.259 Nanodiamonds are promising materials as biocompatibility has 
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been proven.260 Whilst PET/MR nanodiamond agents have yet to be developed, carboxylated nanodiamonds 
have been conjugated to a Gd-DOTA derivative to produce constructs which provide T1 contrast for stand-
alone MRI.261 Nanodiamonds have also been functionalised with a 18F prosthetic group for potential PET 
imaging.262 
Fullerenes 
Finally, fullerenes have potential to be used as nano-sized carbon allotropes in PET/MRI. Fullerenes are carbon 
spheres, forming cage-like structures that can be directly modified or encapsulate materials.  Luo et al. 
encased Gd3N into a C80 cage to provide MRI activity. The cage was then oxidised and the radiolabelled with 
the positron emitting 124I, with the iodo-group attaching directly to the cage in the ortho-position relative to 
the formed hydroxyl group. This produced a water soluble fullerene for PET/MR imaging.263 Whilst this is one 
of the few examples involving fullerenes as PET/MRI agents it highlights the potential of these materials. 
 
1.6.3 Outlook for the development of nanomaterials as PET/MRI agents  
The development of nanomaterials as PET/MR imaging agents is relatively new field of research.  However, 
this brief review of the literature demonstrates that growth has been both rapid and diverse, using a large 
range of different materials and radiolabelling methods. Despite this, with the introduction of molecular 
imaging, it has been more vital than ever to produce imaging agents which are specifically targeted. Therefore, 
this thesis will investigate a range of nanomaterial radiolabelling methods, both classical and non-classical, 
and combine this with the specific targeting of known cancer biomarkers.  
 
1.7 Nanomaterials as theranostic PET agents  
  
Theranostics combine both therapeutic and diagnostic capabilities into a single modularity. For this to be 
possible, a platform is needed which allows the linking of different components, and due to versatility of 
nanomaterials they are often the obvious choices when designing theranostic compounds. As before 
nanomaterials can be either be classically or non-classically radiolabelled providing the diagnostic, PET imaging 
capability. The therapeutic component can then be incorporated into the nanoparticles in different ways. Drug 
molecules can be loaded onto the nanoparticle via surface modification or encapsulation into their structures. 
Nanomaterials can also have therapeutic properties themselves making them ‘intrinsically therapeutic’. 
 
1.7.1 Drug loaded nanomaterials   
In the design of theranostic nanomaterials, a number of researchers have decorated the surface of the 
materials with drug molecules post nanomaterial synthesis. A simple example uses the modified dextran 
coating on SPIONs to covalently attach Quercetin via amide bond formation. Quercetin has chemotherapeutic 
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properties and the resulting nanoparticles show anti-cancer properties in vitro. However, these particles have 
not been radiolabelled for PET imaging.264 In a more sophisticated example, Chen et al. used electrostatic 
interactions to decorate silica nanoparticles with the anti-cancer drug doxorubicin (DOX).265 As the 
nanoparticles are mesoporous, the drug molecules reside in the channels as well as the surface allowing for a 
greater loading capacity. Due to the nature of the electrostatic interactions between the SiO2 particles and 
DOX, acidic conditions protonate the silanols in the nanoparticles and results in the dissociation of the drug. 
Therefore, as nanoparticles enter the acidic environment of cancer cells the drug is released and ex vivo 
tumour analysis showed that this was able to reduce tumour size. The nanoparticles were also radiolabelled 
with 64Cu using the NOTA chelate and antibody targeted towards the CD105 biomarker which is over expressed 
in several cancer lines.265 In a similar example, SPIONs have been loaded with DOX by incorporating the DOX 
molecules into the polymer coating. Particles have then been modified with a radiolabelled mAb to produce 
a therapeutic construct capable of PET/MRI imaging.266 
 
Other nanomaterials encapsulate therapeutics into the core of their structure. Liposomes are particularly 
suitable materials for this as they can both encapsulate materials and withstand surface lipid modifications. Li 
et al. produce multifunctional theranostic material by loading DOX, therapeutic radionuclides 186Re/188Re and 
diagnostic 99mTc into the core of the liposomes. They also modified the lipid heads with fluorescent dyes and 
metal chelators to chelate Gd3+ and 64Cu2+. This producing a final compound which is capable of diagnostic 
PET, SPECT and NIR imaging as well as therapeutic chemo- and radio- therapy.267 Ferritin cages can also be 
used to encapsulate drug molecules (DOX) as well as radionuclides (64Cu) demonstrating their potential as 
theranostic agents for PET imaging.268,269 
 
1.7.2 ‘Intrinsically’ therapeutic nanoparticles  
Photodynamic therapy (PDT) relies on a photosensitiser (PS) which resides at the tumour site and then 
produces reactive oxygen species (ROS) following excitation using light of a particular wavelength. The ROS 
oxidise molecules within the cell, leading to cell death.270 A large range of nanomaterials are used as PS 
carriers, such as mesoporous silica nanoparticles loaded with the PS chlorin e6 and radiolabelled with 64Cu.271 
However,  some nanomaterials are able to generate ROS by their own means. For example, fullerenes absorb 
light in the UV to visible region due to their conjugated π-system. Excitation of fullerenes forms the long-lived 
triplet state, which can generate ROS. Multi-modal fullerenes PS are able to combine this PDT capability with 
imaging moieties. Shi et al. conjugated iron oxide nanoparticles to the fullerene surface for PDT and MR 
imaging.272 However, a similar construct towards PET imaging has not yet been developed. Whilst, 
nanomaterials capable of PDT have not yet been labelled with a positron emitting radionuclide, there is plenty 
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of scope for this to be achieved. For example, cuprous oxide nanoparticles, carbon nanotubes, gold nanorods 
and titanium oxide nanoparticles are just some of the nanoparticles capable of PDT.273–276 
 
Photothermal therapy (PTT) is another treatment option where nanomaterials are used. Light energy 
absorbed by nanoparticles, can be released as luminescence or heat.  Following location of nanomaterials in 
the tumour site, laser light at a specified wavelength can be used to induce localised heating due to the 
presence of the nanomaterials. By combining this with PET imaging produces a theranostic agent where the 
location of laser light application can be determined from the obtained PET image.277 Zhou et al. produced 
folic acid targeted CuS nanoparticles labelled with 64Cu without the use of a chelate. This was achieved via the 
radiochemical doping method, where ‘hot-plus-cold’ CuCl2 was used. In vivo and in vitro analysis indicated 
tumour uptake and thermal ablation on irradiation with a NIR laser.278 In a final example, Cheng et al. develop 
a fully multi-functional theranostic platform combining gold nanospheres capable of PTT with mesoporous 
silica nanoparticles loaded with DOX. The complete construct is radiolabelled using a DOTA mediated 64Cu 




1.8 Aims of Thesis  
This thesis aims to explore the use of nanomaterials as multi-modal agents for use in PET imaging. Chapters 2 
to 5 aim to investigate the synthesis, drug loading, biological targeting and radiolabelling of different 
nanoparticles. Some of these constructs are then investigated in vitro and in vivo. 
 
Chapter 2 focuses on the synthesis and characterisation of iron oxide nanoparticles. A selection of iron oxide 
nanoparticles are synthesised or acquired and compared using various chemical and physical characterisation 
methods. The aim is to synthesise nanoparticles that are appropriately sized, offering potential circulation in 
vivo whilst shortening the T2 relaxation times of surrounding protons. Following successful synthesis, 
nanoparticles must be coated appropriately to allow dispersion in aqueous solution. Again, the effects of 
nanoparticle coatings are evaluated via the characterisation of the products using size analysis, surface charge 
determination and relaxivity measurements. Once nanoparticles have been fully characterised, radiolabelling 
methods are investigated. Initially, chelate based methods are explored by utilising traditional gold-thiol 
interactions and investigating the photoconjugation of photo-activatable chelates to the surface. Following 
this, intrinsic, chelate-free radiolabelling methods are explored with various methods and kinetic parameters 
studied. In later chapters, these particles and radiolabelling techniques are used in application-based projects. 
 
Chapter 3 uses iron oxide nanoparticles to create multi-modal agents for potential application in PET/MRI. By 
utilising the nanoparticles and radiolabelling methods established in Chapter 2, MRI active nanoparticles can 
be radiolabelled with ß+ emitting radionuclides for PET imaging. Constructs are then targeted towards PSMA 
to aid the specific uptake of nanoparticles in prostate tumours. 
 
Chapter 4 aims to produce a tumour-targeted theranostic agent by using a novel graphene-based 
nanomaterial. The nanomaterials are used as scaffolds to load drug molecules for therapeutic action and a 
chelate to bind a ß+ emitting radionuclides.  Similarly to Chapter 3, the constructs are targeted towards cancer 
cells using a small-molecule, PSMA binding vector. Despite successful results in vitro, in vivo analysis indicates 
poor tumour uptake due to rapid excretion. To avert poor pharmacokinetics, Chapter 5 explores the binding 
of antibodies to the graphene nanomaterials. Multi-modal graphene nanomaterials are constructed via the 
addition of gadolinium agents to shorten T1 relaxation times whilst a secondary chelate binds ß
+ emitting 
radionuclides, this producing a PET/MRI agent. We aim to then bind the constructs to an antibody targeting a 
biomarker over-expressed in specific cancers.  The overall goal is to produce a construct that accumulates in 
















2.1 Aims of chapter  
This chapter focuses on the fundamental chemistry of nanoparticle synthesis and radiolabelling. Multiple 
types of iron oxide nanoparticles are synthesised and characterised. Classical and non-classical radiolabelling 
methods are then explored.  
2.2. Nanoparticle synthesis and characterisation  
2.2.1 Introduction 
Feraheme® (FH; ferumoxytol) is an FDA-approved iron oxide nanoparticle used in the treatment of anaemia. 
It is composed of a magnetite SPION core and a carbohydrate coating, polyglucose sorbitol 
carboxymethylether. Particles have an average chemical formula of Fe5874O8752C11719H18682O9933Na414 which 
implies a molecular weight of 796 kDa and an overall size of 17-31 nm.280 Transmission electron microscopy 
(TEM) analysis of FH by Bullivant et al. found a core size diameter of < 5 nm.281 This gives the nanoparticles 
favourable magnetic properties leading to a T2 relaxivity (r2) of 98.45 mM
−1 s−1 showing the potential of the 
particles to be used as MRI contrast agents. Whilst the surface of FH can be modified to create multi-modal 
agents, we wanted to study a range of particles to investigate radiolabelling methods and biological 
applications.199 Therefore, it was desirable to synthesise iron oxide nanoparticles with a range of coatings. 
 
Table 5 seen in chapter 1, highlights some of the ways in which nanoparticles can be synthesised. An extensive 
review of the literature by Wu et al. indicates that the most successful methods are: co-precipitation, thermal 
decomposition, hydrothermal synthesis, microemulsion, and sonochemical synthesis.282 These methods 
produce small, monodisperse particles. Whilst details on the complete synthesis of FH remain proprietary, the 
magnetite core is synthesised via the co-precipitation method followed by addition of the coating. This is a 
technique also utilised by our group. Co-precipitation is well-established as the conventional synthesis route 
and reports date back to 1981.239 It involves the precipitation of ferric (Fe3+) and ferrous (Fe2+) ions in a 2:1 
ratio in aqueous, basic conditions. The pH of the solution is then lowered and the mixture is heated to induce 
the nucleation of the magnetite nanoparticles.283 The process is highly dependent on the reaction conditions; 
changes in the temperature and ionic strengths of solutions influence the final size and morphology of the 
nanoparticles.284–286 
Scheme 2.1. Co-precipitation synthesis of Fe3O4 (Fe2O3:FeO) nanoparticles. 
 
2Fe3+ + Fe2+ + 8OH- Fe(OH)2  +  Fe(OH)3 Fe3O4  + H2O
pH>11 pH<11
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By altering reaction conditions, the co-precipitation synthesis method offers a certain degree of flexibility 
when designing the properties when nanoparticle constructs. However, this also makes reproducing results 
and synthesising monodisperse nanoparticles difficult. Therefore, the thermal decomposition acts as suitable 
alternative toward the synthesis of magnetite nanoparticles. Sun and Zeng report an innovative example using 
Fe(acac)3 which is heated to high temperatures (265 
oC) using diphenylether as the solvent. Here, 1,2-
hexadecanediol is used as a reducing agent to provide Fe2+, whilst oleylamine and oleic acid are used to cap 
and coat the surface of the nanoparticles. This produces monodisperse, size-controlled nanoparticles with a 
diameter of 4 nm.287 However, these nanoparticles can only be dispersed in non-polar organic solvent which 
is a major disadvantage of this synthesis method. Therefore, further surface modification is required in order 
to disperse the nanoparticles in the aqueous solution for biological applications.  
 
In this section both the co-precipitation and thermal decomposition routes toward iron oxide nanoparticle 
synthesis are investigated. Particles are characterised by using several different methods. The hydrodynamic 
diameter of the nanoparticles was obtained by using dynamic light scattering (DLS). This method relies on the 
Brownian motion of the nanoparticles, i.e. the random movement of particles due to their interactions with 
solvent molecules. Due to their relative size, larger particles have a slower Brownian motion and the 
dependence of this velocity (D (m2 s-1); known as the translational diffusion coefficient) on size can be 
calculated via the Stokes-Einstein equation (Equation 2.1). Here d(H) (m) is equal to the hydrodynamic 
diameter, k (m2 kg s-2 K-1) is the Boltzmann constant, T (K) is the temperature, and ! (kg m-1 s-1) is viscosity of 
the liquid. The translational diffusion depends not only on the core and coating size of the nanoparticle, but 
also on the solvation shell which is determined by a number of factors such as surface structure and charge.288 
Therefore, DLS measurements determine the hydrodynamic diameter of the nanoparticles as opposed to TEM 
which measures the core size of the particles. In TEM a beam of electrons passes through the sample. Due to 
the shorter de Broglie wavelength of electrons, the image obtained is at a much higher resolution than a 
conventional light microscope, which is described by Abbe’s equation (Equation 2.2). Here, the maximum 
resolution is defined as the wavelength of the image forming radiation ("), in this case the electron beam, over 
the numerical aperture ($	&'$() of the system.  
 
Equation 2.1. Stokes-Einstein equation describing the hydrodynamic diameter, d(H), obtained from the 







Equation 2.2. Abbe’s equation describing the maximum resolution, d (nm), from the wavelength of image 






The composition of the nanoparticles was characterised by using X-ray diffraction (XRD), spectroscopic assays 
and induction-coupled plasma mass spectrometry (ICP-MS).  As detailed in the introduction, the z-potential 
of nanomaterials is important for their stability and fate in vivo. Therefore, this was measured by using a 
Malvern Zetasizer which passes an electrical current across the nanoparticle sample. Finally, the T2 relaxation 
times of the nanoparticles was obtained by using on a NMR spectrometer.  
 
2.2.2 Results and discussion 
Characterisation of Feraheme® 
Whilst characterisation data could be obtained for FH through the specification information and various 
publications, the hydrodynamic diameter was confirmed via DLS measurements to be 34.6 ± 13.7 nm. This 
size and relatively large error margin corresponds to the manufacturers size specifications of FH (17-31 nm). 
Whilst the surface charge of the nanoparticles is not reported by the manufacturer, we found the ζ-potential 
was -62.4 ± 3.52 mV. This highly negative value is expected due to the polyglucose sorbitol carboxymethylether 
coating which is a modified dextran. This carboxymethyl dextran is highly anionic, and therefore, produced 
nanoparticles which exhibit a highly negative z-potentials. Finally, the T2 relaxation times were obtained for 
FH. This was found to be 0.11 ± 0.2 ms which equates to a relaxivity of 507 ± 78.1 mM-1 s-1. We cannot directly 
compare obtained relaxivity values to those found in the literature. Literature relaxation times are usually 
obtained using a 1.5 or 3.0 T MRI machines whereas a 11.74 T, 500 MHz NMR was used in this study to obtain 
relaxation times. However, as the measured relaxivity describes the relationship between iron concentration 
to relaxation times, r2 values are a valid way to compare synthesised nanoparticles to the FDA approved FH 
directly.  
 
Synthesis of magnetite nanoparticles via the co-precipitation method 
Reaction conditions 
Fe3O4 nanoparticles were obtained via the standard co-precipitation method described above. Fe
2+ and Fe3+ 
ions in the form iron(III) chloride and iron(II) chloride were precipitated in aqueous ammonia solution. The pH 
was reduced by the addition of nitric acid and then the nucleation process was carried out by heating the 
solution to reflux. As explained above, the size of the resulting nanoparticles is highly dependent on reaction 
 64 
conditions used. We investigated the effect of altering the ammonia or nitric acid concentrations and reaction 
times in a number of different screening reactions (Figure 2.1).  
 
Figure 2.1. Effects of altering the (A) concentration of ammonia used during precipitation, (B) the 
concentration of nitric acid used during nucleation, and (C) the reaction time on the hydrodynamic diameter 
of the Fe3O4 nanoparticles produced by the co-precipitation method. 
 
 
Characterisation of nanoparticles  
By selecting the conditions which gave the smallest nanoparticles, we were able to produce nanoparticles with 
a hydrodynamic diameter of 26.51 ± 10.19 nm (Figure 2.2A) and a diameter of 11.31 ± 4.19 nm (Figure 2.2C). 
The obtained XRD pattern (Figure 2.2C) indicated that the major phase present was magnetite. This allowed 
us to determine we had produced Fe3O4 nanoparticles without further oxidation to Fe2O3. 
 
Figure 2.2. Representative characterisation data for Fe3O4 nanoparticles synthesised by co-precipitation (A) a 
DLS profile of particles in water (d(H) = 26.51 ± 10.19 nm). (B) TEM image of nanoparticles (d(TEM) = 11.31 ± 
4.19 nm). (C) Experimental XRD pattern of dried particles overlaid with the magnetite standard pattern (ICSD 




Finally, we determined the iron concentration of the Fe3O4 by using a spectroscopic assay. This method is 
based on measuring the absorbance of iron thiocyanate complexes.289 Briefly, the nanoparticles are dissolved 





which oxidises the Fe2+ ions to Fe3+ which are then complexed by thiocyanate ligands forming [Fe(SCN)6]
3- (7 = 
14100 M-1 cm-1)(Scheme 2.2). This complex has a characteristic absorbance in the UV-visible spectrum with a 
peak at 466 nm. Therefore, by constructing a calibration plot at known iron concentrations (Experimental; 
Figure 6.1), we were able to determine the total concentration of iron in the initial nanoparticle solution 
(Figure 2.3). With this we were able to determine that Fe3O4 contained 12.72 ± 0.04 mmol iron per gram of 
nanoparticle. This means that the nanoparticles are 70.9 ± 0.2% iron by mass. If particles were pure Fe3O4 the 
maximum iron percentage would be 72.4%. This difference can be attributed to the incomplete drying of the 
nanoparticles before the determination process, along with a small amount of oxidation of the magnetite to 
maghemite over time. This determination of iron content allowed us to calculate the relaxivity of Fe3O4. A T2 
relaxation time of 0.49 ± 0.03 ms was determined which was adjusted for iron content to determine a relaxivity 
(r2) of 160 ± 9.2 mM
-1 s-1. Relaxivity was decreased compared to FH due to increased core size. 
 
Scheme 2.2. Summary of the iron determination process. The oxidation of Fe2+ to Fe3+ with ammonium 




Figure 2.3. (A) Representative image of the [Fe(SCN)6]
3- solutions which are formed when different amounts 
of iron oxide nanoparticles are used. Left-to-right 1:3 dilution from 0.1 mg mL-1. (B+C) Plots for the 
determination of iron content in nanoparticles. (B) UV-vis spectrum (350-650 nm) for a variety of [Fe(SCN)6]
3- 
solutions (produced from the dissolution of nanoparticles) with the lmax = 466 nm. (C) Particle concentration 
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Synthesis of magnetite nanoparticles via thermal decomposition 
Reaction conditions  
Fe3O4@OA was obtained by using an adapted method based on the thermal decomposition route.
287 High 
temperatures and a mixture of the surfactants oleic acid and oleylamine were used to produce SPIONs 
dispersed in hexane. This synthesis method is termed ‘thermal decomposition’ because of the thermal 
instability of the Fe(III) acetylacetonate precursor.290 A recent publication from Lak et al. indicated that 
complete dissociation of the acetylacetonate occurs at temperatures >90 oC.291 Following decomposition, a 
portion of Fe(III) is reduced to Fe(II) by using 1,2-hexandecanediol. The precise mechanism of this reduction is 
unknown; however, a proposed scheme is given in Scheme 2.3, whereby oxidation of the diol facilitates the 
reduction of Fe(III).  
 
Scheme 2.3. Proposed reactions that facilitate the reduction of Fe(III) by using 1,2-hexandecanediol.290,291 
 
 
The partial Fe(III) reduction increases the number of suitable monomers in solution. This allows the nucleation 
process to occur, forming magnetite seed crystals. As these form the monomer concentration drops and 
particle growth occurs. These steps are known as the LaMer mechanism which can be summarised in three 
stages; 1) monomer accumulation, 2) homogenous nucleation, and 3) diffusion-controlled growth. We found 
that heating an iron and surfactant solution simultaneously before combining the two created particles which 
were smaller. This method is known as the hot-injection synthesis method and is commonly used during the 
synthesis of a variety of nanoparticles.292 By shortening the time frame in which monomer accumulation 
occurs there is a quick burst of nucleation which then causes growth to occurs from seed crystals that have 
similar sizes. This, in turn, leads to a decrease in size distribution of the nanoparticles.292 Following successful 
synthesis, particles were precipitated in ethanol and dispersed in hexane to remove impurities. 
Characterisation of nanoparticles  
At this stage, the particles were then characterised by using DLS, TEM and XRD analysis. DLS found a 
hydrodynamic diameter of 8.95 ± 3.98 nm (Figure 2.4A) when the particles are dispersed in hexane. A 
diameter of 6.79 ± 3.41 nm was observed with TEM (Figure 2.4B). The XRD pattern of the same nanoparticles 
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Figure 2.4. Representative characterisation data for Fe3O4@OA. (A) A DLS profile of particles in hexane (8.95 
± 3.98 nm). (B) A TEM image of nanoparticles (6.79 ± 3.41 nm). (C) XRD pattern of dried particles. (magnetite 
standard: ICSD collection code: 27899) 
Functionalisation of Fe3O4@OA 
Due to hydrophobic nature of the oleic acid and oleylamine surfactants, the nanoparticles are only stable in 
non-polar solvents and aggregate in aqueous solution. Therefore, to disperse the SPIONs into a desirable 
solvent the surface ligands must be replaced. This was achieved by using two methods creating Fe3O4@Al(OH)3 
and Fe3O4@APTES nanoparticles. The first, based on works from Cui et al., involved the use of aluminium 
chloride to create an aluminium hydroxide coating on the surface.293 The initial sign of successful 
functionalisation is the ready dispersion of the nanoparticles in water, indicating successful displacement of 
the hydrophobic oleic acid and oleylamine surface ligands. To confirm this functionalisation, the IR spectrum 
was obtained which indicated a broad OH stretching mode (3029 cm-1) and deformation mode (1553 cm-1) 
with a disappearance of the CH stretches at 2846 and 3794 cm-1. Particles were further characterised by TEM 
and showed a minor increase in particle size, d(TEM) = 10.6 ± 2.47 nm, which can be assigned to the presence 
of the Al(OH)3 coating. However, DLS measurements showed that there was a significant increase in the 
hydrodynamic diameter (d(H) = 113 ± 51.3 nm) due to the solvation shell of the water molecules. The z-
potential of the particles was +52.8 ± 6.14 mV, which, at first, seemed surprising given the presence of 
hydroxide groups in the coating. However, this highly positive surface potential arises due to the Al3+ ions 
present at the surface and a similar z-potential was reported from Cui et al. Iron content measurements 
indicated that particles contained 11.3 ± 1.1% iron (by mass). These findings were supported by the long T2 
relaxation time (6.52 ± 0.01 ms), which corresponds to a r2 value of 74.5 ± 0.1 mM
-1 s-1. The relaxivity is 
relatively poor (see Table 1) when compared with other nanoparticles investigated in this chapter.  It can be 
assumed that the Al(OH)3 coating protects the iron oxide core and limits the proximity of the surrounding 
water molecules. 
 
The second functionalisation method involved the use of (3-aminopropyl)triethoxysilane (APTES) to displace 
the hydrophobic surfactants and to coat the nanoparticles, creating Fe3O4@APTES. In a similar way approach 
A B C
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to the synthesis of Fe3O4@Al(OH)3, the initial indication of successful functionalisation by ATPES was the 
dispersion of nanoparticles into water without the aggregation. IR measurements indicated the presence of 
both Si-O (1283 cm-1) and Si-C bonds (1396 cm-1). TEM images showed a minor increase in the core size of the 
nanoparticle with a diameter of d(TEM) = 11.4 ± 7.47 nm. However, again the hydrodynamic diameter 
exhibited a dramatic increase (d(H) = 102 ± 68.2 nm) due to the extended aqueous solvation shell. Similarly, 
the ζ-potential of the Fe3O4@APTES nanoparticles was positive (+46.4 ± 9.19 mV) which was expected due to 
the primary amines at the surface. T2 relaxation times were very fast (0.39 ± 0.01 ms), corresponding to a high 
relaxivity (r2 = 611 ± 15.3 mM
-1 s-1). Whilst the nanoparticles exhibit a similar d(H) to the 
Fe3O4@Al(OH)3nanoparticles, the APTES coating is less dense, hence water molecules are at a closer proximity 
to the nanoparticle surface. Therefore, it is the small core size in combination with the organic coating 
efficiently accelerates relaxation of water molecules. 
 










































Figure 2.5. Characterisation data for Fe3O4@APTES and Fe3O4@Al(OH)3 (A) IR spectrum of Fe3O4@Al(OH)3 
(black), Fe3O4@OA particles (blue) and Fe3O4@APTES (red) (B) TEM image of Fe3O4@Al(OH)3 nanoparticles 
(10.6 ± 2.5 nm). (C) DLS profile of Fe3O4@Al(OH)3 (113.0 ± 51.3 nm). (D) TEM image of Fe3O4@APTES 
nanoparticles (11.4 ± 7.5 nm). (E) DLS profile of Fe3O4@APTES (102.0 ± 68.2 nm). 
 
 
Characterisation of Fe2O3@Au nanoparticles 
Fe2O3@Au nanoparticles were kindly synthesised and characterised by Dr. Marcus Yaffee at the University of 
Zurich. The particles consist of a maghemite core with an Au(0) coating with a diameter measured by TEM of 
d(TEM) = 17.8 ± 4.3 nm and a hydrodynamic diameter of d(H) =  51.4 ± 25.3 nm (Figure 2.6). ICP-MS analysis 
determined the composition of metal ions in the nanoparticles; a content of 19% iron and 81% gold (by mass 
of metal ion) was found, this corresponds to ~8.5 Au atoms for each Fe2O3 component. This suggests that the 
particles have a relatively thick Au coating encasing a comparatively small maghemite core. This explains the 
relative long T2 relaxation time (24.68 ± 0.01 ms) and low r2 relaxivity (11.8 ± 0.01 mM
-1 s-1) in comparison to 
other nanoparticles reported in this chapter. The Au(0) coating protects the iron core from direct contact and 
reaction with the water, shielding the surrounding water molecules from the maghemite core. The dense, 
thick, Au(0) coating  provides more shielding than the thinner, lighter Al(OH)3 or APTES coatings, hence poorer 














































































Figure 2.6. Representative characterisation data for Fe2O3@Au. (A) A DLS profile of the particles in water (51.4 




Visual inspection provided an immediate indication that the gold atoms were coating at the surface of the 
nanoparticles (Figure 2.6C). Unlike iron oxide nanoparticles (which appear brown) and similarly to other gold 
nanoparticles, the Fe2O3@Au nanoparticles exhibit a pink/red colour due to the presence of the surface 
plasmon resonance (SPR). The free conduction electrons (d electrons) in solid gold oscillate collectively in the 
presence of light and are known as a plasmon. Plasmons can be excited in the bulk and at the surface, however, 
at the nanoscale, only surface plasmons are expected which is the case for gold nanoparticles. At a specific 
wavelength of light, surface plasmons resonate causing the strong absorbance or scattering of light giving rise 
to the strong observed colour. For gold nanoparticles this results in an absorbance maximum ("max) of around 
510-570 nm in the UV-visible spectrum. The resonance frequency is strongly dependent on a number of 
conditions including the size and shape of the nanoparticles, therefore, modification or aggregation of the 
nanoparticles can be observed from changes in the absorption spectra.294 This phenomena is well-
demonstrated by Haiss et al. who showed that "max red-shifts from 525 to 579 nm as particle diameter 
increases from 32 to 108 nm.295 As expected, the Fe2O3@Au nanoparticles have an "max of 520 nm.  
 
2.2.3 Summary 
Table 1 summarises the nanoparticles synthesised and characterised during this section of the thesis. These 










Table 1. Summary of nanoparticles and their characteristics. N.B. Data is incomplete for Fe3O4@OA as these 






size, d(H) / nm 
 z-potential / 
mV 
T2 relaxation 




> 5 281 34.6 ± 13.7 -62.4 ± 3.52 0.11 ± 0.02 ms 507 ± 78 
 
12.31±5.19 26.5± 10.2  38.1 ± 0.9 0.49 ± 0.03 ms 160 ± 9.2 
 
8.95 ± 3.98  - - - - 
 
10.6 ± 2.47  113 ± 51.3 52.8 ± 6.14 6.52 ± 0.01 74.5 ± 0.12 
 
11.4 ± 7.47 102 ± 68.2 46.4 ± 9.19 0.39 ± 0.01 611 ± 15.3 
 










2.3 Radiolabelling of nanoparticles 
2.3.1 Introduction 
As introduced in Chapter 1, methods for radiolabelling nanoparticles can be classified as classical or non-
classical. The former routes typically involve the use of a chelate or prosthetic group and the latter methods 
explore the intrinsic, chelate-free radiolabelling. This section of the thesis we aimed to explore a range of 
radiolabelling methods whilst addressing some unanswered questions in the field and identifying the best 
methods to create targeted radiolabelled compounds (see Chapter 3). 
 
Chelate-based methods use known chemistries to produce kinetically and thermodynamically stable 
complexes.296,297 The complexation of radiometals using macrocyclic or acyclic chelators is a heavily 
researched and developed topic, and a number of ideal chelates for particular radionuclides have been 
established.154,156,298–301 For example, DOTA is known as an ideal chelator of 111In3+, whilst thermodynamic 
parameters are promising (log K = 23.9), the kinetic inertness of the complex also prevents metal dissociation 
in vivo. 298 Similarly, NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) is known to form complexes with 
68Ga3+ (log K = 31.0) and 64Cu2+ (log K = 23.3) which remain stable under physiological conditions.156,302  
 
Despite the stability offered by using radiometal chelators, these methods may not be optimal when 
radiolabelling nanoparticle constructs. Incorporating a chelate as part of the nanoparticle structure typically 
requires multi-step reactions and results in the addition of bulky groups which may compromise the biological 
targeting and pharmacokinetics. Non-classical, chelate-free methods aim to avoid the use of these groups by 
taking advantage of the intrinsic reactivity and properties of nanoparticles. An example of chelate-free 
radiolabelling is the direct chemisorption of the radionuclide onto the iron oxide nanoparticle surfaces, and 
this is becoming a popular radiolabelling method. Since the first report of this phenomena by Chen et al. 
(synthesis of *As-SPIONs (where * = 71, 72, 74, 76)), several publications have highlighted the versatility of 
the technique  183,196,213,232,303–305 Madru et al. radiolabelled PEGylated SPIONs with 68Ga whilst and Chakravarty 
et al. labelled SPIONs with 69Ge  and our group demonstrated that Feraheme® could be labelled with 64Cu, 89Zr 
and 111In when heated.183,304,305 The mechanism by which this radiolabelling occurs is not fully understood, 
however, electron paramagnetic resonance (EPR) studies performed by our group pointed towards a surface 
interaction with the oxide layer.183 The EPR spectra of Cu2+ labelled of Feraheme® exhibited the a Cu2+ signal 
which would be lost if the Cu2+ ions were incorporated into the superparamagnetic core of the nanoparticle. 
This initial speculation of the radiometal binding mode was supported by recent findings from Patrick et al.306 
They carried out several experiments with both magnetite and maghemite nanoparticles and 89Zr and 111In 
radionuclides to determine that the radionuclide mineralised onto the surface of the nanoparticles.306 57Fe 
Mossbauer spectroscopy indicated that iron atoms remained in the same environment following the 
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radiolabelling process. This suggested that no sub-lattice modification takes place and radiolabelling only takes 
place at the surface of the particles. X-ray photoelectron spectroscopy (XPS) then confirmed this result and 
indicating the presence of In with a 3+ oxidation state assigned as In2O3, and Zr with a 4+ oxidation state 
assigned as ZrO2 at the particle surface. Time-of-flight secondary ion mass spectroscopy (ToF-SIMS), ICP-MS 
and XRD were then used to further support the theory of radiometal binding via the surface oxide layer which 
they termed surface mineralisation. 
 
This section reports our experimental work investigating the chemical and radiochemical scope of the 
radiomineralisation technique using the nanoparticles introduced in Section 2.1. Whilst the chemical 
interaction is now understood to occur via mineralisation, the kinetics of this process has not been studied. 
Our previous work indicated there were differences in binding when labelling Feraheme® with a range of 
metals ions (Zr4+, Tb3+, Eu3+, In3+, Cu2+, Co2+, Ni2+, Mn2+ and Zn2+). Therefore, kinetic data were measured from 
the radiolabelling of Fe3O4 and FH with both 
68Ga and 111In radionuclides. The aim of this was to determine if 
the nature of the particle coating or the choice of radionuclide affects the mineralisation process. As control 
studies and for direct comparison with the chelate-free methods, we also investigated the use of several 
classical radiolabelling methods. Finally, a novel thiol-mediated uptake of 64Cu radionuclides onto gold 
surfaces was studied. 
 
2.3.2 Results and discussion - Classical radiolabelling methods 
Functionalisation of Fe2O3@Au with a dithiolane chelate
 derivative  
Basic principles  
As introduced in the previous section, the Fe2O3@Au nanoparticles comprise of maghemite core with a gold 
coating. Due to the strong affinity between gold and sulphur, the coating of the nanoparticles can be modified 
by the chemisorption of thiols and disulphides onto the surface to form a self-assembled monolayer (SAM). 
Therefore, we decided to use a chelate derivatised with a dithiolane group to the append a radionuclide onto 
the nanoparticle construct. The dithiolane group is speculated to have an increased stability compared with a 
single thiol due to the ‘didentate’ effect of the two sulphur atoms conjugating to the surface.307 When modified 
with dithiolane derivatives we observed a small but significant red shift in the SPR of the Fe2O3@Au-dithiolane-
R nanoparticles where "max increased from 520 nm to 524 nm (Figure 2.7). This minor shift provided the first 






Figure 2.7. (A) Surface modification of Fe2O3@Au nanoparticles, and (B) electronic absorption spectra showing 
the shift in absorption maximum as the nanoparticles are modified with a dithiolane derivative (lipoic acid).  
 
The exact bonding mode of the dithiolane to the gold surface is unknown. Whilst early experiments 
established that S-S bond breaks the during surface functionalisation, the exact chemical transformation at 
the surface, and the resulting structure, is not fully understood.308 Due to the uneven surface of the 
nanoparticle surface, it is believed that the final structure is polymorphic, hence it is difficult to elucidate. 
However, it has been shown by DFT, X-ray diffraction and STM that thiols tend to bind an adatom (an atom 
which lies on the crystal surface) as RS-Au-SR.309,310 In this structure the sulphur atoms can be considered as 
sp3 hybridised forming a bond to the adatom, to the gold surface and to the R group, plus an additional lone 
pair. Evidence for this bonding mode is provided by Knoppe et al. (and other publications from the same group) 
who report chirality in thiol-functionalised gold nanoclusters.311–313 However, the system cannot be as simple 
as that proposed in Figure 2.8B, as the reduction of the disulphide bond requires two electrons, and therefore, 
the oxidation of two gold atoms (Figure 2.8A). Recent work by Carro et al. used DFT calculations to probe the 
ionic nature of the bond between the sulphur atom and the adatom. They suggested a more dynamic system, 
where sulphur atoms would reform disulphides at the surface and bond to multiple adatoms, thus providing 
electrons to satisfy the oxidation states.314 
 
Figure 2.8. Proposed binding method of dithiolane derivatives to the gold surface. 
 
 
Synthesis and radiolabelling of chelate 
The dithiolane derivative (compound 2) was synthesised from a DOTAGA-PEG4 chelate. DOTOGA is an 
established chelator of Ga3+ facilitating radiochemistry with 68Ga. Due to the larger cavity size of DOTA 




























with Ga3+ : log K = 31.0)) the formation constant is lower (log K = 21.3).156 However, unlike chelates such as 
NOTA, DOTAGA provides up to 8 donor atoms.296 This allows DOTAGA to form coordination complexes with 
therapeutic radionuclides 90Y and 177Lu providing flexibility in the system once fully developed.153 For ease of 
functionalisation, lipoic acid (LA) was selected as the dithiolane derivative for coupling to DOTAGA-PEG4-NH2. 
As a dietary supplement used throughout the world, LA is commercially available, inexpensive, and can be 
modified easily to facilitate functionalisation of DOTAGA-PEG4-NH2. The activated N-hydroxysuccinimide (NHS) 
ester was formed before the addition of the DOTAGA-PEG4-NH2 to obtain DOTAGA-PEG4-NH-LA (2) via amide 
bond formation. Following the successful synthesis of compound 2, the natural gallium species was 
synthesised and characterised by using MS and UPLC. The retention time of natGa-2 on a reverse-phase C18 
column served as a reference for characterising the analogous 68Ga compound.  
 





The radiosynthesis of [68Ga]Ga-DOTAGA-PEG4-NH-LA ([
68Ga]Ga-3) was achieved in a reaction time of 10 min at 
70 oC (Scheme 2.6) with a RCC >99% (n = 5). Acetate buffer was used to ensure pH4.4, minimising the formation 



































































DCM,  3 h, 21 oC
1 Ga(NO3)3
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70 oC is required to form the metal complex.296 The reaction was monitored by radio-TLC and after 10 min no 
free 68Ga was observed (Figure 2.9). Radio-UPLC was used to further characterise the product, confirming that 
[68Ga]Ga-2 was synthesised as the elution time (Rt = 6.24 min) was equivalent to that of 
natGa-2. 
 




Figure 2.9. Radiochemical characterisation data for [68Ga]Ga-2 ([68Ga]Ga-DOTAGA-PEG4-NH-LA). (A) Radio-
iTLC with silica gel as stationary phase and citrate buffer (1 M, pH 4.5 CHECK) as the mobile phase. (B) Radio-




Functionalisation of Fe2O3@Au with [
68Ga]Ga-2 
Following the successful synthesis of the 68Ga-radiolabelled chelate, [68Ga]Ga-2, the reaction mixture was 


















































reaction proceeded quickly with a high RCC (>97%, n = 3). By using an unusual TLC eluent (MeOH/H2O 1:1 with 
0.5% HCl) we were able to move the radiometal complex ([68Ga]Ga-2) to the solvent front whilst radiolabelled 
nanoparticles remained at the baseline (Rf = 0.0 – 0.1) (Figure 2.10A). Further characterisation by PD10-SEC 
(SephadexTM desalting column-Size exclusion chromatography) indicated a RCP of 94% (n = 1) (Figure 2.10B). 
Control studies where performed to establish whether it was in fact the LA, dithiolane moiety binding to the 
surface of the [68Ga]Fe2O3@Au-Ga-2 nanoparticles. [
68Ga]Ga-DOTAGA-PEG4-NH2 (
68Ga-3) was synthesised in a 
RCC of 98%. This control compound features the same DOTAA chelate and PEG4 linker as compound 2 but 
without the LA group. When neutralised and added to the Fe2O3@Au nanoparticles, no significant 
radiolabelling was observed using PD10-SEC chromatography (Experimental; Scheme 6.2). This demonstrated 
that the binding of [68Ga]Ga-DOTAGA-PEG4-NH-LA to the Fe2O3@Au nanoparticles was mediated by the 
dithiolane group. 
 
Scheme 2.7. Radiochemical synthesis of [68Ga]Fe2O3@Au-Ga-2. 
 
 
Figure 2.10. Radiochemical characterisation data for [68Ga]Fe2O3@Au-Ga-2. (A) Radio-iTLC with silica gel as a 
stationary phase and MeOH/H2O 1:1 with 0.5% HCl as the mobile phase. (B) PD10-SEC profile with water as 
eluent. (C) RCC to [68Ga]Fe2O3@Au-Ga-2 product with changing concentration of [
68Ga]Ga-2 (in order to find 
































It was important to ascertain the maximum loading capacity of the nanoparticles to achieve the best possible 
specific activity. Therefore, we carried out a titration experiment, increasing the amount of radiolabelled 
chelate with respect to the nanoparticle. We found that a 2.33 µM concentration of [68Ga]Ga-2 saturated a 
solution of nanoparticles with a Au(0) concentration of 0.54 mM (Figure 2.11). We then used this 
concentration to extract kinetic data by taking samples of the reaction of mixture at various time points. As 
the reaction proceeded so quickly, reliable data could only be achieved by cooling the reactions to 4 oC to slow 
down the rates of conversion. By fitting the obtained data to a second-order rate law, a rate constant of k2 = 
6.25 (±1.2) x 10-2 M-1 s-1 was obtained. These data demonstrates how quickly the final radiolabeling step takes 
place, which is essential when working with short-lived radionuclides such as 68Ga. From generator elution, 
radiolabelled nanoparticles can be produced in <20 min. 
 
Figure 2.11. Kinetic data showing (A) the change of RCC over time during the synthesis of [68Ga]Fe2O3@Au-
Ga-2, and (B) the corresponding linear plot of 1/[[68Ga]Ga-2] concentration versus time in seconds. 
 
 
Photoconjugation of a radiolabelled photo-activatable complex to nanoparticle surface 
Basic Principles  
Recently, our group demonstrated the light-induced bioconjugation of photoactivatable chelates to mAbs. 
Here, photoactivatable chelates are radiolabelled and conjugated to protein lysine residues via a light-induced 
activation of an arylazide (ArN3) group on the complex.
63,315–317 The proposed mechanism for this conjugation 
is given in Scheme 2.8. Following light absorption (typically with "max 365 – 395 nm), dinitrogen is released to 
produce a short-lived, singlet, open-shell nitrene. This nitrene undergoes a series of reactions where 
intramolecular rearrangement first produces an bicyclic benzazirine and finally a ketenimine species. The 
ketenimine is a powerful electrophile that can be attacked by a strong nitrogen-based nucleophile to produce 
a 2-azepin product.63 Hydrolysis of the ketenimine competes with the nucleophile producing a azepin-2-ol 
species or the corresponding tautomers. Remarkably, experimental and computational data indicate that 
primary amines react preferentially over background quenching processes. To create radiolabelled mAbs the 




Scheme 2.8. Proposed mechanism of the nucleophilic addition following photoactivation of an ArN3. 
  
 
We hypothesised that by using amine-functionalised nanoparticles, we could conjugate radiolabelled 
photoactivatable chelates to the surface. Initially, we considered using the previously synthesised 
Fe3O4@ATPES. However, due to the positive z-potential of the nanoparticles, they were not stable at the 
optimum pH required for the photoconjugation. As the reaction depends on the nucleophilic attack of the 
primary amine (pKa ~ 10.5), a pH >7.5 is necessary to produce sufficient deprotonation.316 Therefore, we 
produced FH@APTES nanoparticles through hydrolysis of the APTES before overnight agitation with FH. The 
modified coating of FH providing sufficient stability at the required pH. Following synthesis and purification of 
FH@APTES, functionalisation was measured by using a Kaiser assay to determine the amount of amine present 
on the nanoparticle surface. This concentration of amine was found to be 31.5 mM in a 1 mg mL-1 sample of 
nanoparticle. The chelate selected for photoconjugation was a previously synthesised DOTA-PEG4-ArN3, kindly 
donated by Larissa Eichenberger.316  
 
Photoconjugation to FH@APTES  
DOTA-PEG4-ArN3 was radiolabelled with 
68Ga using previously described methods to produce [68Ga]Ga-DOTA-
PEG4-ArN3 with a RCC > 99% and a RCP of 98% (Figure 2.12). This was then used for further photoconjugation 
reactions where FH@APTES was irradiated with the chelate at 365 nm for 10 min at pH8. Due to aggregation 
of the nanoparticles a pH>8 could not be used, however more basic condition would ideal for the 
photoconjugation as it would promote the deprotonation of the free amine (pKa ~10.5).
316 Initial 
photoconjugation reactions used a chelate concentration of 2.2 mM with an amine concentration of 22.5 mM. 
At this concentration and pH negligible radiolabelling was observed with a RCC of 1.4%. Hydrolysis reactions 
can compete with the nucleophilic addition of the amine and subsequent nanoparticle conjugation. 
Decreasing the concentration of the chelate by 100-fold, increased the RCC to 4.1% (Figure 2.13A). The 
product was then purified via PD10-SEC to obtain [68Ga]Ga-DOTA-PEG4-APTES-FH with a RCP of 97%. To ensure 
that the radiolabelling was occurring via photoconjugation, several control experiments were carried out. FH 
particles with no APTES functionalisation (no amine) were irradiated with [68Ga]Ga-DOTA-PEG4-ArN3 (‘RCC’ = 
1.3%) and FH@APTES was incubated with [68Ga]Ga-DOTA-PEG4-ArN3 in the dark (‘RCC’ = 0.7%) (Figure 2.13B). 
These both produced negligible conjugation to the nanoparticles, as did irradiation of the chelate alone (‘RCC’ 










Figure 2.12. Radiochemical characterisation data for [68Ga]Ga-4 ([68Ga]Ga-DOTA-PEG4-ArN3). (A) Radio-iTLC 
with silica gel as stationary phase and citrate buffer as the mobile phase. (B) Radio-UHPLC with a C18 column 
stationary phase and 5-95% MeCN in H2O as the mobile phase. 
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0.2 M NaOAc, 70 oC
([68Ga]FH@APTES-(Ga-4))
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Figure 2.13. SEC-PD10 radiochemical characterisation data for (A) [68Ga]FH@APTES-(Ga-4) and (B) Control 
reactions where [68Ga]Ga-DOTA-PEG4-ArN3 and FH@APTES were incubated with no irradiation and [
68Ga]Ga-4 
and FH (no amine) are irradiated. 
  
Photoconjugation to Fe3O4@Alendronate 
Whilst FH@APTES could be radiolabelled by photoconjugation methods, the RCC was still relatively low at 
4.1%. We hypothesised that whilst the dextran modified coating was providing stability at the required pH, its 
steric bulk was affecting the reactivity of the primary amines. Therefore, we modified the Fe3O4 nanoparticles 
synthesised by the co-precipitation method with alendronate, a method which has been previously reported 
to functionalise the surface of iron oxide nanoparticles.318 Functionalisation was achieved via overnight 
agitation of the particles with alendronate followed by PD10-SEC purification, the amine content of the 
Fe3O4@Alendronate nanoparticles was determined to be 4.9 mM of amine in a 1 mg mL
-1 solution of 
nanoparticle. The z-potential was determined to be -48.6 ± 7.9 mV which imbues the nanoparticles with the 
required stability at the pH necessary for photoconjugation.  
 





































The photoconjugation was carried out by using the same conditions as before, with irradiation at 365 nm for 
10 min at pH8. However, due the slightly lower amine concentration on the Fe3O4@Alendronate nanoparticles 
in comparison to FH@APTES, the chelate concentration was lowered further. Here, a chelate concentration of 
70 µM was present in the reaction with an amine concentration of 4.9 mM resulting in a RCC of 7.4 ± 0.3% (n 
= 3). Purification by PD10-SEC yielded [68Ga]Ga-DOTA-PEG4-azepine-Alendonate-Fe3O4 (Figure 2.14) in a 
decay-corrected RCY of 6.0 ± 0.2% (n = 3) and a RCP of 91% (n = 1)(Figure 15A). Again, controls were carried 
out analogous to those in the previous example (Figure 2.15B). Both the no amine (‘RCC’ = 1.6%) and no 
irradiation (‘RCC’ = 1.7%) indicated negligible conjugation, demonstrating the radiolabelling of 
Fe3O4@Alendronate with [
68Ga]Ga-DOTA-PEG4-ArN3 was occurring via a photochemical process.  
 
Figure 2.15. PD10-SEC radiochemical characterisation data for, (A) [68Ga]Fe3O4@Alendronate-(Ga-4), and (B) 
control reactions where [68Ga]Ga-DOTA-PEG4-ArN3 and FH@Alendronate were incubated with no irradiation 
and [68Ga]Ga-DOTA-PEG4-ArN3 and Fe3O4 (no amine) are irradiated. 
 
2.3.3 Results and discussion - Intrinsic radiolabelling of iron oxide nanoparticles 
Radiomineralisation of nuclides onto nanoparticle surfaces  
The intrinsic radiolabelling of a range of nanoparticles (Figure 2.16) has been tested using 68Ga3+. Due to the 
gold coating of the Fe2O3@Au nanoparticles, chelate-free radiolabelling was not possible. However, an 
alternative method using 64Cu ions is presented in section 3.3.2. All other nanoparticles could be radiolabelled 
intrinsically with 68Ga3+.  
 





Fe3O4@Al(OH)3 and Fe3O4@ATPES radiolabelling 
Initially, nanoparticles synthesised using the thermal decomposition route (Fe3O4@Al(OH)3 and Fe3O4@ATPES) 
were tested. Whilst the particles have the same iron oxide core, due to the difference in coatings, different 
temperatures were necessary to allow complete radiolabelling. At room temperature, Fe3O4@ATPES could be 
radiolabelled in 10 min at pH4.4 with a RCC of 98.2%. In contrast, the radiolabelling of Fe3O4@Al(OH)3 at room 
temperature (10 min, pH4.4) only resulted in a RCC of 37.2% and elevated temperatures of 70 oC (10 min, 
pH4.4) were required to obtain a reasonable RCC of 96.1%.  
 
Figure 2.17. Radio-iTLC for the intrinsic radiolabelling of, (A) Fe3O4@Al(OH)3, and (B) Fe3O4@ATPES. Silica gel 





FH and Fe3O4 radiolabelling with 
68Ga3+  
Next, we compared the radiolabelling of FH and Fe3O4. This study was carried out in more depth to investigate 
the effects of the nanoparticle coating and to gain some insight into the kinetics of the intrinsic radiolabelling. 
As expected, heating the nanoparticles in the presence of 68Ga3+ led to incorporation of the radionuclide on 
the nanoparticle surface. Alternative TLC conditions were required due to the migration of the nanoparticles 
to the solvent front when using a standard citrate solution as the running buffer. For Fe3O4 we used a 1:1 
H2O:MeOH mixture acidified with 1% HCl. This moved any free 
68Ga3+ whilst ensuring that the radiolabelled 
nanoparticles remained at the baseline. Conversely, we used H2O to move FH particles, whilst 
68Ga3+ remained 
at the baseline. When radiolabelling the nanoparticles with 68Ga3+ at 70 oC for 10 min, these TLC conditions 
allowed us to determine a RCC of >98% (n = 3) for both nanoparticle constructs. We then used these 
established TLC conditions to determine the change in RCC over time with differing reaction temperatures 




 Figure 2.18. (A-C) Data associated with 68Ga3+radiolabelling of Fe3O4 ; (A) Change in RCC over time, (B) associated second-order kinetics plot and (C) Eyring plot. 
(D-F) Data associated with 68Ga3+radiolabelling of FH ; (D) Change in RCC over time, (E) associated second-order kinetics plot and (F) Eyring plot.  (G-I) Data 
associated with 111In3+radiolabelling of Fe3O4 ; (G) Change in RCC over time, (H) associated second-order kinetics plot and (I) Eyring plot. (J-L) Data associated 

















Kinetic interpretation of the data  
It was initially assumed that reactions would follow pseudo-first-order kinetics. If we consider a particle with 
a diameter of 12.3 nm (diameter of Fe3O4), and we assume a spherical structure, this would equate to a volume 
of ~974 nm3 and a surface area of ~475 nm2. Magnetite has an inverse spinel structure with a unit cell formula 
of (8Fe3+)(8Fe2+ + 8Fe3+) 32O2- which equates to a volume of 0.59 nm3. Each face of the unit cell has 8 O atoms 
at the surface and a surface area of 0.69 nm2. From this we are able to deduce that there are 5.3 x 104 O atoms 
in the nanoparticle with 5.5 x 103 O atoms at the surface. Therefore ~10% of oxygen atoms reside at the 
nanoparticle surface. Each reaction contained 0.1 mg of iron, which would equate to 1.79 µmol iron and 2.4 
µmol oxygen. With 10% of oxygen atoms at the surface, this would result in 0.24 µmol of surface oxygen atoms 
available in the reaction. Each reaction contained 0.19 nmol of Ga atoms which was calculated from obtaining 
the molar activity. With a 103-fold excess of surface oxygen atoms compared to Ga, an initial assumption of 
pseudo first-order is not unreasonable but the particle concentration is considerably lower. However, results 
proved otherwise. By fitting data to both pseudo-first-order and second-order kinetics, it was found that the 
experimental data reproducibly favoured second-order rate constants with increased regression coefficient 
(R2) values (Table 2.2). From this second-order fitting, bimolecular (k2 / M-1 s-1) rate constants were obtained 
(Figure 2.18, Table 2.3). Transition state theory was applied and data were fitted using the Eyring equation 
(Equation 2.2) to obtain transition state energies.  
 











Equation 2.2. Linear Eyring equation. 
ln $%&' =	
−Δ,‡












90 0.36 0.96 
70 0.79 0.99 
50 0.72 0.97 







70 0.85 0.98 
50 0.81 0.99 
37 0.97 0.97 
21 0.97 0.99 
B 
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FH and Fe3O4 radiolabelling with 
111In3+  
To further investigate the process of chelate-free radiolabelling we also measured the radiolabelling kinetics 
with 111In3+. Again, radio-iTLC conditions were established that allowed separation of the free 111In3+ and the 
radiolabelled nanoparticles (Experimental; Section 6.2.2). Using this method, reactions were monitored at 
different temperatures and the data obtained were fitted by using both first-order and second-order rate 
equations. As with 68Ga3+ labelling, R2 values proved higher when data were fitted to a second-order kinetic 
profile, and therefore, this model was used to find associated rate constants (Table 2.3). 
Thermodynamic transition state parameters 
Table 2.3 summarises the measured rate constants obtained and the corresponding thermodynamic transition 
state parameters from the kinetics studies on 68Ga3+ and 111In3+ radiolabelling of FH and Fe3O4. Whilst further 
experiments would be required to draw concrete conclusions, these initial data allows us to speculate on the 
factors affecting radiomineralisation.  
 
Table 2.3. Rate constants associated with intrinsic radiolabelling of Fe3O4 and FH. Transition theory was used 
to calculate transition energies with ∆G‡ calculated at 298.15 K. 
Nanoparticle  Radionuclide  Temperature / 
oC 
Rate constant / 
M-1 s-1 
∆H‡ / kJ mol-1 ∆S‡ / J K-1 mol-1 ∆G‡ / kJ mol-1 
Fe3O4 
68Ga3+ 70 7.46 x 104 121.2 ± 11.3  203.36 ± 36.9  
 
60.6 ± 22.2  
 
50 1.25 x 104 
37 1.02 x 103  
21 6.25 x 101 
FH 68Ga3+ 90 6.31 x 104 103.8 ± 6.66 132.6 ± 20.3 64.3 ± 12.1 
70 1.01 x 104  
50 1.21 x 103  
37 1.37 x 102  
Fe3O4 111In3+ 90 1.39 x 105  60.9 ± 12.1 19.5 ± 36.5 55.1± 22.9 
70 3.00 x 104  
50 1.80 x 104  
37 2.65 x 103  
FH 111In3+ 70 8.64 x 105  126.9 ± 43.2 241.9 ± 134.7 54.7 ± 19.4 
50 2.65 x 105 
43 5.51 x 104 
37 4.10 x 103  
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There is a positive enthalpy of activation (∆H‡) associated with 68Ga3+ and 111In3+ radiolabelling of both Fe3O4 
and FH. This was expected as our previous experiments had established that this was a heat-induced 
radiolabelling.319 We can largely assign the positive enthalpy of activation to the energy required to de-solvate 
the 68Ga3+ and 111In3+ aqua complexes, [68Ga][Ga(OH2)6]3+ and [111In][In(OH2)6]3+. However, this does not explain 
the differences in ∆H‡ observed between the Fe3O4 and FH nanoparticles when comparing the identical 
radionuclides. When observing the activation enthalpy for 68Ga3+ radiolabelling it was found to be larger for 
the non-coated Fe3O4 nanoparticles (∆H‡ = 121.2 ± 11.3 kJ mol-1) compared to the coated FH (∆H‡ = 103.2 ± 6.7 
kJ mol-1). A reasoning behind this can be found when we look at little closer at the z-potentials of the 
nanoparticles. The ζ-potentials of Fe3O4 and FH are -62.4 ± 3.5 and +38.1 ± 0.9 respectively. Whilst the 
carbohydrate coating of FH may cause a physical barrier between the radionuclide and the metal oxide 
surface, the negative charge of the coating is attractive to the metal cation and there is a reduction in 
electrostatic repulsion between the metal cation and the nanoparticle surface. As the carbohydrate coating is 
not present in the Fe3O4 nanoparticles, there is increased electrostatic repulsion between the nanoparticle 
surface and the metal cation resulting in an increased ∆H‡. The radiolabelling of Fe3O4 with 111In3+ resulted in 
a lower ∆H‡ (60.9 ± 12.1 kJ mol-1) in comparison to 68Ga3+. 111In3+ is a softer Lewis acid than 68Ga3+ and the 
smaller charge-to-size ratio reduces the electrostatic repulsions felt due to the positive ζ-potential of the 
nanoparticles. 
 
As radiolabelling is an associative mechanism, a negative entropy of activation (∆S‡) might be expected. 
However, a positive ∆S‡ is observed for all experiments. This can mainly be attributed to two factors; (i) the 
de-solvation of the 68Ga3+ and 111In3+ aqua complexes and (ii) the disruption to the EDL solvation shell 
surrounding the nanoparticle surface. We could assume a greater change in ∆S‡ for [68Ga][Ga(OH2)6]3+ de-
solvation due to the hard water ligands binding tightly to the hard Ga3+ centre, however, there are no distinct 
patterns when comparing ∆S‡ for 68Ga3+ and 111In3+ radionuclides. Therefore, we chose to investigate the 
disruption to the EDL solvation shell by monitoring the change surface charge. To do this we measured z-
potential at different time points following the addition of Ga3+ and In3+ to FH and Fe3O4 (Figure 20). There is 
a dramatic increase in z-potential when Fe3O4 is labelled with Ga3+ which explains the increased entropy of 
activation (∆S‡). As the z-potential increases there is an alteration in the solvation shell resulting in a large 
rearrangement of solvation molecules during the transition state. The ∆S‡ value is less pronounced with FH as 
the coating shields surrounding water molecules and prevents major changes of the solvation shell, causing a 
smaller change in transition state entropy with ∆S‡  = 19.5 ± 36.5 J K-1 mol-1. These properties of In3+ also cause 
a subtle change in the z-potential as it mineralises on the surface. This results in a smaller disruption of the 
solvation shell and a smaller ∆S‡ in comparison to 68Ga3+ labelling. Unfortunately, it is a little more difficult to 
draw conclusions from the 111In3+ labelling of FH. Due to the increased pH of the FH nanoparticles, an acetate 
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buffer was necessary as the formation of the insoluble In(OH)3 was observed. Therefore, this reaction has a 
large ∆S‡ (241.9 ± 134.7 J K-1 mol-1) associated, however, this is likely due to the dissociation of the indium 
acetate complex.  
 
Figure 2.20. Change in the z-potential of, (A) Fe3O4, and (B) FH over time at room temperature with following 
the addition of 68Ga3+ and 111In3+. 
 
 
Thiol mediated radiolabelling of Fe2O3@Au 
Basic Principles  
Due to the Au coating of the Fe2O3@Au, surface radiomineralisation onto the iron oxide cannot occur and 
intrinsic radiolabelling with 68Ga3+ ions could not be achieved by using the same methods described above. 
Zhao et al. have reported chelate-free radiolabelling of gold nanoparticles, although this was achieved via the 
radiochemical doping (‘hot plus cold’ precursor) method.210 To our knowledge, there are no reports of the 
chemisorption of radionuclides onto the surface of pre-fabricated gold nanoparticles. Therefore, we sought 
to develop a method to achieve the chelate free radiolabelling of Fe2O3@Au.  
 
Research from the group of Thomas Bürgi (University of Geneva) demonstrated the thiol mediated exchange 
of metal ions between stoichiometrically discrete gold nanoclusters with the molecular formula 
Au38(SC2H4Ph)24.320,321 They discovered that the gold nanoclusters acquire small concentrations of silver atoms 
through interactions with the thiol groups present in the structure of the clusters. Based on these 
observations, we hypothesised that intrinsic radiolabelling of Au nanoparticles could occur via a thiol-
mediated process. 
 
Radiolabelling with 64Cu2+ 
Initially, we established whether radiolabelling could be achieved without thiol functionalisation. Bare 
Fe2O3@Au nanoparticles were incubated with 64Cu2+. After 60 min, radio-iTLC indicated confirmed 
A B
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radioactivity remained unbound and did not associate with the nanoparticle surface (Figure 2.23). Following 
this, we functionalised the Fe2O3@Au particles with thiol PEG which provided the surface thiol groups 
necessary whilst also offering stability. Incubation (1 h at 21 oC) of Fe2O3@Au with CH3-PEGn-SH  (where n = 
800) prior to treatment with 64Cu2+ indicated successful radiolabelling. By using radio-iTLC, it was established 
that the radioactivity remained associated with the nanoparticles (Figure 2.21A); with 50 mM DTPA as the 
mobile phase ‘free’ 64Cu2+ migrated to the solvent front whilst the nanoparticle product ([64Cu]Fe2O3@Au-(-S-
PEGn-CH3)-Cu) remained at the baseline. To determine the best reaction conditions varying temperatures were 
tested with aliquots taken at various time points (Figure 2.21B). It was found that at temperatures between 4 
- 37 oC, RCCs increased between 0 - 60 min, whilst at 50 oC, RCCs increased until 20 min, when the nanoparticles 
precipitated from solution. Following the study, it was determined that the highest RCC occurred when heating 
at 37 oC for 1 h (RCC = 91.1 ± 1.8%, RCP = 85.3 ± 8.6%; n = 2) (Figure 2.22B) and 50 oC for 20 min (RCC = 93.3 
± 1.2%, RCP = 93.3 ± 1.2%; n = 2)(Figure 2.22A). Due to the increased RCP of the crude product at 50 oC for 20 
min, the product was purified giving the radiolabelled product with a RCY of 74.8% and RCP of 99.6% (Figure 
2.22C). Finally, it was necessary to establish that binding was not occurring via complexation to free thiol 
groups. Therefore, control reactions were performed by incubating 64Cu2+ with CH3-PEGn-SH. Radio-iTLC 
confirmed that the activity did not associate with the CH3-PEGn-SH and remained free 64Cu2+ (Figure 2.23). 
 




























Figure 2.21. (A) Radio-iTLC for the thiol-mediated intrinsic radiolabelling of Fe2O3@Au(-S-PEGn-CH3) with 
64Cu2+. Silica gel as stationary phase and 50 mM DTPA as the mobile phase. (B) RCCs with differing 
temperatures and reaction times.  
 
 
Figure 2.22. PD10-SEC profiles of crude reactions at, (A) 50 oC for 20 min, and (B) 37 oC for 1 h. (C) PD10-SEC 
profiles of purified product obtained from the reaction at 50 oC for 20 min. 
 
 
Figure 2.23. Control studies for thiol-mediated radiolabelling. Radio-iTLC of (A) Bare Fe2O3@Au and 64Cu2+ and 










These experiments have demonstrated the thiol-mediated uptake of 64Cu2+ radiometal ions into Fe2O3@Au(-
S-PEGn-CH3) nanoparticles. Whilst the incorporation of other radionuclides has not been attempted, previous 
works demonstrate the uptake of Ag atoms, which indicates that this method has the potential to act as a 
versatile method to intrinsically label gold nanoparticles.320 
 
2.4 Conclusion 
Here, we have presented studies on the synthesis and characterisation of a variety of nanoparticle structures 
and their corresponding radiolabelling methods. Nanoparticles were synthesised by using the co-precipitation 
and thermal decomposition routes. For the latter, surface modifications allowed the transfer of nanoparticles 
from a dispersion in organic solvent to an aqueous phase, which was necessary for the subsequent 
radiochemistry and any potential biological applications.  
 
Initially, classical radiolabelling routes were explored. Fe2O3@Au nanoparticles were labelled with a high RCC 
and RCP when using a disulphide, chelate-based method. FH and Fe3O4 nanoparticles were radiolabelled by 
using a photoconjugation method. To our knowledge, this is the first study of its kind, and data demonstrate 
that photoradiolabelling methods can potentially be adapted for use with nanoparticles. However, this 
photoconjugation route produced very low yields and further optimisation is required. 
 
Chelate-free, intrinsic methods of radiolabelling were also investigated. Nanoparticles could be radiolabelled 
without the use of a chelate or prosthetic group which produces minimal change to the nanoparticle structure 
or properties. Our kinetic studies of 68Ga3+ and 111In3+ surface mineralisation have indicated that nanoparticles 
can be radiolabelled with high RCC in <5 min. This is beneficial as rapid radiolabelling in the final step of 
synthesis is an ideal method for making radiotracers with short-lived radionuclides. We have also developed 
a method for allowing the chelate-free radiolabelling of gold nanoparticles where thiols mediate uptake of the 
radionuclide, again fast reaction times and high RCCs highlight the benefits of employing this technique.  
 
Overall, we have synthesised and investigated several nanoparticle constructs and explored methods by which 
to radiolabel them. In Chapter 3 we use these develop constructs to produce radiolabelled, biologically 
















3.1 Aims of the chapter 
Due to recent developments in PET/MRI technology, there is now a need for the development of multi-modal 
imaging agents. By combining PET and MRI capabilities into one construct, it would be possible to administer 
only one contrast agent into a patient as opposed to two. This prevents unreliable results due to differing 
pharmacokinetics and pharmacodynamics of the two contrast agents. As mentioned in the introduction, iron 
oxide nanoparticles are of importance in the design of PET/MR imaging agents due to their ability to accelerate 
the T2 relaxation times of nearby protons. They can also be radiolabelled with a positron emitting radionuclide 
via classical or non-classical methods for PET imaging.  
 
In this chapter, we utilised both the classical and non-classical radiolabelling methods which were developed 
in Chapter 2. Specifically, experiments used the 68Ga-DOTGA-PEG4-LA conjugation to Fe2O3@Au nanoparticles 
and the chelate free 68Ga radiolabelling of the Feraheme® (FH). 68Ga is an ideal radionuclide because it is 
readily available from a commercial 68Ge/68Ga generator and the relatively short half-life of 68Ga minimises 
radiation exposure to the patients. A major aim of this work was to synthesise biologically targeted 
nanoparticles. For this purpose, we chose to target the nanoparticles towards PSMA. Here, we report the 
synthesis of two PSMA-targeted, radiolabelled nanoparticle constructs. This research is key in the 
development in PET/MR imaging agents for molecular imaging.  
 
3.2. PSMA targeting 
As introduced in Chapter 1 (Section 1.2.3), PSMA is a transmembrane glycoprotein that is over-expressed in a 
number of prostate cancers.24 Despite antibody binding being a possibility, small-molecule binders tend to be 
more favourable when developing diagnostic imaging agents as they exhibit shorter circulation times and increased 
tumour penetrability.42 A large number of reported small-molecule binders belong to the group of urea-based 
compounds including Glu- NH-CO-NH-Lys analogues which are potent PSMA binders. For example, [68Ga]Ga-Glu-
NH-CO-NH-Lys(Ahx)-HBED-CC, which is commonly known as 68Ga-PSMA-11, has a dissociation constant (Kd) value of 
2.89 ± 0.55 nmol L-1 when binding to PSMA-expressing LNCaP cells.322,323 Therefore, we selected small-molecule Glu-
NH-CO-NH-Lys derivatives to target our nanoparticle constructs. 
 
The synthesis of Glu-NH-CO-NH-Lys (9) is typically achieved via a resin-based approach.324 However, solid-phase 
peptide synthesis (SPPS) is often only suitable for producing small quantities of product due to the use of expensive 
resins and preparative HPLC purification. Therefore, by modifying a published resin based synthesis, we devised a 
route where larger quantities of compound 9 could be obtained by simply purifying each product at each synthetic 
step (Scheme 3.1).324 The Glu-NH-CO-NH-Lys residue contains two chiral centres. Due to the shape of the PSMA 
binding pocket the S,S (L-Glu, L-Lys) configuration exhibits binding, whilst the R,R enantiomer (D-Glu, D-Lys) and the 
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R,S (D-Glu, L-Lys) and S,R (L-Glu, D-Lys) diastereoisomers are reported as non-binders.325 To obtain the S,S-
configuration, the naturally occurring L-glutamic acid and L-lysine were used as starting materials. For compatibility 
with the triphosgene-mediated urea formation, a benzyl carbamate group (CBz) was used to protect the amine 
group in the lysine side chain. This CBz group allows selective deprotection, leaving the t-butyl carboxylic acid 
protecting groups in place. This produced compound 8 (in an overall yield of 11%), the tris-t-butyl protected Glu- NH-
CO-NH-Lys residue where the free amine is available for further conjugation. The t-butyl groups can be removed by 
using acidic conditions to produce the fully deprotected compound 9. These compounds are further used during this 
chapter to selectively targeted nanoparticles towards PSMA expressing cells.  
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3.3 Chelate conjugated, 68Ga radiolabelled, PSMA targeted gold coated iron oxide 
nanoparticles for PET/MR imaging  
 
3.3.1 Introduction 
In chapter 2, we introduced the Fe2O3@Au nanoparticles and their radiolabelling with a DOTAGA lipoic acid 
derivative ([68Ga]Ga-2). Radiolabelling was easily achieved with high RCC and RCP. Whilst a two-step synthesis 
was necessary, the product could be obtained quickly in only 20 minutes from generator elution. Also, the 
disulphide interaction with gold was initially selected due to the reported strength of the Au-S bond and 
resistance to dissociation (Au-S bond dissociation energy, Do298 = 418 ± 25 KJ mol-1).326–328 The radiolabelled 
Fe2O3@Au construct, therefore, became an ideal candidate to modify further for biological applications. 
 
3.3.2 Results and discussion 
Synthesis and Characterisation 
As we had established the success of radiolabelling using a lipoic acid moiety, it was logical to functionalise 
compound 9 by using the same NHS activated lipoic acid (Chapter 2). The final compound, 10, was obtained 
and characterised by NMR and HR-MS before functionalising the Fe2O3@Au NPs (Scheme 3.2). Since the 
maximum disulphide loading capacity of Fe2O3@Au was established previously by using [68Ga]Ga-2, we worked 
at this total disulphide concentration with a 1:1 ratio of [68Ga]Ga-2 and 10. Whilst we had established that the 
reaction was completed with [68Ga]Ga-2 in around 60 s, we incubated the reaction at room temperature for 5 
min to ensure complete conjugation of compound 10 to the Fe2O3@Au NPs. Characterisation of 
[68Ga]Fe2O3@Au-(Ga-2)-10 by radio-iTLC gave a RCC >94% (n = 3), and PD10-SEC chromatography indicated a 














Scheme 3.2. (A) Chemical synthesis of the Glu-NH-CO-NH-Lys lipoic acid derivative (Glu-NH-CO-NH-Lys-LA, 10) (B) 





Figure 3.1. Radiochemical characterisation data for [68Ga]Fe2O3@Au-(Ga-2)-10 (A) Radio-iTLC with silica gel as 


















































































Following the successful synthesis of [68Ga]Fe2O3@Au-(Ga-2)-10, we obtained two constructs for further 
characterisation and biological evaluation (Figure 3.2). [68Ga]Fe2O3@Au-(Ga-2) was loaded with the same 
amount of [68Ga]Ga-2 to obtain equal specific activities for both constructs (12.1 kBq µg-1). DLS analysis of the 
corresponding non-radiolabelled (‘cold’) constructs showed modification of the nanoparticle surface had little 
effect on the hydrodynamic diameter (Figure 3.3 and Table 3.1). Repeated measurements were also taken 24 
hours after functionalisation, indicating the stability of the functionalised nanoparticles in water with respect 
to aggregation over time. Functionalisation causes slight changes in T2 relaxation times. Whilst these are only 
small variations, addition of the diamagnetic Ga3+ subtly decreased the T2 relaxation time of the Fe2O3@Au-
(Ga-2) construct in comparison to the bare Fe2O3@Au. In contrast, the Fe2O3@Au-(Ga-2)-10 construct showed 
a slight increase in T2 relaxation time. We postulate that this may be due to saturated disulphide layer limiting 
the proximity of the water molecules with the NP surface. z-potential measurements do not vary significantly 
and exhibit large errors, but the observed trends in the measured mean values are indicative of 
functionalisation. Functionalisation with Ga-2 causes a decrease in z-potential with addition of the 









































































Stability studies  
Whilst particles are stable in water, it was noticed that the nanoparticle constructs begin to aggregate in salt 
solutions (saline or PBS) over significant periods of time (>24 h). Stable Fe2O3@Au nanoparticles exhibit a 
pink/red appearance due to the SPR effect.329 Following addition of saline or PBS particles appear black (Figure 
3.4A) indicating aggregation of the nanoparticles. It was established that the addition of protein stabilised the 
nanoparticles via the formation of a protein corona.330 When nanoparticles are exposed to protein, a dynamic, 
multi-layered ‘cloud’ is formed around the surface. This acts as a surfactant and prevents aggregation when 
nanoparticles are exposed to a highly ionic solution. Figure 3.4 shows that the addition of fetal bovine serum 
(FBS) at concentrations of 10% and 1% stabilises the nanoparticles, preventing aggregation. The formulation 
at 1% was then used for further biological assays. 
 
Figure 3.4. (A) Visible aggregation of the nanoparticles following addition of saline and PBS. Photograph was 
taken 24 hours after addition of solutions and samples were vortexed before immediately before to re-
disperse aggregated particles. (B) UV-visible spectra recorded between 500-600 nm. Samples exhibit strong 
























time / ms 
Fe2O3@Au 48.6 ± 25.0 -33.7 ± 14.7 24.86 ± 0.01 
Fe2O3@Au-(Ga-2) 49.7 ± 24.53 -40.6 ± 10.4 23.70 ± 0.01 
Fe2O3@Au-(Ga-2)-10 45.7 ± 22.3 -42.5 ± 13.3 28.77 ± 0.02 
Table 3.1. Characterisation data for [68Ga]Fe2O3@Au-(Ga-2) and 
[68Ga]Fe2O3@Au-(Ga-2)-10 (Fe2O3@Au present for comparison). 
Figure 3.3. DLS profiles of 
constructs 
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Prior to biological assays, it was important to establish the stability of the functionalised nanoparticles in 
physiologically relevent conditions. By incubating in different media, we were able to determine if free 68Ga3+ 
or chelate bound 68Ga3+ ([68Ga]Ga-2) dissociated from the nanoparticle construct (Figure 3.5). Standard 
solutions of saline and PBS (both with the addition of 1% FBS) saw negligible dissociation of activity from the 
nanoparticles. An EDTA solution (pH7.1, 25 mM) was used as a chelate challenge and again, minimal loss of 
activity was observed. Due to the presence of disulphides and thiols in vivo it was important to establish their 
potential to displace [68Ga]Ga-2. For this we used a solution of cysteine (25 mM) at a concentration far in 
excess of that found in vitro and in vivo.331–333 We found that the majority of the activity remain bound to the 
particles. However, the greatest dissociation was seen at 2 h for [68Ga]Fe2O3@Au-(Ga-2)-10. Here, 59% of 
activity remained bound. The greater loss was attributed to this nanoparticle having a more saturated surface 
than [68Ga]Fe2O3@Au-(Ga-2), hence more displacement of the [68Ga]Ga-2 took place. Although a significant 
amount of dissociation is observed, both constructs remain relatively intact at the 1 h time point. Given the 
short half-life of 68Ga, this time frame is acceptable for cell assays and in vivo imaging.  
 
Figure 3.5. RCP over time of [68Ga]Fe2O3@Au-(Ga-2) and [68Ga]Fe2O3@Au-(Ga-2)-10 when incubated with, (A) 










Cellular assays  
Following successful synthesis and stability studies, the specific binding of the radiolabelled nanoparticles on 
PSMA-expressing cells was investigated. LNCaP cells are human prostate cancer cells derived from a metastatic 
site and are known to over express PSMA.334 When incubating LNCaP cells (PSMA +ve) with [68Ga]Fe2O3@Au-
(Ga-2) and [68Ga]Fe2O3@Au-(Ga-2)-10 we observed an increase in uptake associated with the Glu- NH-CO-NH-
Lys containing construct, [68Ga]Fe2O3@Au-(Ga-2)-10 (Figure 3.6). This is an initial indication that specific uptake 
is observed when the Glu-NH-CO-NH-Lys is present. It also acts as a positive indication that modification with 10 
was successful, which was to be expected given that the chemistry of the conjugating group was identical to that of 
[68Ga]Ga-2. To further investigate the specificity of the cellular uptake, a parallel experiment with the addition 
of 0.1% sodium azide was performed. Azide inhibits phagocytosis, preventing the internalisation of the 
nanoparticles. When azide was present, an approximate 3-fold decrease in uptake was observed for both 
[68Ga]Fe2O3@Au-(Ga-2) and [68Ga]Fe2O3@Au-(Ga-2)-10, which indicated a large proportion of nanoparticle 
uptake is due to phagocytosis of the nanoparticles. A blocking study was also carried out where cells were pre-
incubated with the free PSMA ligand (Glu-NH-CO-NH-Lys, 9). This prevents the binding of [68Ga]Fe2O3@Au-(Ga-
3)-10 causing an approximate 2-fold decrease in comparison to the non-blocked sample. Finally, we compared 
the binding of the nanoparticles on LNCaP (PSMA +ve) cells with that observed on PC-3 (PSMA -ve) cells which 
do not express the PSMA protein. When using PC-3 cells (highlighted in blue, Figure 6), no significant difference 
was observed in the binding of [68Ga]Fe2O3@Au-(Ga-2) and [68Ga]Fe2O3@Au-(Ga-2)-10, indicating that the 
cellular association was non-specific. Also by comparing [68Ga]Fe2O3@Au-(Ga-2)-10 in LNCaP (PSMA +ve) and 
















Figure 3.6. Cellular binding assay of [68Ga]Fe2O3@Au-(Ga-2) and [68Ga]Fe2O3@Au-(Ga-2)-10 with the LNCaP 
(PSMA +ve) and PC-3 (PSMA –ve) cell lines. Data given as activity bound per 1 mg mL-1 of protein. Where stated 
cell media contained 0.1% azide and protein content was measured using a BCA assay. For the LNCaP cell line: 
[68Ga]Fe2O3@Au-(Ga-2) versus [68Ga]Fe2O3@Au-(Ga-2)-10, p≤0.01. When azide was present: [68Ga]Fe2O3@Au-
(Ga-2) vs. [68Ga]Fe2O3@Au-(Ga-2)-10, p ≤0.05. Blocking assay with the LNCaP (PSMA +ve) cell line pre-treated 
with free Glu-NH-C(O)-NH-Lys ligand (5 µM) before addition of radiotracers. For [68Ga]Fe2O3@Au-(Ga-2)-10: 
blocked vs. non-blocked: p ≤0.01. Comparison of cell lines: PC-3 versus LNCaP [68Ga]Fe2O3@Au-(Ga-2)-10, p 
≤0.01; [68Ga]Fe2O3@Au-(Ga-2), ns. Note: Student’s t-test analysis: ns = not significant, * = P-value <0.05, ** = 





In vivo studies  
Following the success of the cellular assays, the distribution of the PSMA-targeted [68Ga]Fe2O3@Au-(Ga-2)-10 
was evaluated via the acquisition of PET images (Figure 3.7). For ethical reasons, an initial pilot study was 
performed by using a single athymic nude mouse bearing a subcutaneous LNCaP tumour. Unfortunately, no 
significant tumour uptake was observed. By 30 min the majority of activity was found in liver where it 
remained, with very little change observed at 3 h. Activity can also be seen in the bladder which is indicative 
of chelate dissociation or demetallation of the 68Ga3+ from the nanoparticle. However, the excretion of activity 
by the renal pathway was minimal in comparison to the retention of activity in the liver allowing us to conclude 
that the particles remain relatively stable whilst in the blood pool. It can be assumed that liver uptake is due 
to macrophage uptake, particularly phagocytic Kupffer cells. Whilst the surface charge is already negative this 
could be improved further by, for example, the addition of a PEG coating. Furthermore, the presence a protein 
corona may alter the surface charge in vivo and this may flag the constructs to macrophages. Due to the rapid 
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blood pool clearance, and dominant sequestration of the activity in the liver observed in the pilot study, no 
further imaging experiments were performed on these constructs. 
 
Figure 3.7. Coronal PET images recorded at 30 min and 3h post-administration of [68Ga]Fe2O3@Au-(Ga-2)-10 





In summary, we have synthesised Fe2O3@Au nanoparticles targeted towards PSMA and radiolabelled with 
68Ga using a DOTAGA-PEG derivative. Whilst promising radiochemical and cellular results were obtained, 
imaging in vivo proved unsuccessful. Whilst a small PEG chain is conjugated to the nanoparticles, experimental 
evidence indicated that this is insufficient to prevent clearance from the blood pool and uptake via the 
macrophage system causing accumulation and retention of the activity in the liver. To improve this, a longer 
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3.4. Chelate free, 68Ga radiolabelled, PSMA targeted Feraheme® nanoparticles for PET/MR 
imaging 
3.4.1 Introduction 
Following the successful chelate free 68Ga radiolabelling of FH, we chose this method to develop a biologically 
targeted, chelate-free radiolabelled nanoparticle. To modify the nanoparticles, we chose to use a 
bisphosphonate anchor. Bisphosphonates are known to have a high affinity for metals and can even 
coordinate to numerous different metal ions forming complexes.335 They are also known to conjugate to the 
surface of iron oxide nanoparticles.336 Therefore, research focused on the synthesis of a Glu-NH-CO-NH-Lys 
bisphosphonate derivative. The resulting compound was used to modify FH before subsequent radiolabelling and 
biological studies.  
 
3.4.2 Results and discussion 
Synthesis of small molecules 
Scheme 3.3. Synthesis of the PEGylated ethyl protected bisphosphonate, 13, NH2-CH2-CH2-PEG4-C(O)NH-
C(PO(OEt)2)2. 
 
To allow for easier purification, the ethyl protected bisphosphate (11) was first synthesised by using literature 
methods.337 An amide coupling was then performed to conjugate a tert-butyloxycarbonyl (BOC) protected 
PEG4 linker. Following deprotection, compound 13 was obtained in 81% yield which provided a basis for 
further modification at the free amine. Two derivatives of 13 were synthesised, the first being the Glu-NH-CO-
NH-Lys in the S,S (L-Glu, L-Lys) configuration (Scheme 3.4). A urea linkage between 9 and 13 was synthesised by 
using the triphosgene-generated isocyanate intermediate of 9. This was attacked by the free amine of 13 creating 




























































groups were deprotected by using bromotrimethylsilane (TMBS). This yielded the final compound 16 in an overall 
yield of 31%. The second derivative of 13 synthesised was the negative control, featuring the R,R enantiomer (D-Glu, 
D-Lys) of Glu-NH-CO-NH-Lys. In this configuration, no binding to PSMA is reported. In analogous conditions 21 was 
synthesised (Experimental; Scheme 6.11). 
 
Scheme 3.4. (A) Chemical synthesis of the functionalisation of the PEGylated bisphosphonate with the PSMA 








































































































































Functionalisation of FH 
Following the successful synthesis of the bisphosphonate Glu- NH-CO-NH-Lys derivatives, compounds 16 and 21 
were used to modify FH nanoparticles. After overnight reactions and PD10-SEC purification, FH-16 and FH-21 were 
obtained. ICP-MS measurements and z-potentials were initially used to establish successful modification. ICP-MS 
analysis indicated that phosphorous was present in comparison to non-functionalised FH particles. FH-21 contained 
2.99 ± 0.11 µg of phosphorous per 1 mg of iron compared with FH which only contained 0.049 ± 0.001 µg. 
Secondly, z-potential measurements indicated lower z-potentials when functionalised with the 16 and 21 (Table 
3.2). This is expected due to the addition of both the bisphosphonate group and the carboxylated PSMA groups. 
Interestingly, z-potentials differ before and after PD10-SEC, for example, bare FH goes from -57.8 ± 6.29 mV to -
7.51 ± 0.54 mV. This is partially due to the fact saline is used as the eluent, hence, this highly ionic solvent alters the 
solvation shell. However, this decrease could also be due to a break-down in the dextran coating. Unfortunately, we 
did not study the stability of the coating towards Sephadex® material used as the stationary phase in the PD10 
column; however, this could be a possible cause for the dramatic increase in z-potential.  
 
Table 3.2. z-potential measurements of FH, FH-16 and FH-21. This highlights the importance of dispersant and the 
effects of exposing the nanoparticles to PD10-SEC. 
 
Particle type Before/after PD10-SEC Dispersant z-potential / mv 
FH Before Water -57.8 ± 6.29 
FH After Saline -7.51 ± 0.54 
FH-16 After Saline -17.0 ± 0.52 
FH-21 After Saline -15.3 ± 1.59 
 




Radiolabelling was achieved in 20 min with gentle heating (70 oC) of the nanoparticles. For both FH-16 and FH-
21, a RCC >98% was achieved and RCP >94% (Figure 3.9). This provided high specific activities of 1.15 MBq  
µg-1 for [68Ga]FH-16-Ga and [68Ga]FH-21-Ga. The radio-mineralisation process facilitates this high loading of 
68Ga3+ ions onto the nanoparticle surface. Therefore, this method of non-classical chelate-free radiolabelling 
provides high specific activities with high RCCs and RCPs in a simple, one-step synthesis. The stabilities of the 
[68Ga]FH-16-Ga and [68Ga]FH-21-Ga constructs were evaluated by incubation in saline, PBS and EDTA (40 mM, 
pH7.1) (Figure 3.10). Constructs remained stable when incubated with saline and PBS for 2 h at 37 oC, with 
minimal dissociation of activity from the nanoparticle surface. The chelate challenge showed a considerable 
amount of dissociation (50%) when particles were exposed to EDTA. However, up to 1 h this loss is negligible, 
and the concentration is considerably higher than any conditions that would be experienced in vivo.  
 
Figure 3.9. Radiochemical characterisation data for [68Ga]FH-16-Ga and [68Ga]FH-21-Ga. (A) Radio-iTLC data 
with silica gel as stationary phase and citrate buffer as mobile phase. RCCs were extracted and found to be 
99.1 ± 0.5% for [68Ga]FH-16-Ga and 98.6 ± 0.3% for [68Ga]FH-21-Ga (where n = 3). (B) PD10-SEC traces with 
saline as eluent. RCPs were found to be 95.2% for [68Ga]FH-16-Ga and 94.3% for [68Ga]FH-21-Ga. 
 
 
Figure 3.10. RCP over time of [68Ga]FH-16-Ga and [68Ga]FH-21-Ga when incubated with (A) PBS, (B) saline, 






Cellular assays  
Following successful radiochemical stability studies, cellular assays were performed to evaluate the specific 
uptake of the nanoparticle constructs. Figure 3.11A shows the cellular binding of constructs [68Ga]FH-16-Ga 
and [68Ga]FH-21-Ga to LNCaP (PSMA +ve) cells. When no azide is present, no significant difference was 
observed between the binding of [68Ga]FH-16-Ga and [68Ga]FH-21-Ga on LNCaP cells. Whilst the mean cell 
associated activity is in favour of increased [68Ga]FH-16-Ga uptake, it would appear that non-specific 
internalisation is causing a large error associated with the result. When cells are exposed to azide during the 
cellular binding assay, a significant difference in cell uptake was observed between [68Ga]FH-16-Ga versus  
[68Ga]FH-21-Ga. Here, internalisation is prevented and results reflect the PSMA binding on the surface of the 
cell. To confirm this specific uptake, a blocking assay was performed (Figure 11B). In contrast to other PSMA 
blocking assays performed during this thesis, here, 2-PMPA was used as opposed to the free Glu-NH-CO-NH-
Lys ligand (10). 2-PMPA is a well-known PSMA binder, introduced in Chapter 1 (Section 1.2.3).25  When cells are 
treated with 2-PMPA prior to the addition of [68Ga]FH-16-Ga, a significant decrease in the uptake of the 
radiotracer was observed.  
 
Figure 3.11. (A) Cellular binding assay of [68Ga]FH-16-Ga and [68Ga]FH-21-Ga with the LNCaP (PSMA +ve) cell 
line. Data given as the percentage of activity bound normalised per 1 mg mL−1 of total protein. When stated 
cell media contained 0.1% azide, and protein content was measured using a BCA assay. [68Ga]FH-16-Ga vs. 
[68Ga]FH-21-Ga (with azide), p ≤ 0.001; [68Ga]FH-16-Ga vs. [68Ga]FH-21-Ga (no azide), ns. (B) Blocking assay 
with the LNCaP (PSMA +ve) cell line pre-treated with 2-PMPA (5 μM) before addition of [68Ga]FH-16-Ga. 
Blocked [68Ga]FH-16-Ga: with azide, p ≤ 0.05; without azide, p ≤ 0.001. Note: Student's t-test analysis: ns = not 






In vivo studies  
Small-animal PET images were acquired by using athymic nude mice bearing subcutaneous LNCaP tumours (n 
= 3). By 30 min post-administration, the majority of the activity associated with [68Ga]FH-16-Ga accumulated 
in the liver and no significant tumour uptake was observed (Figure 3.12A). At t = 2 h post-injection, mice were 
euthanised and biodistribution studies performed. Ex vivo analysis confirmed that the majority of the activity 
remained in the liver and spleen with very little tumour uptake. Due to the lack of success of the initial imaging 
study with [68Ga]FH-16-Ga, no further control studies were carried out in order to minimise the number of 
animals used. Despite the poor pharmacokinetic profiles and negligible tumour uptake, minimal activity was 
observed in the bladder and in the kidney following the biodistribution. The larger size of the nanoparticle 
constructs means that uptake into the liver is expected, whilst any dissociated activity would likely be excreted 
via the renal system. It is, therefore, logical to conclude that the activity remained bound to the nanoparticles 
demonstrating the stability of the constructs in vivo. This highlights the potential of using chelate-free, intrinsic 
radiolabelling in the radiosynthesis of metal oxide-based radiotracers.  
 
Figure 3.12. (A) PET image of a mouse bearing a LNCaP tumour, T = tumour. 30 min coronal PET image 
recorded following injection with [68Ga]FH-16-Ga. (B) Biodistribution data showing the accumulation of 





FH nanoparticles have been modified with a Glu-NH-CO-NH-Lys bisphosphonate derivative (16) to create a 
PET/MR agent targeted towards PSMA (FH-16). The radiolabelling of FH-16 provided specific activities of 1.15 MBq 
µg-1. This is 100-fold greater than the specific activities achieved with the chelate based methods in the 
radiolabelling of Fe2O3@Au nanoparticles (12.1 kBq µg-1). Although cellular studies proved promising, in vivo 







z-potential of the nanoparticles was not sufficiently negative to avoid macrophage uptake. Future work should 
concentrate on modifying the coating which could provide a particle size and surface charge sufficient to avoid 
accumulation in the liver. On a positive note, our experiments provide strong support that chelate-free 
intrinsic radiolabelling can be used to radiolabel nanoparticles, with advantages of simplicity and superior 









Chapter 4: Multi-functionalised graphene nanoflakes as tumour-
targeting theranostic drug-delivery vehicles  
 
 
Adapted from  




4.1 Aims of chapter  
In this chapter, we present a theranostic agent synthesised using graphene nanoflakes (GNFs). GNFs consist 
of a graphene sheet approximately 30 nm in diameter with a pristine aromatic system and an edge terminated 
with carboxylic acid groups. Their high water solubility and relative ease of functionalisation using carboxylate 
chemistry means that GNFs are potential scaffolds for the synthesis of theranostic agents. In this work, GNFs 
were multi-functionalised with derivatives of (i) a peptide-based Glu-NH-C(O)-NH-Lys ligand that binds 
prostate-specific membrane antigen (PSMA), (ii) a potent anti-mitotic drug (R)-ispinesib, (iii) the chelate 
desferrioxamine B (DFO), and (iv) an albumin-binding tag reported to extend pharmacokinetic half-life in vivo. 
Subsequent 68Ga radiochemistry and experiments in vitro and in vivo were used to evaluate the performance 
of GNFs in theranostic drug design.  
 
4.2 Introduction  
In recent years, graphene-based nanomaterials have been studied for potential use in various biological 
applications.338 For instance, modified graphene nanomaterials and carbon nanotubes have potential for use 
in anti-cancer treatments, as drug delivery vehicles, and in diagnostic imaging.255,339–341 If these different 
applications can be combined then graphene nanomaterials could be used in the synthesis of theranostic 
agents.342 The covalent modification of graphene sheets and carbon nanotubes is chemically challenging. 
Disrupting the delocalised p-bonding network of the graphene sheet is thermodynamically unfavourable, due 
to steric and electronic factors.343 Most reactions that lead to graphene or nanotube functionalisation 
overcome these issues by exposing the material to harsh reagents and conditions.344 As a result, the activation 
chemistry often forms a heterogeneous surface consisting of different graphene oxide (GO) and reduced 
graphene oxide (rGO) groups.345–347 Modification of the oxygen-containing functional groups on GO and rGOs 
is relatively simple and the increased polarity improves water solubility of the sheets.  
 
While GO and rGO are promising scaffolds for drug design, the heterogenous chemical nature of graphene 
materials is an issue. Specifically, standard GO and rGO materials contain varying amounts of oxide, hydroxide 
and epoxide groups scattered throughout their structure. This makes it challenging to control the chemo- and 
regioselectivity of functionalisation reactions. In addition, heterogeneity in the starting materials hinders 
batch-to-batch reproducibility by increasing variability in the product.  
 
In an effort to circumvent some of these issues, the group of Prof. Dr Christoph Salzmann (University College 
London, United Kingdom) synthesised edge-carboxylated graphene nanoflakes (GNFs) via the acidic 
breakdown of chemical vapour deposition (CVD) of multi-walled carbon nanotubes.348,349 Unlike GO and rGO 
materials, GNFs consist of a single graphene sheet approximately 30 nm in diameter with a pristine aromatic 
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system. The GNF edge is terminated with carboxylic acid groups that can form carboxylic anhydrides (Figure 
4.1A).349 The high water-solubility, negative z-potential (-37 ± 10.2 mV), and relative ease of functionalisation 
using carboxylate chemistry means that GNFs are potentially suitable platforms for the design of theranostic 
agents, whereby derivatisation reactions take place regioselectively at the carboxylated edge. An atomic force 
microscopy image of GNFs spin-coated from an aqueous dispersion onto highly oriented pyrolytic graphite is 
shown in Figure 4.1B. 
 
Figure 4.1. (A) Schematic chemical structure of a small per-carboxylate edge-terminated GNF (not to scale). 
(B) Atomic force microscopy image of GNFs spin-coated onto highly oriented pyrolytic graphite (Figure 





In this chapter, we used pristine GNFs (provided through collaboration with Prof. C. Salzmann) to synthesise a 
series of theranostic agents for targeted drug delivery and PET imaging. With this in mind, the GNFs were 
decorated with several different components. DFO is a well-known chelator for Fe3+, Zr4+ and Al3+ ions (among 
others) but also binds gallium with high affinity (formation constant, logb = 28.2).350 (R)-Ispinesib is an 
extremely potent anti-mitotic, anti-cancer drug which targets the kinesin spindle protein (KSP); a motor 
protein that plays a critical role in mitosis by mediating centrosome separation and bipolar spindle 
formation.351 Inhibiting KSP causes cell cycle arrest at the mitotic phase, eventually leading to apoptosis.352 
Alongside its potency and selectivity, (R)-ispinesib is a convenient choice of drug for GNF modification as it 
bears a free primary amine which lies outside of the KSP binding pocket and is available for chemical 
modification.351 Next, we sought to deliver the theranostic constructs to a tumour by incorporating a 
biologically active vector that targets a biomarker on cancer cells. For this purpose, we selected the previously 
introduced urea-based, PSMA binding, Glu-NH-C(O)-NH-Lys group.  Finally, due to the small size of the GNFs, 
we hypothesised that they would exhibit rapid excretion in vivo. Therefore, we also decorated the GNFs using 





































proteins. Selection of the pharmacokinetic modifying group was based on a report from Trüssel et al. who 
used lipophilic compounds which interact with albumin to extend the blood-pool half-life of antibody 
fragments.353 In summary, the synthesis, in vitro and in vivo evaluation of a theranostic GNF vehicles with up 
to four different functionalities was explored. 
 
4.3 Results and discussion 
4.3.1 Functionalisation of GNFs 
Four different GNF constructs (GNF-1, -2, -3 and -4, Figure 4.2) were synthesised to evaluate the use of GNFs 
as a platform for the construction of theranostic agents. GNF-1 was produced by pre-activating the carboxylate 
edge with HATU and conjugating to DFO via amide bond formation. The DFO chelate can be radiolabelled 
readily with 68Ga3+ ions using established methods, allowing the use of radiochemistry to determine the 
success of the chemical reaction.354 Radiolabelling (see below) confirmed that the DFO functionalisation 
reaction and purification was successful,  indicating that the chemistry performed at the carboxylated edge 
was effective. With this information, we then used the same conjugation chemistry to functionalise the GNF 
nanoparticles with Glu-NH-C(O)-NH-Lys and (R)-ispinesib producing GNF-2. The free amine on all components 
allowed functionalisation via a one-pot, multi-component reaction. Purification was achieved on silica gel; 
interestingly, when 100% water was used as the mobile phase, the modified GNFs moved to the solvent front, 
allowing efficient separation from the other compounds in the reaction mixture which were retained 
(Experimental; Figure 6.63). 
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Figure 4.2. Schematic structures of [68Ga]GNF-1, -2, -3, and -4. In each case, the GNFs are functionalised with 
multiple copies of each component. (A) GNF-1 with the chelate DFO. (B) GNF-2 with (R)-ispinesib, DFO, and 
the PSMA binding motif. (C) GNF-3 with (R)-ispinesib, and the PEG4-PSMA binding motif. (D) GNF-4 with (R)-




GNF-3 and GNF-4 were then synthesised by using the same components and chemistry with added 
modifications. We hypothesised that by creating some distance between the GNF and Glu-NH-C(O)-NH-Lys, 
PSMA binding would be improved, and hence, increasing the specific uptake in target cells (LNCaP [PSMA 
+ve]). GNF-3 included a short polyethylene glycol (PEG)4 linker between the GNF and the PSMA ligand. The 
synthesis of Glu-NH-C(O)-NH-Lys-NH-C(O)-PEG4-NH2 (Experimental; Scheme 6.12) allowed the free amine to 
be used in the equivalent amide bond formation as before. Next, it was also speculated that the relatively 







































































































hypothesis was based on previous works, which demonstrate the rapid excretion of carbon nanotubes via the 
renal system.355 Therefore, GNF-4 sees the further addition of N-(4-aminobutyl)-6-(4-iodophenyl)butylamide 
– a recognised affinity tag for albumin – in an attempt to increase circulation times. Anti-body fragments with 
similar derivatisation have been reported to bind albumin, and in turn, showed increased circulation half-life 
in vivo.353,356 
 
Following the synthesis of the four GNF constructs, the z-potentials were measured. GNF-1 and -2 exhibited 
similar z-potentials (-36.0 ± 4.87 and -39.5 ± 8.12 mV, respectively) compared to the native, non-functionalised 
GNFs (-37.0 ± 10.2 mV, consistent with previous reports349). GNF-3 displayed a decrease in z-potential (-60.7 
± 10.3 mV) consistent with the additional PEG4 ether groups causing an increase in negative charge at the 
slipping plane. Despite also containing the PEG4 linker, GNF-4 displayed a less negative z-potential (-42.3 ± 
7.80 mV) arising from the addition of the lipophilic N-(4-aminobutyl)-6-(4-iodophenyl)butylamide group. 
 
4.3.2 Radiochemistry 
Radiochemical synthesis  
DFO modification allowed for the efficient radiolabelling of GNF-1, -2, -3 and -4, using the same general 
procedure for each construct. [68Ga][Ga(H2O)6]Cl3(aq.) (~40 MBq) was added to an aqueous solution of the 
functionalised GNFs (25 µg) buffered with NaOAc (0.2 M, pH4.4) and incubated for 10 min at 21 oC (n = 3, 
independent reactions per compound). Radiochemical reactions were monitored by using radio-instant thin-
layer chromatography (radio-iTLC) and size-exclusion chromatography (SEC) (Figure 4.3). Radiochemical 
conversions (RCCs) for the synthesis of 68Ga-labelled GNF-1, -2, -3 and -4 were typically >97% (measured by 
radio-iTLC), with specific activities ranging from 8.7±2.4 to 10.4 ± 3.0 GBq mg-1 (activity per mass of GNF)(Table 
4.1). Extending reaction times and heating the mixtures to 70 oC did not improve the percentage of 
radiochemical conversion. Chelate-free radiolabelling of rGO with 64Cu2+ has been reported.219 A chelate-free 
approach can be beneficial as the addition of chelates to a nanoparticle (or other biological vector) can often 
alter the properties of the graphene, hence changing results in vivo.192 The intrinsic radiolabelling of the GNFs 
with 68Ga was attempted, but no labelling was observed, which provided further confirmation that the DFO 
functionalisation was successful. 
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Figure 4.3. Radiochemical data on the 68Ga-radiolabelling of GNF-1, -2, -3 and -4. (A) Radio-iTLC with silica gel 





By using the experimentally measured molar activity of the [68Ga][Ga(H2O)6]Cl3(aq.) stock solutions, 
radioactive titrations allowed the quantification of the amount of DFO loaded per unit mass of GNF. Titration 
experiments showed that the functionalised compounds GNF-1, -2, -3, and -4 contained similar amounts of 
DFO (ranging from ~44 – 53 nmol DFO per mg GNF), indicating that the conjugation reactions proceeded with 
similar efficiency for each compound (Figure 4 and Table 1).  
 
Figure 4.4. Plots showing percentage RCC when a standard aliquot of 68Ga was titrated with varying 






Table 4.1. Characterisation data associated with [68Ga]GNF-1, -2, -3 and -4. 
 
 [68Ga]GNF-1 [68Ga]GNF-2 [68Ga]GNF-3 [68Ga]GNF-4 
RCC /% 99.1±0.7 98.6±0.2 97.4±0.6 97.3±0.4 
Specific Activity 
/GBq mg-1 
9.08±2.59 8.79±0.40 10.41±2.98 8.7±2.44 
Mole of DFO per mass of 
GNF / nmol mg-1 
46.1±13.1 44.6±2.26 52.8±15.1 44.4±12.4 
logD value -3.34±0.02 -2.48±0.01 -3.14±0.06 -1.75±0.07 
z-potential / mV -36.0±4.87 -39.5±8.12 -60.7±10.3 -42.3±7.80 
Lipophilicity measurements   
Estimates of the lipophilicity of the samples were obtained by measuring distribution coefficients (logD) using 
standard n-octanol / PBS (pH7.4) partition experiments (Table 4.1). As expected, radiolabelled compounds 
[68Ga]GNF-1, -2, -3 and -4, were found to have negative logD values in the range -1.75 to -3.34. 
Functionalisation of the GNF-DFO flakes with Glu-NH-C(O)-NH-Lys and (R)-ispinesib (GNF-2) reduced the 
hydrophilicity (logD value of -2.48 ± 0.01, n = 3), which suggested that the lipophilic quinazolinone drug was 
loaded onto the particles. For GNF-3, the presence of the PEG4-spacer between the nanoparticle and the Glu-
NH-C(O)-NH-Lys group increased the hydrophilicity (logD = -3.14 ± 0.06, n = 3). Also, as anticipated, loading 
the nanoflakes with the N-(4-aminobutyl)-6-(4-iodophenyl)butylamide tag made construct GNF-4 less 
hydrophilic (logD = -1.75 ± 0.07, n = 3). Overall, the changes in measured lipophilicity values map to the 
anticipated changes associated with functionalisation of GNFs with the different components. 
Stability studies 
Stability studies in vitro confirmed that the 68Ga-radioactivity remained bound to the particles when incubated 
in solutions of saline (2 h), PBS (2 h) or human serum (2.5 h) at 37 oC (Figure 4.5). 
 
Figure 4.5. Percentage radiochemical purity (RCP) of [68Ga]GNF-1, -2, -3 and -4 determined from (A) radio-
iTLC following incubation with PBS up to 2 h at 37 oC, (B) radio-iTLC following incubation with saline up to 2 h 




4.3.3 Cellular studies 
To determine the presence and activity of the (R)-ispinesib and Glu-NH-C(O)-NH-Lys on GNF-2, -3, and -4, a 
range of different cellular assays were performed. The PSMA positive and overexpressing cell line LNCaP was 
used in all cell assays, with PC-3 (PSMA -ve) cells used in selected control experiments.357 
Anti-proliferation assays 
Cellular anti-proliferation (MTT) assays in vitro were used to measure growth inhibition induced by incubation 
of LNCaP cells with varying concentrations of the different GNF constructs. In positive control experiments, a 
classic biphasic profile was observed after incubating cells for 48 h with (R)-ispinesib (Figure 4.6).351 Analysis 
of the growth curves gave two distinct values for the growth-inhibition (GI50) values with a GI50(1) of 3.3 ± 2.3 
µM and a second GI50(2) value of 0.7 ± 26.7 nM. At high concentrations, the compound is cytotoxic to cells 
which corresponds to the first GI50(1) value. At lower concentrations between the values of GI50(1) and GI50(2), 
a plateau region is observed in which the cells are cytostatic with cell cycle arrest occurring in the G2/M phase. 
As the drug concentration decreases into the nanomolar range, a second step is observed corresponding to 
the GI50(2) value, followed by recovery of cellular proliferation to control levels.  
 
Figure 4.6. Cellular anti-proliferation (MTT) curves showing the response of LNCaP (PSMA +ve) cells to 
treatment with (R)-ispinesib. 
 
 
To determine the success of the functionalisation of the GNF with (R)-ispinesib, cells were exposed to GNF-2 
to observe the effect on proliferation. GNF-2 exhibited a similar biphasic profile to the drug alone (Figure 4.6), 
indicating that the nanoflake was successfully modified with (R)-ispinesib and was also a potent inhibitor of 
cellular growth and proliferation (Figure 4.7A). To determine if further functionalisation of a graphene 
nanoflake with PEG4 linkers and additional pharmacokinetic modifying groups (the albumin binder) had an 
impact on the anti-proliferative activity, equivalent MTT assays were conducted using GNF-3 and GNF-4 
(Figures 4.7B and 4.7C). Again, a biphasic profile was observed for both compounds which suggested more 
extensive derivatisation of a nanoflake did not alter the drug loading capacity. Similar to (R)-ispinesib, two 
separate growth inhibition values could be extracted from the biphasic curves giving values centred in the 
micro- (GI50(1) / µg mL-1) and nano- (GI50(2) / ng mL-1) mass concentration ranges for GNF-2, GNF-3 and GNF-
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4 (Table 4.2). It is worth noting that anti-proliferation assays with (R)-ispinesib alone requires the use of DMSO 
to solubilise the compound. The high water-solubility of the GNFs means that the use of DMSO was 
unnecessary when using the GNF constructs. This simplified formulation provides additional support for 
development of nanoflakes as potential drug-delivery vehicles. 
 
Figure 4.7. Cellular anti-proliferation (MTT) curves showing the response of LNCaP (PSMA +ve) cells to 
treatment with (A) GNF-2, (B) GNF-3 and (C) GNF-4. In each plot, the black data points correspond to 
treatment of the LNCaP cells with the native (non-functionalised) GNF in the same formulation as the active 
compounds.  
 




GNF-2 GNF-3 GNF-4 
Log(GI50(1)/mg mL-1) -5.70±0.11 -5.73±0.73 -5.52±0.18 
Log(GI50(2)/mg mL-1) -1.11±0.41 -0.63±0.50 -1.02±0.18 
 
Cell cycle analysis 
Although the biphasic profile in MTT assays is a characteristic feature of KSP inhibition using (R)-ispinesib, as 
additional confirmation, the mechanism of cell cycle inhibition was evaluated by using fluorescence-assisted 
cellular sorting (FACS). After treatment of LNCaP cells for 36 h with two different concentrations of GNF 
constructs, (12 ng mL-1 and 120 ng mL-1 of GNF, GNF-2, -3 and -4) the DNA content was measured by staining 
cells with propidium iodide (PI). Fluorescence-activated cell sorting (FACS) analysis showed that samples 
treated with GNF-2, -3 or -4 exhibited a dramatic and statistically significant increase in the proportion of cells 
in the G2/M phase compared with vehicle-treated cells or cells treated with GNF alone (Figure 4.8, and Table 
4.3). For example, cells treated with 120 ng mL-1 GNF-2 showed an increased number of cells in the G2/M 
phase (~87%) in comparison with control samples which gave relative G2/M phase populations of 9% in 
untreated samples, and 7% in GNF treated samples. Interestingly, the proportion of cells in the G2/M phase 

































































was also seen by FACS to be concentration dependent. For LNCaP cells treated with a lower concentration of 
GNF-2 (12 ng mL-1), the percentage of cells in G2/M phase reduced to 29%. This observation is consistent with 
the biphasic curve seen in the anti-proliferation assay. Collectively, the anti-proliferation assays and FACS data 
support the conclusion that GNF-2, -3 and -4 were successfully functionalised with (R)-ispinesib and that the 
drug remained active toward KSP inhibition. 
 
Figure 4.8. Cell cycle profiles derived from FACS analysis with concentrations (A) 120 ng mL-1 and (B) 12 ng mL-
1 of GNF compounds. 2N (diploidy) refers to the G0/G1 phase whilst 4N (tetraploidy) refers to G2/M phase. 
 
 
Table 4.3. Percentage of cells in the G0/G1, S and G2/M phase. Data extracted from cell cycle analysis using the 


















  Cells associated with each cell cycle phase / % 
Sample  Concentration / 
ng mL-1 
G0/G1 S G2/M 
Untreated  N/A 74.1 15.8 8.97 
GNF 120 71.2 10.6 7.24 
12 69.2 11.6 10.2 
GNF-2  120 4.92 5.21 87.3 
12 38.2 9.51 29.3 
GNF-3 120 4.15 4.06 89.6 
12 4.43 10.8 78.7 
GNF-4 120 5.79 6.49 77.6 
12 36.4 12.5 36.7 
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Confocal Microscopy 
As a final confirmation that the mechanism of G2/M phase arrest was associated with KSP inhibition, confocal 
microscopy images of cells that were incubated with GNF, GNF-2, -3 or -4 (and controls) were obtained (Figure 
4.9). Untreated samples and slides treated with the control GNF sample showed predominantly cells in 
interphase region of the cell cycle with DNA (stained with Hoechst 33342) concentrated in a well-defined 
nucleus. These control experiments showed no evidence of G2/M phase arrest and confirmed that the native 
GNFs do not interfere with the cell cycle which provided further corroboration of the FACS data (see above). 
In comparison, cells treated with GNF-2, -3 or -4 exhibited a characteristic punctate pattern of DNA distributed 
throughout the cell with no defined nucleus. The phenotype observed in these confocal cellular fluorescence 
microscopy data is consistent with previous reports on the mechanism of action of (R)-ispinesib in various 
cancer cells.351,358,359  
 
Figure 4.9.  Confocal microscopy images showing the effects of treatment of LNCaP cells with GNF, GNF-2, 
GNF-3 and GNF-4. Microtubules stained with Alexa Flour 568 (red) and DNA stained with Hoechst 33342 




Cellular association assays 
As previously discussed (Chapter 1; Section 1.2.3) PSMA is a membrane-bound zinc metalloenzyme which is 
upregulated in many prostate cancer cells. The Glu-NH-C(O)-NH-Lys group is a well-documented inhibitor of 
PSMA and many urea-based, small-molecule radiotracers have been tested in vivo and in human 
trials.354,324,360–362 To determine if GNF-2, -3 and -4 were successfully functionalised with the PSMA binding 
motif, radioactive cellular binding and blocking assays were conducted using LNCaP cells (PSMA +ve; Figure 
10A). [68Ga]GNF-2, [68Ga]GNF-3 and [68Ga]GNF-4 showed an increased uptake in LNCaP cells compared with 
[68Ga]GNF-1. PC-3 cells (PMSA –ve) were used as a negative control cell line. A statistically significant decrease 
in cellular uptake was observed in PC-3 cells compared with the activity accumulation in the LNCaP cells for 
[68Ga]GNF-2 (P-value < 0.01), [68Ga]GNF-3 (P-value  < 0.001) and [68Ga]GNF-4 (P-value < 0.0001). These results 
were encouraging and suggested that the functionalisation of GNFs with tumour-targeting groups was 
successful. However, in both the PC-3 and LNCaP cell lines, absolute uptake of the radioactivity was relatively 
low and non-specific binding accounted for up to ~50% of the cell-associated activity. For instance, this non-
specific binding component can be seen in the relative amount of [68Ga]GNF-1 versus the ‘targeted’ GNF 
constructs ([68Ga]GNF-2, -3 and -4). Non-specific binding is difficult to circumvent and is likely due to the non-
specific interactions of the GNFs with cellular proteins. Protein interactions have been observed for other 
nanographene materials.363,364 
 
We hypothesised that increasing the distance between the GNFs and the Glu-NH-C(O)-NH-Lys targeting 
vector using a PEG4 linker could potentially increase the cellular uptake and specificity for LNCaP cells. 
However, no difference was observed between the cell-associated uptake of [68Ga]GNF-2 and [68Ga]GNF-3 
(Figure 4.10A). It is possible that the short PEG4 chain is insufficient to shift the uptake mechanism away 
from non-specific accumulation and toward specific PSMA-mediated binding. Also of note, the slightly higher 
cell-associated activity observed for [68Ga]GNF-4 in LNCaP cells was simply attributed to an increased non-
specific uptake which was seen in the data using PC-3 cells. 
Cellular blocking assay 
The cellular association assays suggested that a two-state mechanism of cellular binding, involving both 
specific and non-specific accumulation, was operating for the targeted constructs GNF-2, -3, and -4. Therefore, 
to provide further confirmation of the presence of the Glu-NH-C(O)-NH-Lys group on GNF-2, -3, and -4, and to 
evaluate the fraction of specific binding observed using the LNCaP cells, blocking studies were performed. 
LNCaP cells were first incubated with ~1000-fold excess of the free Glu-NH-C(O)-NH-Lys ligand (5 µM) for 1 h 
prior to the addition of radiotracers (Figure 4.10B). The blocking studies confirmed that the radioactivity 
associated with the LNCaP cells could be reduced by 32 ± 9% for [68Ga]GNF-2, 76 ± 36% for [68Ga]GNF-3 and 
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37 ± 10% for [68Ga]GNF-4. Whilst a low percentage of cellular association and the relatively high fraction of 
non-specific binding indicate that more work is required to optimise these constructs, the blocking 
experiments confirmed that GNFs can be targeted toward specific biomarkers on cancer cells. 
 
Figure 4.10 (A) Cellular binding assay of [68Ga]GNF-1, -2, -3 and -4 with the LNCaP (PSMA +ve) and PC-3 (PSMA 
–ve) cell lines. Data given as activity bound per 1 mg mL-1 of protein. All cell media contained 0.1% azide and 
protein content was measured by using a BCA assay. For the LNCaP cell line: [68Ga]GNF-1 vs. [68Ga]GNF-2, P-
value<0.01; [68Ga]GNF-1 vs. [68Ga]GNF-3 P-value < 0.001; [68Ga]GNF-1 vs. [68Ga]GNF-4, P-value < 0.0001.  
Comparison of cell lines: PC-3 vs. LNCaP [68Ga]GNF-2, P-value < 0.01; [68Ga]GNF-3, P-value < 0.001; and 
[68Ga]GNF-4, P-value < 0.0001  (B) Blocking assay with the LNCaP (PSMA +ve) cell line pre-treated with free 
Glu-NH-C(O)-NH-Lys ligand (5 µM) before addition of radiotracers. Note: Student’s t-test analysis: ns = not 




4.3.4 In vivo studies 
Next, to gauge the potential of using nanoflakes in vivo, we performed dynamic PET imaging to measure the 
pharmacokinetic (PK) distribution and excretion profiles of [68Ga]GNF-3 and [68Ga]GNF-4 in athymic nude mice 
bearing subcutaneous LNCaP tumours (n = 3 mice / compound). The main goal was to measure time-activity 
curves to obtain a baseline PK profile of GNFs, and to evaluate if functionalisation of the GNF constructs with 
an albumin binding tag could modulate blood pool concentrations, circulation times and excretion pathways.  
 
Pilot PET imaging experiments indicated that the small size and high hydrophilicity of the [68Ga]GNF-3 and 
[68Ga]GNF-4 facilitated rapid extraction from the blood pool by a renal excretion pathway and  elimination 
through the bladder (Figure 4.11). Renal clearance of [68Ga]GNF-3 and [68Ga]GNF-4 is an interesting 
observation that may help to minimise the radiation burden to background tissues and facilitate further 
A B
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optimisation of radiotracers based on GNFs. Time-activity curves (TACs) showed that [68Ga]GNF-3 was 
essentially first-pass extracted from the blood pool by the kidneys. Peak uptake in the kidney reached 38 ± 4 
%ID cm-3 within in the first two minutes post-administration. Concordantly, accumulation of 68Ga-radioactivity 
in the bladder was observed to increase immediately after injection confirming that the [68Ga]GNF-3 particles 
are not retained in the kidney (Figure 4.11B). In contrast, the peak in radioactivity in the kidneys for [68Ga]GNF-
4 occurred between 4 – 6 minutes post-administration with a similar time delay observed before activity was 
seen to accumulate in the bladder (Figures 4.11C). For both [68Ga]GNF-3 and [68Ga]GNF-4, blood pool activity 
(as measured by manually drawing volumes of interest [VOIs] over the left ventricle of the heart) showed a 
peak in the first frame after bolus injection of the radiotracer and a rapid decrease over the imaging time 
window. In comparison to [68Ga]GNF-3, the slight delay in extraction of the [68Ga]GNF-4 activity from the blood 
pool by the kidney, gave a higher blood pool peak activity of 48 ± 5 %ID cm-3. Kinetic analysis of the TACs found 
that the effective half-life of [68Ga]GNF-3 in the blood pool (heart) was 3.85 ± 0.35 min. whereas for [68Ga]GNF-
4  the half-life increased to 5.22 ± 0.61 min (p < 0.05). These TAC data indicate that modification of the GNF 
particles with the albumin binding tag has a small but significant effect on prolonging the circulation time and 
reducing the elimination rate of [68Ga]GNF-4. 
 
Figure 4.11. PET images recorded in mice bearing LNCaP tumours, T = tumour. (A) 2 h coronal PET image 
recorded following injection with [68Ga]GNF-4. TACs plotted with data extracted from 30 min dynamic PET 
analysis (15 ´ 2 min scans) with injection of (B) [68Ga]GNF-3 (n = 3) and (C) [68Ga]GNF-4 (n = 4) at t = 2 min. 




For both [68Ga]GNF-3 and [68Ga]GNF-4, tumour-associated radioactivity was found to be low and non-specific. 
The TAC profiles of VOIs drawn over the tumours showed that the PK profile followed the same trend as the 
blood pool associated activity, indicating that the constructs do not show specific accumulation in the 
tumours. This result is partially consistent with the cellular data which also showed low absolute accumulation 







non-specific binding found for GNFs on LNCaP cells, the rapid excretion profile, and potentially, a reduced 
access or affinity of the Glu-NH-C(O)-NH-Lys binding ligand for the PSMA target when bound to the GNF 
particles. In spite of the absence of tumour uptake, the PET imaging data provided valuable information, which 
will facilitate further optimisation of the GNFs as potential drug delivery vehicles and theranostic agents. The 
following chapter of this thesis addresses issues of rapid excretion and low tumour uptake by conjugating 
GNFs to mAbs.  
 
4.4 Conclusions 
GNFs were used as scaffolds for the synthesis of targeted theranostic agents. Multi-functionalised GNFs can 
be prepared with a diverse range of components including metal-binding chelates, tumour-targeting ligands, 
cytotoxic drugs and pharmacokinetic modification groups. Derivatisation of GNFs with the potent drug 
molecule (R)-ispinesib gave constructs that remained pharmacologically active with the mode of action 
consistent with mitotic phase arrest induced by KSP motor protein inhibition. An additional advantage of using 
a nanoflake carrier is that binding (R)-ispinesib to the GNFs enabled the drug to be solubilised in water.365 In 
addition, GNFs functionalised with the Glu-NH-C(O)-NH-Lys group exhibited enhanced cellular uptake. 
Although a significant fraction of cellular association was assigned to non-specific interactions, it was found 
that targeted GNFs showed specific binding toward PSMA expressing cells. Dynamic PET imaging found that 
functionalised GNFs have rapid blood pool clearance and renal excretion, but experiments also demonstrated 
that functionalising with an albumin-binding tag results in meaningful modulation of the pharmacokinetic 
profile. Further optimisation is required to enhance the uptake kinetics and distribution of functionalised GNFs 
in vivo. In summary, experimental data has supported our conclusion that GNFs are a highly versatile platform 














5.1 Aims of Chapter 
In Chapter 4, we demonstrated the potential of using GNFs as tumour-targeted drug delivery vehicles.366 
However, despite successful results in vitro, poor pharmacokinetics in vivo led to rapid excretion via the renal 
system and negligible tumour uptake. Modification of the GNFs with albumin binding groups led to a small, 
but significant increase in the blood half-life, confirming that transient binding to globular proteins in serum 
can alter the pharmacokinetic profile. Therefore, in Chapter 5 we sought to develop a multi-modal GNF 
construct featuring a stable covalent conjugate bond to an antibody (mAb). The hypothesis was that attaching 
mAbs to GNF constructs would simultaneously increase blood pool circulation times, and facilitate target-




Graphene materials have been previously conjugated to larger biomolecules (e.g. mAbs) using a number of 
different techniques.367–375 Li et al. modified rGO film with pyrene carboxylic acid via π-π interactions. 
EDC/sulfo-NHS was then used to activate the free carboxylic acids, facilitating conjugation to the protein using 
lysine residues.368 Alternatively, McDevitt et al. conjugated rituximab to carbon nanotubes by using a 
maleimide coupling to the cysteine residues.369 These conjugation methods were later used to modify carbon 
nanotubes with the E4G10 mAb indicating the versatility of the method.375 Despite successful conjugation, the 
use of GO and rGO materials produces highly heterogeneous products reducing batch-to-batch 
reproducibility. GNFs consist of a single graphene sheet 30 ± 9 nm in diameter with a pristine aromatic system 
and an edge that is terminated with carboxylic acid groups.348,349 As we demonstrated previously that selective 
modification of the carboxylated edge can be achieved by using simple amide bond forming reactions, by using 
GNFs as a scaffold we can remove a certain degree of heterogeneity in the obtained product when compared 
with other GO, rGO or nanotube constructs.  
 
Due to the recent advent of combined PET/MR scanners, there is now a need for the development of imaging 
agents that combine both PET and MR imaging capabilities in a single construct (Chapter 1; Section 1.3.2). As 
GNFs can be multi-functionalised with a variety of compounds, the material is an ideal candidate to act as a 
platform for incorporating both MRI and PET agents in the same molecule. To create this multi-functional 
construct, we chose to decorate the GNFs with the GdDOTAGA complex and the DFO chelate. Here, the 
paramagnetic Gd3+ ions shorten the T1 (longitudinal) relaxation times of nearby protons in water providing a 
positive contrast in T1-weighted MR images. Meanwhile, the DFO chelate can form coordination complexes 
with both 68Ga3+ and 89Zr4+ ions allowing PET imaging.  
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To target the multi-modal GNFs toward cancer-specific biomarkers, both onartuzumab (MetMAbTM; 
Genentech) and trastuzumab (HerceptinTM; Genentech) were tested. Onartuzumab binds to the human 
hepatocyte growth-factor receptor (c-MET) whilst trastuzumab targets an epitope on the human epidermal 
growth-factor receptor 2 (HER2/neu). These target proteins are both over-expressed in a number of cancer 
cell lines and tumour types (Chapter 1; Section 1.2.3). Due to the complexity of forming a covalent GNF-
antibody conjugation, a fluorescent GNF derivative was synthesised to facilitate characterisation and 
optimisation of the reaction conditions. The ease of tracking molecules with fluorescent tags allows for the 
efficient measurement of the conjugation success and determination of whether the attachment of the GNF 
alters the specific cellular binding and uptake by the antibody-antigen interaction. Therefore, in this work, 
initial conjugation and cellular studies were carried out by using a GNF decorated with a boron-
dipyrromethene (BODIPY) derivative. BODIPY dyes are known to be highly fluorescent whilst offering thermal 
and photochemical stability under aqueous conditions.376 Hence, BODIPY dyes provide a suitable basis from 
which to carry out the pilot studies; allowing us to design and optimise the conjugation methodology to 
produce GNF-mAb constructs. Furthermore, BODIPY derivatives are commonly used as optical imaging agents 
so the production of a fluorescent BODIPY-GNF-mAb could find further application in confocal microscopy, 
tissue staining, or fluorescence mediated tomography (FMT) in vivo.377–381 This demonstrates the potential of 
the GNF constructs to also offer further imaging functions. 
 
Overall, we report the synthesis and characterisation of several GNF-mAb derivatives for potential use in 
PET/MR imaging. Initial conjugation techniques were developed via the use of a GNF-BODIPY derivative, 
where tests are carried out using both trastuzumab and onartuzumab. The obtained products were evaluated 
in vitro by using FACS analysis. The methods developed were then used to conjugate GNF-GdDOTAGA-DFO to 
trastuzumab which was further radiolabelled with 89Zr yielding [89Zr]GNF-GdDOTAGA-ZrDFO-trastuzumab. 
Following characterisation of the radiolabelled product, the construct was evaluated in vitro and in vivo by 
using small-animal PET imaging and biodistribution studies. 
 
5.3 Results and discussion 
5.3.1 BODPIY-GNF antibody conjugates 
Synthesis of GNF-BODIPY 
The synthesis of the BODIPY-GNF was achieved via methods previously established by our group (see Chapter 
4).366 Briefly, a BODIPY aniline (compound 28, see experimental for details) was synthesised in accordance 
with reported procedures.382 The aniline derivative provided a free amine which was coupled to the 
carboxylated edge using standard amide coupling procedures (Experimental; Section 6.5.1). Once GNF-
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BODIPY (Figure 5.1) was obtained the absorption/emission spectra was measured (5abs max = 498 nm,	5ems max = 
510 nm), and the maximum emission intensity was measured for solutions of different concentrations.  
 
Figure 5.1. (A) Schematic structure of BODIPY-GNF. Note, the GNF is functionalised with multiple copies of the 
BODIPY aniline derivative. (B) Absorption/emission spectrum of BODIPY-GNF (C) Change in emission intensity 




Conjugation of BODIPY-GNF to trastuzumab 
Following the synthesis of BODIPY-GNF, conjugation to pre-purified trastuzumab was carried out by using 
EDC/NHS mediated coupling. The unique absorption maxima of the BODIPY-GNF (5max = 498 nm) construct 
allowed us to characterise reactions by monitoring SEC-HPLC at both 490 nm and 280 nm (for tracking the 
protein component). This spectroscopic monitoring facilitated optimisation of the reaction conditions. As the 
particle size and the precise number of free carboxylic acids on the BODIPY-GNF is unknown, this optimisation 
process required a certain amount of ‘trial and error’ to find the correct conditions. To avoid larger aggregates, 
it was necessary to limit the possibility of multiple antibodies conjugating to each GNF. It was also necessary 
to avoid larger mAb conjugates which may form due to polymerisation with excess EDC/NHS. Initial reaction 
conditions yielded a product that appeared to have a larger amount of aggregate (Figure 5.2A), especially 
when observing absorption at 490 nm. This is indicative of aggregate formation and multiple antibodies 
conjugating to each GNF. To avoid this, follow up reaction conditions involved lowering the amount of GNF 
and EDC/NHS in comparison to protein. This produced a structure that was analysed in Figure 5.2B. Here, little 
aggregate was present, yet it was apparent that the conjugation between the GNF and the mAb was 
successful; by following the BODIPY-GNF channel (5 = 490 nm) on the chromatogram, the primary peak 
observed corresponds to the correct elution time (18.1 min) associated with elution of the protein. 
 





































Figure 5.2. (A&B) SEC-HPLC chromatograms of trastuzumab, BODIPY-GNF and the BODIPY-GNF-trastuzumab 
conjugates. When more than one mAb is present on each GNF (mAb-to-GNF ratio, n ≥ 2) the construct elutes 
at 16.2 min.  Elution at 18.3 min relates to either non-functionalised mAb or a GNF functionalised with 1 mAb 
(n = 1).  Non-functionalised GNF and GNF-BODIPY (n = 0) elutes at 24.6 min and small molecules elute at 28.6 
min. (C) Pictorial representation of constructs assigned on chromatograms. 
 
 
It is possible to determine the amount of GNF present in the mAb conjugate by measuring the emission of the 
obtained product and comparing this to the data seen in Figure 5.1C. Here, it should be noted that it was 
assumed that the emission of the construct did not change when conjugated to the mAb. However, the 
emission of the sample allowed us to approximate that the sample contained 12.3 ± 0.7 µg of GNF per 1 mg 
of protein. By observing previously obtained STM images, it can be seen that the GNF flakes have a length of 
approximately 30 nm and a width of approximately 10 nm.348 From this size estimation, and previous data 
reported by Vorontsov et al., we can approximate the molecular weight of a GNF to be 12,000 g mol-1 giving 
1.02  nmol of GNF in the product.383 Due to the large molecular weight of trastuzumab (145 kDa), 1 mg is 
equivalent to 6.87 nmol. From the estimated moles of GNF and the measured moles of protein we can 
determine that on average, the constructs contain ~7 mAbs per GNF. It should be noted that this calculation 
uses several approximations and assumptions, since accurate determination of the number of moles (or 
concentration) of nanoparticles remains challenging, but given the size of the GNFs, the estimated loading 
ratio seems feasible. 
Cellular binding of BODIPY-GNF-trastuzumab 
Following successful conjugation of the BODIPY-GNF to trastuzumab, our next goal was to establish whether 
the BODIPY-GNF-trastuzumab constructs retained affinity and specificity toward the target biomarker 
(HER2/neu). The SK-OV-3 ovarian cancer cell line is known to overexpress the HER2/neu antigen, and 
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intensity of the emission associated with cells, FACS analysis was used (Figure 5.3). FACS experiments 
demonstrated that the fluorescence intensity is significantly higher (~2.7-fold) in cells that are treated with 
BODIPY-GNF-mAb compared with the vehicle-treated (P-value < 0.01). As a further measure of specificity, the 
binding of the control compound BODIPY-GNF was measured which showed a dramatic decrease (~2.2-fold) 
in fluorescence intensity compared with BODIPY-GNF-trastuzumab (P-value < 0.05). Finally, as additional proof 
of specific cellular binding, a blocking study was performed in which cells were pre-treated with an excess of 
trastuzumab (333-fold excess) before treatment with BODIPY-GNF-trastuzumab. Blocking resulted in a ~2.2-
fold decrease in mean fluorescence intensity (P-value < 0.05), giving a signal intensity that was statistically 
identical to the vehicle-treated and BODIPY-GNF controls. Collectively, these cellular binding studies provide 
convincing experimental evidence that BODIPY-GNF-trastuzumab exhibited specific binding via the mAb-
antigen interaction.  
 
Figure 5.3. FACS analysis of cells treated with BODIPY-GNF-mAb and relevant controls. (A) Histogram of 
obtained data following appropriate gating using the Flowjo software. (B) The mean fluorescence intensity of 
each sample was extracted using Flowjo software and values were directly compared (n = 3). Note: Student’s 
t-test analysis: ns = not significant, * = P-value < 0.05, ** = P-value < 0.01, *** = P-value < 0.001. 
 
Conjugation of BODIPY-GNF to onartuzumab (MetMAb) 
Whilst conjugation to trastuzumab was successful, we wanted to demonstrate the versatility of the constructs 
by also conjugating BODIPY-GNF to an alternative mAb, pre-purified onartuzumab. Conjugation was achieved 
by using our previously established methods (vide supra). SEC-HPLC (Figure 5.4A) allowed us to determine 
that the conjugation was successful by monitoring the co-elution of the BODIPY (490 nm) channel with that of 
the protein (280 nm). Due to the smaller size of onartuzumab (99.16 kDa), complete separation and removal 
of free BODIPY-GNF was not achieved and this can be observed from the peak in the SEC-HPLC (24 min.; Figure 
4A blue trace). From the integrated absorption profile of the BODIPY channel the purity of the BODIPY-GNF-
onartuzumab was estimated to be 84%. In spite of the difficulties in purifying the BODIPY-GNF-onartuzumab, 
FACS analysis was conducted with the same controls (including the impurity molecule BODIPY-GNF) as 
A B
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mentioned in the previous section (Figure 5.4B&C). In this case, MKN-45 gastric carcinoma cells 
(overexpressing the c-MET receptor) were treated with BODIPY-GNF-onartuzumab and an increased 
fluorescence intensity (~2.5-fold) was observed compared with the vehicle-treated control (P-value < 0.001). 
The onartuzumab blocking control and the BODIPY-GNF control samples both gave a significant decrease in 
fluorescence intensity (~1.5-fold; P-value < 0.001 and P-value < 0.01, respectively), confirming the specific 
binding of the BODIPY-GNF-onartuzumab. In contrast to the BODIPY-GNF-trastuzumab studies where a ~2.2-
fold difference was observed between the experiments and the control studies, BODIPY-GNF-onartuzumab 
gave a slightly lower difference of ~1.5-fold. In part this may be explained by the fact that onartuzumab is a 
monovalent, one-armed engineered antibody whereas trastuzumab is bivalent and thus has a higher avidity 
and a reduced likelihood of compromising the immunoreactivity during the GNF conjugation reactions. This 
indicates the robustness of using the larger bivalent mAb, trastuzumab. For this reason, subsequent studies 
focused on the use of GNF-trastuzumab constructs. 
 
Figure 5.4. (A) SEC-HPLC of BODIPY-GNF-onartuzumab with PBS as mobile phase. (B) FACS analysis of cells 
treated with BODIPY-GNF-onartuzumab and relevant controls. Histogram of obtained data following 
appropriate gating using the Flowjo software. (C) The mean fluorescence intensity of each sample was 
extracted and values were directly compared (n = 3). Note: Student’s t-test analysis: ns = not significant, * = 
P-value < 0.05, ** = P-value < 0.01, *** = P-value < 0.001. 
 
5.3.2 DFO-GNF antibody conjugates 
Synthesis of DFO-GNF conjugates 
With conjugation methods established, our next aim was to create radiolabelled GNF-mAb conjugates for PET 
imaging. To achieve this, the previously synthesised DFO-GNF was used (Chapter 4, GNF-1). Conjugation of 
DFO-GNF to trastuzumab was achieved by using conditions identical to those optimised during the BODIPY-
GNF synthesis. SEC-HPLC analysis of both DFO-GNF and DFO-GNF-trastuzumab (Figure 5.5) indicated that 
conjugation was successful with absorption at 400 nm (following the GNF chromophore) for the DFO-GNF-
trastuzumab (18.3 min).  
A B C
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Figure 5.5. (A) Schematic structure of DFO-GNF-trastuzumab. Note, the GNF is functionalised with multiple 
copies of DFO. (B) SEC-HPLC analysis of DFO-GNF and DFO-GNF-trastuzumab with PBS as mobile phase. 
 
Radiolabelling DFO-GNF antibody conjugates 
Due to the large size of trastuzumab and subsequent long circulation times in vivo, 89Zr (t1/2 = 78.41 h) was 
chosen to radiolabel the constructs due to the long half-life of the radionuclide. Radiolabelling was achieved 
in 45 min to synthesise [89Zr]ZrDFO-GNF-trastuzumab with a decay-corrected RCY of 27.6%. Purification was 
achieved by using 100 kDa spin-centrifugation filters, but it was found that complete removal of the free 
radiolabelled [89Zr]ZrDFO-GNF was challenging. For this reason a small peak associated with [89Zr] ZrDFO-GNF 
was still observed in the radiotrace and the final [89Zr]ZrDFO-GNF-trastuzumab formulation had a measured 
RCP of 82% (Figure 5.6). We note that previous studies (Chapter 4) established that radiolabelled GNFs which 
are not bound to protein are rapidly excreted via the kidney with no uptake in tumours, and negligible uptake 
was observed in cells. Therefore, the presence of this [89Zr]ZrDFO-GNF was not anticipated to compete with 
the binding of [89Zr]ZrDFO-GNF-trastuzumab in vitro or in vivo. 
 
Figure 5.6. Radiochemical data for [89Zr]ZrDFO-GNF-trastuzumab. (A) PD10-SEC with PBS as eluent (B) Radio-


























Cellular uptake of [89Zr]ZrDFO-GNF-trastuzumab 
FACS analysis with BODIPY-GNF-trastuzumab demonstrated specific binding to SK-OV-3 cells. This indicated 
that the trastuzumab remained immunoreactive and bound to HER2/neu despite functionalisation with the 
GNF. To further investigate the cell binding of these GNF-trastuzumab conjugates, a radiochemical cellular 
binding assay with [89Zr]ZrDFO-GNF-trastuzumab was carried out. A standard Lindmo assay confirmed that 
[89Zr]ZrDFO-GNF-trastuzumab remained immunoreactive with an IF value of 58.0 ± 2.3% (Figure 5.7).384–389 
Under the conditions employed, complete saturation was not fully reached, however, blocking studies further 
highlight the specific uptake of these constructs and the graphical analysis and linearisation allowed for 
estimation of the immunoreactive fraction of the product. 
 
Figure 5.7. Lindmo cell binding assay (A) Saturation binding of [89Zr]ZrDFO-GNF-trastuzumab to SK-OV-3 cells. 
(B) Lindmo straight line transformation of [89Zr]ZrDFO-GNF-trastuzumab. 
 
 
5.3.3 GdDOTAGA-DFO-GNF antibody conjugates 
Functionalisation of GNFs with GdDOTAGA and DFO 
As previous studies demonstrated the successful multi-functionalisation of the GNFs, the GNF-mAb conjugates 
became suitable candidates for creating a multi-modal PET/MR imaging agent. In pursuit of this aim, GNFs 
were functionalised with DFO (vide supra) for the conjugation of a PET isotope, and a GdDOTAGA derivative 
for MRI contrast. The DOTAGA chelate offers 8-donor atoms and is known to bind Gd3+ with a high 
thermodynamic stability (logß = 25.6) and greater kinetic stability than DTPA complexes, thus making it a 
suitable candidate for further derivatisation.390 Despite this, complex formation kinetics led to a slow reaction 
and heating was required to obtain the GdDOTAGA complex in a reasonable time scale.391 Due to the thermal 
decomposition of the GNF constructs under elevated temperatures, the metallation must be performed prior 
to GNF linkage (Scheme 5.2). Compound 29 was isolated and characterised by using HR-MS and HPLC analysis 





Scheme 5.2. Chemical synthesis of GdDOTAGA-PEG4-NH2 (29). 
 
 
Following complexation of the Gd3+, compound 29 was conjugated to the carboxylated edge of the GNF by 
utilising the free amine on the GdDOTAGA-PEG4-NH2 in a standard amide coupling reaction. This reaction was 
carried out in situ with the DFO coupling, the conditions for which are detailed in Chapter 4 (Section 4.3.1). 
As before, complete separation of starting materials versus. the functionalised GNF product on silica gel (Rf = 
0.0-0.1 vs. Rf = 0.9-1.0, respectively; Experimental; Figure 6.70) allowed us to purify the GdDOTAGA-DFO-GNF 
product in high purity. Radiolabelling of the product with a known concentration of 68Ga allowed us to 
determine that the product contained 13.4 ± 1.8 nmol of DFO per mg of GNF (n = 2). T1 measurements allowed 
us to calculate the r1 relaxivity of GdDOTAGA-DFO-GNF to be 0.88 ± 0.03 mL mg-1 s-1, confirming that the 
paramagnetic Gd3+ ion was present on the material. By taking the T1 relaxation time at a given concentration 
of GNF we are able to calculate that the GNF contains 45.0 ± 4.3 nmol of GdDOTAGA-PEG4-NH2 per mg of GNF 
giving a GdDOTAGA complex to DFO chelate ratio of approximately 3.4 : 1 on the GNF. 
Radiochemical studies of GdDOTAGA-DFO-GNF 
The synthesised GdDOTAGA-DFO-GNF was radiolabelled with 89Zr4+ in 10 min at pH7.9 giving a RCC of 97% 
(determined via radio-iTLC). Due to range of sizes of the GNFs, PD10-SEC does not give adequate separation 
(Figure 5.8A). Therefore, radio-SEC-HPLC was used where the radiolabelled [89Zr]GdDOTAGA-ZrDFO-GNF 
eluted at 24.1 min and small molecules eluted at 28.5 min (Figure 5.8B). This allowed us to determine a RCP 
of 98% for the purified [89Zr]GdDOTAGA-ZrDFO-GNF. To assess the pharmacokinetic behaviour of the 
[89Zr]GdDOTAGA-ZrDFO-GNF construct the radiotracer was administered via i.v. tail vein injection into an 
athymic nude mouse bearing a subcutaneous SK-OV-3 tumour (0.25 MBq, 40 µg GNF in 200 µL PBS). An initial 
PET image was acquired 5 min post-injection and showed that the majority of the activity was already cleared 
from the blood pool, extracted via kidneys, and was excreted though the bladder. This control study confirmed 
our previous observations and our hypothesis that radiolabelled GNF impurities that are not bound to protein 
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amounts of radioactivity in the mouse and only a minor amount of activity retained in the kidneys and bone 
(~3 kBq in total; 1.2% of injected dose). 
 
Figure 5.8. (A) Analytical PD-10-SEC elution profiles and (B) SEC-UHPLC chromatograms of [89Zr]GdDOTAGA-
ZrDFO-GNF. 
 
Conjugation of GdDOTAGA-DFO-GNF to trastuzumab 
Once again, the methods established during the BODIPY-GNF conjugation were used to conjugate the 
GdDOTAGA-DFO-GNF to trastuzumab (Figure 5.9). Purification was carried out by using PD10 SEC and spin 
filtration (100 kDa) and product formation was confirmed by using SEC-HPLC. The r1 relaxivity of GdDOTAGA-
DFO-GNF-trastuzumab was measured by NMR to be 0.077 ± 0.001 mL mg-1 s-1 confirming that the Gd3+ ions 
remained present in the construct. By taking a known concentration of GdDOTAGA-DFO-GNF-trastuzumab we 
are able to determine a GdDOTAGA concentration of 0.99 ± 0.09 nmol per mg of protein. As we know the 
concentration of GdDOTAGA per unit mass of GNF, we are able to determine a GNF mass of 22.0 ± 0.1 µg per 
mg of protein. This corresponds to approximately 4 mAbs per GNF. It should be noted that due to the low 
concentrations of GdDOTAGA, these estimated numbers should be treated with caution. However, these 
approximations give us figures within the same order of magnitude as estimated obtained from the GNF-
BODIPY experiments (vide supra). 
 
Figure 5.9. Schematic structure of GdDOTAGA-DFO-GNF-trastuzumab. Note, the GNF is functionalised with 



























































Radiolabelling of GdDOTAGA-DFO-GNF-trastuzumab with 89Zr 
Radiolabelling was achieved in 2 h to synthesise [89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab with a RCY of 9.4 
± 4.5 % (n = 3). A lower RCY is reported here in comparison to [89Zr]ZrDFO-GNF-trastuzumab as a large excess 
of radioactivity was added in order to push the radiolabelling reaction to completion and obtain sufficient 
product for use in vivo. PD10-SEC analysis of the crude product indicated a RCP of 6.3 ± 2.2 % (n = 3). 
Purification was achieved by using spin filtration (100 kDa) and PD10-SEC analysis of the purified 
[89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab product gave a RCP of 91.4 ± 1.4 % (n = 3). The specific activity of 
the obtained product was found to be 1.72 ± 0.13 MBq mg-1 (n = 2; note: mass refers to protein mass only as 
determined experimentally from a BCA assay). Following characterisation, the stability of the 
[89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab construct was tested by using a chelate challenge assay. The 
construct was incubated in DTPA (pH7.1, 50 mM) for 24 h, and by using PD10-SEC it was determined that 84% 
of the activity remained bound to [89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab (Experimental; Figure 6.72).  
 
Figure 5.10. Radiochemical data for [89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab. (A) PD10-SEC with PBS as 
eluent (B) Radio-iTLC with silica gel as stationary phase and 50 mM DTPA as mobile phase. (C) Radio-SEC-HPLC 
with PBS as mobile phase. 
 
 
Cellular uptake of [89Zr]GNF-GdDOTAGA-ZrDFO-trastuzumab 
To investigate the specificity of [89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab for HER2/neu, a radiochemical 
cellular binding assay was carried out by using SK-OV-3 cells. A standard Lindmo assay confirmed that 
[89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab remained immunoreactive (IF = 62 ± 11%) (Figure 5.11). Blocking 
with a 1000-fold excess of free trastuzumab produced negligible binding of [89Zr]GdDOTAGA-ZrDFO-GNF-





Figure 5.11. Lindmo cell binding assay (A) Saturation binding of [89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab to 




Small-animal PET imaging of [89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab  
Based on the successful results in vitro, the pharmacokinetic profile and tumour uptake of [89Zr]GdDOTAGA-
ZrDFO-GNF-trastuzumab was evaluated in vivo by using the PET imaging and biodistribution studies in athymic 
nude mice bearing subcutaneous SK-OV-3 tumours on the right flank. Mice were administered with 
[89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab (0.11-0.14 MBq, 65-82 µg of mAb in 200 µL PBS) via i.v. tail vein 
injection, with a blocking formulation containing an additional 15.4-fold (1 mg total protein) of mAb. PET 
images were recorded at 1, 14, 24, 48, 72 and 90 h post-administration for both the normal and blocking 
groups (n = 4 mice / group). Visual inspection of images showed uptake of the [89Zr]GdDOTAGA-ZrDFO-GNF-
trastuzumab radiotracer into tumour tissue from 14 h onwards in the normal group (Figure 5.12). This uptake 
was not observed at the equivalent time points in the blocking group (Experimental; Figure 6.73). A large 
fraction of the injected radiotracer accumulated and was retained in the liver. Given the large size of the 
[89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab construct, liver uptake was expected and is likely unavoidable 
unless the GNF-mAb constructs are redesigned to include coatings that could mask recognition by the 
reticuloendothelial system. Furthermore, significant bone uptake was also observed from 14 h onwards. 89Zr4+ 
is known to accumulate in the bone of mice, and this observation is indicative of radiotracer metabolism 








Figure 5.12. [89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab PET images recorded in mice bearing SK-OV-3 tumours 
on the right flank. T = tumour, H = heart, L = liver, S = spleen, B = bladder, Bo = Bone. “Block” = co-injected 
with non-radiolabelled trastuzumab. 
 
Volume of interest (VOI) analysis was used to quantify radiotracer distribution in different tissues based on 
the calibrated PET images (Figure 5.13A). Tumour uptake was higher for the normal group (Tumour VOI = 4.41 
± 0.83 %ID g-1, 90 h, normal, n = 4;) when compared to mice that received the blocking formulation (Tumour 
VOI = 2.12 ± 0.48 %ID g-1, 90 h, normal, n = 4). These data indicate that [89Zr]GdDOTAGA-ZrDFO-GNF-
trastuzumab displayed specific uptake in the tumour. VOI analysis of the heart is representative of activity 
circulating in the blood pool. From this we extracted a blood pool half-life (t1/2) for the two groups where 
t1/2(normal) = 7.05 ± 1.03 h (n = 4) and t1/2(block) = 8.14 ± 0.58 h (n = 4) (Figure 5.13B). In comparison to our 
previous work with 68Ga-radiolabelled GNFs (Chapter 4) and to [89Zr]GNF-ZrDFO control described above 
(Figure 5.8C), the blood pool circulation time of [89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab was greatly 
extended (c.f. Chapter 4: GNF-4 t1/2 = 5.22 ± 0.61 min). This extended blood pool half-life is strong evidence 
that the GNFs were successfully, and stably, conjugated to the mAb. At the 1 h time point, activity was found 
in the bladder for both groups of animals (Bladder VOI = 19.2 ± 7.2 %ID g-1, 1 h, normal, [n = 4]; Bladder VOI = 
21.5 ± 6.3 %ID g-1, 1 h, block, [n = 4]). However, this activity was quickly excreted. The fraction of activity that 
displayed rapid renal elimination from the animals was is indicative of 89Zr-radiolabelled GNFs not bound to 
protein or small molecule contaminants in the formulation of [89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab. This 
initial excretion is also observed in the dose calibrator measurements of the whole-body activity in the mice 
(Figure 5.14). From 0-1 h there was a decrease (normal, 16.3 ± 5.4%; block, 7.2 ± 1.5%) in the retained activity. 
However, from 1-90 h this decrease followed the physical decay profile of 89Zr. For comparison, when no mAb 
is conjugated to the GNF construct ([89Zr]GNF-GdDOTAGA-ZrDFO), the majority of activity (76%, n = 1) is 


























Figure 5.13. (A) Time-activity bar chart showing the activity associated with different tissues (VOI) versus. time 
from quantitative analysis of the PET images in units of %ID g-1.  
 
 
Figure 5.14. (A) Plot of the time-activity curves from the VOI analysis of the heart/blood pool measured by 
PET imaging. These data were used to extract the blood-pool half-life. (B) Plot of the measured whole-body 
activity retained in the normal (blue) and blocking (black) groups versus time after administration of 
[89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab in SK-OV-3 tumour bearing mice. For reference the fast excretion 
of [89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab is plotted (red), as well as the physical decay of 89Zr (purple).  
 
Biodistribution studies  
Biodistribution studies were performed ex vivo after the final imaging time point at 90 h post-administration 
of [89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab in SK-OV-3 tumour bearing mice (Figure 5.15). Following 
acquisition of the 90 h PET image, mice were euthanised by exsanguination under anaesthesia. Tissues were 
removed, washed, dried, weighed and the associated 89Zr radioactivity was counted by using a gamma 
counter. Experimental; Table 6.8 shows the full biodistribution data set. The data shows an increased 
accumulation of [89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab in the normal group (7.53 ± 0.96 %ID g-1, normal, 
n = 4) when compared to the block group (4.21 ± 1.05 %ID g-1, block, n = 4). These data confirm that radiotracer 
uptake in vivo is facilitated via specific binding of the trastuzumab to the HER2/neu. In both groups, a large 
amount of activity was associated with the liver (20.87 ± 2.29 %ID g-1, normal, n = 4; 22.95 ± 2.12 %ID g-1, block, 
BA
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n = 4). This is to be expected given the large size of the constructs. In general, the biodistribution data are in 
excellent agreement with the quantitative analysis of the calibrated PET images. 
 
Figure 5.15. Biodistribution data showing the accumulation of [89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab 
radioactivity in different tissues at 90 h post-administration in mice bearing SK-OV-3 tumours.  
 
5.4 Conclusion 
To conclude, we have successfully conjugated GNF constructs to both trastuzumab and onartuzumab, which 
allowed us to create multi-modal constructs for application in PET/MR imaging. GNF constructs were 
decorated with GdDOTAGA and DFO for subsequent 89Zr radiolabelling. Following this, conjugation to 
trastuzumab allowed targeting of HER2/neu on SK-OV-3 cells and tumours which was demonstrated by using 
cellular binding assays. Finally, the pharmacokinetics and tumour-specific uptake of the [89Zr]GdDOTAGA-
ZrDFO-GNF-trastuzumab conjugate was evaluated in vivo by using small-animal PET imaging and 
biodistribution studies. Image analysis and biodistribution data indicated specific uptake in SK-OV-3 tumours, 






In this thesis, we have on focused the development of multi-modal imaging agents based on iron oxide 
nanoparticles and GNFs. We have explored various stages of radiotracer construction; from basic synthesis 
and radiochemistry, to cellular and animal studies.  
 
Chapter 2 concentrated on the fundamental principles of nanoparticle synthesis and radiolabelling. Initially, 
we investigated two methods for the synthesis of iron oxide nanoparticles; co-precipitation and thermal 
decomposition. Both routes produced nanoparticles which were sufficiently small, accelerating the transverse 
relaxation of local water molecules to a range suitable for MR imaging. We also characterised and compared 
the commercially available nanoparticles, FH, as well as Fe2O3@Au nanoparticles obtained via a collaboration. 
The next section of Chapter 2 developed and investigated radiolabelling methods.  Initially, classical, chelate-
based methods were used to label nanoparticles with 68Ga. The methods explored involved the use of 
traditional surface-based chemistries to label Fe2O3@Au with a 68Ga, dithiolane chelate, as well as new method 
of conjugation using a photoactivatable chelate to derivatise the nanoparticle coating. We also studied 
intrinsic, chelate-free methods of radiolabelling nanoparticles which produced higher RCCs in shorter times 
timescales. To explore the mechanism of chelate-free radiolabelling further, the first kinetic studies were 
performed. 
 
In Chapter 3 we built on the concepts developed in Chapter 2 to produce constructs for the potential use in 
PET/MRI. Both constructs were specifically targeted to cancer cells using the PSMA binding motif, and 
Fe2O3@Au nanoparticles were radiolabelled using a chelate method, whilst FH nanoparticles were 
radiolabelled using an intrinsic, chelate-free method. Following 68Ga radiolabelling, constructs were tested in 
vitro using PSMA expressing, LNCaP cells which indicated specific uptake facilitated by the PSMA binding motif. 
Unfortunately, both constructs performed poorly when tested in vivo with small-animal PET imaging using 
athymic nude mice demonstrating rapid liver uptake and insignificant localisation in the tumour. Future work 
should involve altering the nanoparticles to improve the pharmacokinetic profile, and potentially enable the 
uptake of radiotracer into tumour tissue. 
 
In Chapters 4 and 5, we have used GNFs to produce multi-modal imaging agents. Chapter 4 uses the GNFs as 
a scaffold to produce targeted theranostic agents. GNFs were loaded with derivatives of (i) a PSMA targeting 
vector, (ii) a potent anti-mitotic drug (R)-ispinesib, (iii) the chelate DFO for 68Ga labelling, and (iv) an albumin-
binding tag reported to extend pharmacokinetic half-life in vivo. Following synthesis and radiolabelling, in vitro 
experiments showed that constructs exhibited toxicity and specific uptake in LNCaP cells. Unfortunately, due 
to poor pharmacokinetics in vivo, GNFs were rapidly excreted and no significant tumour uptake was observed. 
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To address these issues, Chapter 5 conjugated an antibody to the GNF, improving specific uptake into target 
cells and increasing circulation times in vivo. The chemistries established in Chapter 4 were used to 
functionalise the GNFs with DFO for 89Zr labelling and GdDOTAGA for MRI contrast, producing constructs with 
PET/MRI capabilities. The functionalised GNFs were then conjugated to the HER2/neu targeting mAb, 
trastuzumab, and subsequent in vitro assays demonstrated uptake in SK-OV-3 cells. Final small-animal PET 












Chapter 6: Experimental 
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6.1 Standard Methods 
6.1.1 Synthesis and Characterisation 
NMR Spectroscopy  
1H, 13C, 31P and 19F NMR spectra were measured in deuterated solvents on a Bruker AV-300, a Bruker AV-400, 
or a Bruker AV-500 spectrometer. Chemical shifts (d) are expressed in parts per million (ppm) relative to the 
resonance of the residual solvent peaks or internal reference, for example, with DMSO dH = 2.50 ppm and dC 
= 39.5 ppm with respect tetramethylsilane (TMS, dH and dC = 0.00 ppm). Coupling constants (J) are reported in 
Hz. Peak multiplicities are abbreviated as follows: s (singlet), d (doublet), dd (doublet of doublets), t (triplet), 
q (quartet), m (multiplet), and br (broad). 
Mass Spectrometry 
High-resolution electrospray ionisation mass spectra (HR-ESI-MS) were measured by the mass spectrometry 
service at the Department of Chemistry, University of Zurich.  
UV-Visible Spectroscopy  
Electronic absorption spectra were recorded using a NanodropTM OneC Microvolume UV-Vis 
Spectrophotometer (ThermoFisher Scientific, supplied by Witec AG, Sursee, Switzerland). 
Sourcing of chemicals  
Unless otherwise stated, all other chemicals were of reagent grade and purchased from SigmaAldrich (St. 
Louis, MO), Merck (Darmstadt, Germany), Tokyo Chemical Industry (Eschborn, Germany), abcr (Karlsruhe, 
Germany) or CheMatech (Dijon, France). Water (>18.2 MΩ·cm at 25 ºC, Puranity TU 3 UV/UF, VWR 
International, Leuven, Belgium) was used without further purification. Solvents for reactions were of reagent 
grade, and where necessary, were dried over molecular sieves. 
Chromatography  
Column chromatography was performed by using Merck silica gel 60 (63 – 200 µm) with eluents indicated in 
the experimental section. Standard thin-layer chromatography (TLC) for synthesis employed Merck TLC plates 
silica gel 60 on an aluminium base with the indicated solvent system. The spots on TLC were visualised either 
by UV/visible light (254 nm) or by staining with potassium permanganate or ninhydrin.  
Transmission Electron Microscopy (TEM) 
Samples (1 uL) were loaded onto 3 mm grids.  TEM images were then measured on a Philips CM100 100 kV 
transmission electron microscope equipped with a digital CCD camera.  
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Dynamic Light Scattering (DLS)  
Hydrodynamic size was measured with a Zetasizer Nano ZS90 (ZEN3690, Malvern Instruments Ltd, Malvern, 
UK) using polystyrene disposable cuvettes (Sarstedt AG &Co, Germany). 
Zeta Potential measurements 
z-potentials were measured with a Zetasizer Nano ZS90 (ZEN3690, Malvern Instruments Ltd, Malvern, UK) 
using Malvern disposable folded capillary cells. z-potential measurements consist of 20 runs (n=3). 
XRD 
Powder X-ray diffraction patterns (PXRD) were measured on an STOE STADI P diffractometer in transmission 
mode using Mo Kα1 radiation in a flat-plate sample holder with Ge monochromator and a position-sensitive 
microstrip solid-state detector (MYTHEN 1K). 
IR measurements 
Fourier transform infrared spectroscopy (FT-IR) was performed using a Bruker-Vertex 70 spectrometer. 
Iron content calibration curve  
A dilution series of iron(III) chloride (24-480 µM) was made in 2 M HCl. To 1 mL of each solution, 1.5 M 
ammonium thiocyanate solution (200 µL) was added. The solutions were mixed for 5 min and the absorbance 
measured.  
 
Figure 6.1.  Calibration plots for the determination of iron content in nanoparticles. (A) UV-vis spectrum (350-
650 nm) for a variety of [Fe(SCN)6]3- solutions with the lmax = 466 nm. (B) [Fe(SCN)6]3- concentration vs. 
absorbance at lmax = 466 nm. 
 
 
Amine content calibration (Kaiser assay) 
Kaiser assay reagents 
Reagent A – Potassium cyanide (1.65 mg, 25 µmol) was dissolved in water (2.5 mL). 100 µL of this solution was 
then added to pyridine (4.9 mL). 
A B
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Reagent B – Ninhydrin (0.1 g, 0.56 mmol) dissolved in n-butanol (2 mL). 
Reagent C – Phenol (4 g, 42.5 mmol) in n-butanol (2 mL). 
Calibration curve 
A dilution series of glutamic acid (0.3-4.6 mM) was made in water. To a 1 mL aliquot of sample reagent A (20 
µL), reagent B (20 µL), and reagent C (20 µL) were added.  The solution was heated to 100oC for 5 min and the 
absorbance measured. 
Figure 6.2. Calibration plots for the determination of amine content. (A) UV-vis spectrum (500-650 nm) for a 
variety of amine concentrations with the lmax = 568 nm. (B) Amine concentration vs. absorbance at lmax = 568 
nm. 
 
6.1.2 Cell culture 
LNCaP 
The human prostate cancer cell line LNCaP clone FCG (PSMA/positive, American Type Culture Collection 
(ATCC® CRL-1740™), Manassas, VA) was used. Cells were cultured at 37 oC in a humidified 5% CO2 atmosphere 
in RPMI Medium 1640 containing [+]-L-glutamine (2.5 mM), supplemented with fetal bovine serum (FBS, 10% 
(v/v), ThermoFisher Scientific) and penicillin/streptomycin (P/S, 1% (v/v) of penicillin 10000 U/mL and 
streptomycin 10 mg/mL). Cells were grown by serial passage and were harvested by using trypsin (0.1%). 
PC-3 
The human prostate cancer cell line PC-3 (American Type Culture Collection (ATCC® CRL-1435™), Manassas, 
VA) was used. Cells were cultured at 37 oC in a humidified 5% CO2 atmosphere in DMEM/F12 (1:1) (Dulbecco’s 
Modified Eagle Medium, F-12 Nutrient mixture (Ham), ThermoFisher Scientific, Schlieren, Switzerland) 
medium containing [+]-L-glutamine (2.5 mM), supplemented with fetal bovine serum (FBS, 10% (v/v), 
ThermoFisher Scientific) and penicillin/streptomycin (P/S, 1% (v/v) of penicillin 10000 U/mL and streptomycin 
10 mg/mL). Cells were grown by serial passage and were harvested by using trypsin (0.5%). 
SK-OV-3 
The human ovarian cancer cell line SK-OV-3 (HER2/neu-positive, American Type Culture Collection (ATCC- HTB-
77), Manassas, VA) was used. Cells were cultured at 37 oC in a humidified 5% CO2 atmosphere in DMEM/F12 
A B
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(1:1) (Dulbecco’s Modified Eagle Medium, F-12 Nutrient mixture (Ham), ThermoFisher Scientific, Schlieren, 
Switzerland) medium containing [+]-L- glutamine (2.5 mM), supplemented with fetal bovine serum (FBS, 10% 
(v/v), ThermoFisher Scientific) and penicillin/streptomycin (P/S, 1% (v/v) of penicillin 10000 U/mL and 
streptomycin 10 mg/mL). Cells were grown by serial passage and were harvested by using trypsin (0.5%). 
MKN-45 
The human gastric cancer cell line MKN-45 (Leibniz Institute DSMZ- German collection of Microorganisms and 
Cell cultures (ACC 409) was used. Cells were cultured at 37 oC in a humidified 5% CO2 atmosphere in RPMI 
Medium 1640 containing [+]-L-glutamine (2.5 mM), supplemented with fetal bovine serum (FBS, 10% (v/v), 
ThermoFisher Scientific) and penicillin/streptomycin (P/S, 1% (v/v) of penicillin 10000 U/mL and streptomycin 
10 mg/mL). Cells were grown by serial passage and were harvested by using trypsin (0.25%). 
BCA Assay  
Working reaction buffer was freshly prepared by adding Cu(SO4)2 (4%) to Pierce BCA Protein Assay Reagent A 
(ThermoFisher Scientific) in a 1:50 ratio. Cell lysate (5 μL) was added to the working reaction buffer (50 μL) in 
triplicate in a 96 well plate. The plate was incubated for 30 min at 37 oC. The absorbance was measured on 
Hidex-Sense Plate Reader using the BCA Assay programme. Absorbance was compared to a standard solution 
curve (using BSA protein). The protein concentrations of cell lysates were normalised by dilution in saline. 
Xenograft models  
All experiments involving mice were conducted in accordance with an animal experimentation licence 
approved by the Zurich Canton Veterinary Office, Switzerland (Jason P. Holland). Experimental procedures 
also complied with guidelines issued in the Guide for the Care and Use of Laboratory Animals. Athymic nude 
mice (Crl:NU(NCr)-Foxn1nu, 27 – 35 g, 6 – 8 weeks old) were obtained from Charles River Laboratories Inc. 
(Freiburg im Breisgau, Germany) and were allowed to acclimatise at the University of Zurich Laboratory Animal 
Services Center vivarium for at least 1 week prior to implanting tumour cells. Mice were provided with food 
and water ad libitum. Tumours were induced on the shoulders by sub-cutaneous (s.c.) injection of either 
LNCaP (2.5 x 106 cells) or SK-OV-3 (7 x 10 6) cells. The cells were injected in a 200 μL suspension of a 1:1 v/v 
mixture of PBS and reconstituted basement membrane (Corning® Matrigel® Basement Membrane Matrix, 
obtained from VWR International). Tumours developed after a period of between 3-8 weeks depending on 
cell line. Tumour volume (V / mm3) was estimated by external Vernier caliper measurements of the longest 
axis, a / mm, and the axis perpendicular to the longest axis, b / mm. The tumours were assumed to be 
spheroidal and the volume was calculated in accordance with Equation 6.1. All mice injected with cancer cells 
developed tumours and the average volume of the LNCaP tumours was 325 ± 133 mm3 (n = 6 mice). 
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Equation 6.1. Approximation of tumour volume. 





6.1.3 Radiochemical Methods 
All instruments for measuring radioactivity were calibrated and maintained in accordance with previously 
reported routine quality control procedures.393 
Gallium-68 
[68Ga][Ga(H2O)6]Cl3(aq.) was obtained from 68Ge/68Ga-generators (Eckert&Ziegler, Model IGG100 Gallium-68 
Generator), eluted with 0.1 M HCl(aq.). The eluted 68Ga activity was trapped and purified by using a strong 
cation exchange column (Strata-XC, [SCX], Eckert&Ziegler). [68Ga][Ga(H2O)6]Cl3(aq.) was eluted from the SCX 
cartridge by using a solution containing 0.13 M HCl(aq.) and approx. 5 M NaCl(aq.) (SCX eluent). The generator 
gave varying molar activities. For radiolabelling experiments the 68Ga stock solution was typically added as the 
limiting reagent to an aqueous reaction mixture buffered with NaOAc (approx. 0.2 M, pH4.4).  
Zirconium-89 
[89Zr][Zr(C2O4)4]4- (aq.) was obtained as a solution in ~1.0 M oxalic acid from PerkinElmer (Boston, MA, 
manufactured by the BV Cyclotron VU, Amsterdam, The Netherlands) and was used without further 
purification. 
Indium-111 
[111In]InCl3(aq.) dissolved in HCl (~0.1 M) was obtained from a commercial source and used without further 
purification (B.e. imaging, Schwyz, Switzerland). 
Copper-64 
[64Cu]CuCl2(aq.) dissolved in HCl (~0.5-3.0 M) was obtained from a commercial source and used without further 
purification (IPHC, Paris, France). 
Radio-iTLC 
Radioactive reactions were monitored by using instant thin-layer chromatography (iTLC). Glass-fibre iTLC 
plates impregnated with silica-gel (iTLC-SG, Agilent Technologies) were developed in water (>18.2 MΩ·cm) 
and analysed on a radio-TLC detector (SCAN-RAM, LabLogic Systems Ltd, Sheffield, United Kingdom). 
Radiochemical conversion (RCC) was determined by integrating the data obtained by the radio-TLC plate 
reader and determining both the percentage of radiolabelled product and ‘free’ 68Ga, 89Zr, 64Cu or 111In. 
Integration and data analysis were performed by using the software Laura version 5.0.4.29 (LabLogic). 
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Size Exclusion Chromatography  
Samples were analysed by using two methods of SEC. The first was an automated size-exclusion column (Bio-
Rad Laboratories, ENrich SEC 70, 10 ± 2 µm, 10 mm ID x 300 mm) connected to a HPLC device (Rigol L-3000, 
Contrec AG, Switzerland) equipped with a UV/visible detector (absorption measured at 400 nm) as well as a 
radioactivity detector (FlowStar2 LB 514, Berthold Technologies, Zug, Switzerland). Isocratic elution with 
phosphate buffered saline (PBS, pH7.4) with 200 mM arginine was used. The second method used a manual 
procedure involving size-exclusion column chromatography using a PD-10 desalting column (Sephadex G-25 
resin, 85-260 μm, 14.5 mm ID x 50 mm, >30 kDa, GE Healthcare). For analytical procedures, PD-10 columns 
were eluted with sterile saline or PBS. A total of 40 x 200 μL fractions were collected up to a final elution 
volume of 8 mL. Note that the loading/dead-volume of the PD-10 columns is precisely 2.50 mL which was 
discarded prior to aliquot collection. For quantification of radioactivity, each fraction was measured on a 
gamma counter.  
Quantification of radioactivity 
For quantification of radioactivity, each fraction was measured on a gamma counter (HIDEX Automatic Gamma 
Counter, Hidex AMG, Turku, Finland) using  a counting time of 30 s and an energy window between 480 – 558 
keV for 68Ga (511 keV emission), between 480 – 558 keV for 89Zr (511 keV emission), 15 – 2047 keV for 111In, 
and 480-558 keV for 64Cu (511 keV emission). Appropriate background and decay corrections were applied 
throughout. 
Calculation of the molar activities of radionuclides 
The molar activities of radionuclides were determined via the titration of the nuclide with a known 
concentration of appropriate chelate (68Ga-DFO, 89Zr-DFO, 64Cu-DTPA, 111In-DTPA).  
For example: The molar activity of 68Ga is determined via titration with DFO. Briefly, DFO samples were 
prepared at a variety of concentrations and buffered with NaOAc (0.2 M, pH 4.4). Aliquots of 
[68Ga][Ga(H2O)6]Cl3(aq.) stock solution (ca. 16 MBq) were added to each sample and after 10 min radio-iTLC 
was used to gain a RCC.  Data prior to saturation was fitted linearly (Figure 3).  This was used to obtain a molar 




Figure 6.3. DFO titration to calculate the molar activity of the 68Ga generator. 
 
 
PET image acquisition  
Mice were anesthetised by inhalation of between 2 – 4% isoflurane (AttaneTM, Piramal Enterprises Ltd, India, 
supplied by Provet AG, Lyssach, Switzerland)/oxygen gas mixture.  PET imaging experiments were conducted 
on a Genesis G4 PET/X-ray scanner (Sofie Biosciences, Culver City, CA).394 For each mouse the tail vein was 
warmed gently using a warm water bath, a catheter inserted in the tail vein and then placed on the scanner 
bed in the prone position. PET images were acquired using a γ-ray energy window of 150–650 keV, and a 
coincidence timing window of 20 ns. Images were reconstructed by iterative ordered subset maximum 
expectation (OSEM; 60 iterations) protocols. The reported reconstructed spatial resolution is 2.4 µL at the 
centre of the field-of-view (FOV). Image data were normalised to correct for non-uniformity of response of 
the PET, attenuation, random events, dead-time count losses, positron branching ratio, and physical decay to 
the time of injection, but no scatter or partial-volume averaging correction was applied. An empirically 
determined system calibration factor (in units of [Bq/voxel]/[MBq/g] or [Bq/cm3]/[MBq/g]) for mice was used 
to convert voxel count rates to activity concentrations. The resulting image data were normalised to the 
administered activity to parameterise images in terms of %ID cm-3 (equivalent to units of %ID/g assuming a 
tissue density of unity). Images were analysed by using VivoQuantTM 3.5 patch 2 software (InviCRO, Boston, 
MA). For image quantification and measurements of time-activity curves (TACs), 3-dimensional volumes-of-
interest (VOIs) were drawn manually to determine the maximum and mean accumulation of radioactivity (in 
units of %ID cm-3 and decay corrected to the time of injection) in various tissues. 
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6.2. Experimental methods associated with Chapter 2   
6.2.1 Synthesis and characterization of nanoparticles  
Co-precipitation synthesis of Fe3O4 nanoparticles  
 




NB. All solutions used during this synthesis were degassed by the bubbling of nitrogen through the solutions 
for 5 h. As well as this, care was made to avoid oxygen reaching the reaction mixture during synthesis.  
 
To a solution of iron(III) chloride hexahydrate (400 mg, 1.48 mmol) and iron(II) chloride (94 mg, 0.74 mmol) in 
water (13 mL), 30% ammonia (1.5 mL) solution was added. The resulting black precipitate was collected and 
transferred to a round bottom flask using water (15 mL) and sonication. 2M nitric acid (3.2 mL) and iron(II) 
nitrate nonahydrate (327 mg, 0.81 mmol) was added and the reaction was refluxed for 1.5 h. Following this, 
the reaction was allowed to cool to room temperature and then dialysed (dialysis tubing: MWCO = 14,000 g 
mol-1) against 0.01M nitric acid for 3 days. Centrifugation (4000 rpm, 2 h) was used to remove aggregates and 
the dispersion was decanted to yield Fe3O4 as dark brown solution. 
Iron content determination of Fe3O4 nanoparticles  
Fe3O4 (1.0 mg) was dissolved in 10 M HCl (0.5 mL) and heated to 70 oC for 3 h. A portion of this solution (0.2 
mL) was diluted into ammonium persulfate (1.5 M, 0.8 mL). Following this, ammonium thiocyanate solution 
(0.2 mL, 1.5 M) was added to all samples. After 5 min a dilution series was performed and the UV-vis spectra 
were recorded. Using previously determined extinction coefficients the particles were found to contain 
12.72±0.04 mmol iron per g of nanoparticle. This means nanoparticles are 70.9 ± 0.2% iron by mass. 
Chemical synthesis of Fe3O4@OA nanoparticles  
Reaction carried out under nitrogen. A solution of iron(III) acetylacetone (150 mg, 0.42 mmol) in diphenyl 
ether (2 mL) was prepared. Separately, in the reaction vessel a solution of oleic acid (0.21 mL, 0.67 mmol), 
oleylamine (0.22 mL, 0.67 mmol), and 1,2-hexandecanediol (290 mg, 1.12 mmol) in diphenyl ether (1.2 mL) 
was prepared.  Simultaneously, both mixtures were heated to 120oC and then then 1 mL of the iron solution 
was injected into the reaction vessel. The reaction was then heated to 200oC for 30 min and then 265oC for a 
further 30 min. The reaction was allowed to cool to room temperature and ethanol (4 mL) was added.  The 
resulting precipitate was collected and re-dispersed in a solution of oleic acid (5 µL) and oleylamine (5 µL) in 
hexane (4 mL).  Solution was then centrifuged (4000 rpm, 5 min) and solution decanted.  The addition of 
2Fe3+  +  Fe2+  +  8OH- Fe3O4  +  H2O
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ethanol (6 mL) then caused precipitation which was collected and re-dispersed in hexane (4 mL) to yield 
Fe3O4@OA as a dark brown solution.IR: vmax/cm-1 2846 (CH), 2794 (CH), 985 (FeO), 480 (FeO). 
Iron content determination of Fe3O4@OA 
Fe3O4@OA (20.27 mg) was dissolved in 10 M HCl (1 mL) and heated to 70 oC for 3 h. A portion of this solution 
(0.2 mL) was diluted into ammonium persulfate (1.5 M, 0.8 mL). Following this, ammonium thiocyanate 
solution (0.2 mL, 1.5 M) was added to all samples.  After 5 min a dilution series was performed and the UV-vis 
spectra were recorded. Using the previously obtained calibration plot the particles were found contain 
5.14±0.48 mmol per g of nanoparticle. This equates to a 28.5±2.9% iron content by mass. 
Al(OH)3 functionalisation of Fe3O4@OA to synthesise Fe3O4@Al(OH)3 
To a solution of Fe3O4@OA in diethyl ether (1 mL, 2.25 mg mL-1) a solution of AlCl3 (0.36 mg, 2.70 µmol) in 
diethyl ether (0.5 mL) was added. The reaction was sonicated for 5 min and then acetone (400 µL) was added. 
The resulting precipitate was collected via centrifugation (16000 RPM, 20 min), dried and then re-dispersed 
into water (2 mL). IR: vmax/cm-1 3029 br (OH), 1553 (OH), 856 (FeO), 522 (Fe-O). 
Iron content determination of Fe3O4@Al(OH)3 
Fe3O4@Al(OH)3 (7.52 mg) was dissolved in 10 M HCl (1 mL) and heated to 70 oC for 3 h. A portion of this 
solution (0.2 mL) was diluted into ammonium persulfate (1.5 M, 0.8 mL). Following this, ammonium 
thiocyanate solution (0.2 mL, 1.5 M) was added to all samples. After 5 min a dilution series was performed 
and the UV-vis spectra were recorded. Using the previously obtained calibration plot the particles were found 
contain 2.04±0.14 mmol per g of nanoparticle. This equates to a 11.3±1.1% iron content by mass. 
APTES functionalisation of Fe3O4@OA to synthesise Fe3O4@APTES 
To a solution of Fe3O4@OA in hexane (10 mL, 1 mg mL-1) a solution of APTES (30 µL, 28.3 µg, 0.13 µmol) in a 
1:1 H2O:EtOH (1 mL) was added. The reaction was shaken vigorously for 14 h.  The resulting precipitate was 
washed with hexane (3 x 5 mL) and the particles were dispersed in dilute HCl (0.1 mM, 10 mL). IR: vmax/cm-1  
2909 (CH), 2831 (CH), 1507 (NH), 1396 (Si-C), 1283 (Si-O), 1036 (Fe-O), 541 (FeO). 
Iron content determination of Fe3O4@APTES 
Fe3O4@APTES (3.12 mg) was dissolved in 10 M HCl (1 mL) and heated to 70 oC for 3 h. A portion of this solution 
(0.2 mL) was diluted into ammonium persulfate (1.5 M, 0.8 mL). Following this, ammonium thiocyanate 
solution (0.2 mL, 1.5 M) was added to all samples. After 5 min a dilution series was performed and the UV-vis 
spectra were recorded. Using the previously obtained calibration plot the particles were found contain 
4.20±0.31 mmol per g of nanoparticle. This equates a 23.4±1.8% iron content by mass. 
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Amine content determination of Fe3O4@APTES 
In a test tube, a solution of Fe3O4@APTES (1 mg mL-1, 20 µL) and the Kaiser assay reagents (20 µL A, 20 µL B 
and 20 µL C) was prepared. As a comparison, a tube with Fe3O4@OA (20 µL) the Kaiser assay reagents (20 µL 
A, 20 µL B and 20 µL C) was prepared. Both test tubes were heated to 110 oC for 5 min, with a blue colour 
being observed in the Fe3O4@APTES test tube. The absorbance was recorded and using the amine content 
calibration curve (Figure 2) the amine content was found to be 1.3 mM.  
Determination of Fe2O3@Au composition (ICP-MS) 
Samples measured by UZH ICP-MS service. Samples were dissolved in nitric acid (3 mL, 2%) in a 1:1000 dilution 
before measurements were carried out on an Agilent 8800 ICP-MS. Data was then compared to iron and gold 
calibration plots. Samples were found to contain 24.8 ± 0.4 µg ml-1 iron and 106.0 ± 0.1 µg ml-1 gold.  
T2 relaxation times 
T2 relaxation times were measured for nanoparticles using a Bruker AV-III 11.74 T 500 MHz NMR. 
Nanoparticles were measured at a concentration of 1 mg mL-1 and then the relaxivity was calculated (Chapter 
1; Equation 1.3) using the known iron concentration. T2 relaxation of pure water was found to be 363.7 ms. 
 
6.2.2 Radiolabeling of nanoparticles  
Chelate based radiolabeling of Fe2O3@Au  
Synthesis of (R)-lipoic acid-(PEG)4-DOTAGA (2) and chelation to gallium (
natGa-2) 
 
Synthesis of compound 1 
To a solution of (±)-a-Lipoic acid (400 mg, 1.92 mmol) in DCM (20 mL), EDC (423 mg, 2.21 mmol) and NHS (254 
mg, 2.21 mmol) were added. After 3 h the reaction was washed with water (3 x 30 mL) and brine (1 x 30 mL), 
dried with anhydrous MgSO4, and solvent removed under reduced pressure to isolate product as a yellow solid 
(438 mg, 1.44 mmol, 76%). 1H NMR (400 MHz, CDCl3) δ 3.61 (dq, J = 8.3, 6.4 Hz, 1H), 3.26 – 3.10 (m, 2H), 2.87 
(s, 4H), 2.66 (t, J = 7.4 Hz, 2H), 2.56 – 2.44 (m, 1H), 1.96 (s, 1H), 1.82 (p, J = 7.4 Hz, 2H), 1.78 – 1.69 (m, 2H), 















Synthesis of compound 2 
To a solution of compound 1 (13.1 mg, 43.2 µmol) in DMF (1 mL) and TEA (40 µL), NH2-(PEG)4-DOTAGA (30 
mg, 43.2 µmol) was added. The solution was stirred for 24 h at room temperature before further addition of 
compound 1 (16.9 mg, 28.8 µmol). The reaction was then stirred for a further 24 h and then the solvent was 














































yield 2 as an off-white solid (12.1 mg, 13.8 µmol, 32%). 1H NMR (500 MHz, D2O) δ 4.10 – 2.83 (m, 46H), 2.58 – 
2.54 (m, 2H), 2.50 (dq, J = 12.3, 6.1 Hz, 1H), 2.27 (t, J = 7.3 Hz, 2H), 2.00 (d, J = 13.7, 6.7 Hz, 3H), 1.76 (dtd, J = 
13.6, 7.9, 5.5 Hz, 1H), 1.69 – 1.56 (m, 3H), 1.42 (p, J = 7.4 Hz, 2H). 13C NMR (126 MHz, D2O) δ 176.99, 176.98, 
176.95, 69.64, 69.59, 69.42, 69.40, 68.88, 68.76, 56.52, 40.26, 38.93, 38.88, 38.06, 35.46, 33.70, 27.81, 25.01. 
HRMS (ESI+) (m/z): calculated for C37H68N6O14S22+ ([M+2H]2+): 442.2112; found: 442.2118) (100%). 
 























































































Synthesis of compound natGa-2 
To a solution of compound 2 (3 mg, 3.4 µmol) in water (100 µL) gallium nitrate (0.93 mg, 3.4 µmol) was added. 
The solution was heated at 70 oC for 10 min and to yield natGa-2 in a quantitative yield. tR (RP-HPLC) = 6.24 min 
(detection at λ = 254 nm). RP-HPLC method: A flow rate of 1.0 mL min-1 with a linear gradient of A (distilled 
H2O containing 0.1% TFA) and B (acetonitrile): t = 0 min, 95% A; t = 12 min, 5% A; t = 15 min, 5% A. HRMS (ESI+) 




























































Radiolabelling of compound 2 - Synthesis of [68Ga]Ga-2 
Radiolabelling reactions to prepare [68Ga]LA-(PEG)4-DOTAGA-Ga ([68Ga]Ga-2) were accomplished by addition 
of an aliquot of [68Ga][Ga(H2O)6]Cl3(aq.) stock solution (ca. 12.8 MBq) to an aqueous solution of 2 (5 µL, 11.3 
µg, 12.8 nmol) buffered with NaOAc (0.2 M, pH 4.4). The reaction was monitored by using radio-iTLC and was 
found to be complete after 10 min. at 70 oC giving a radiochemical conversion (RCC) >99% (n = 5, Rf = 0.00 – 
0.20, eluent: 0.2 M citrate buffer). The product was characterised by analytical HPLC (Nucleodur EC 250/4, 4 
mm ID x 250 mm (C18 HTec, 5 µm) at a flow rate of 1.0 mL min-1 with a linear gradient of A (distilled H2O 
containing 0.1% TFA) and B (acetonitrile): t = 0 min, 95% A; t = 12 min, 5% A; t = 15 min. Note that the UV/vis 
detector and radioactivity detector were arranged serially with an offset time of approximately 0.10 min. The 
identity of the radiolabelled compound 68Ga-2 was confirmed with an authenticated sample of natGa-2. 
 
Chemical synthesis of [68Ga]Fe2O3@Au-(Ga-2) 
[68Ga]Ga-2 was prepared as described above and then neutralised with NaOH (1M, approx. 25 µL).  An aliquot 
of [68Ga]Ga-2 (3.5 µL, 0.17 nmol) was added to Fe2O3@Au (190 µL, 24.8 µg, 102.03 nmol of Au) and reaction 
vortexed. After 5 mins radio-iTLC (stationary phase: silica gel, mobile phase: MeOH/H2O 1:1 with 0.5% HCl) 
indicated a RCC>97% (n = 3, Rf = 0.0 – 0.23). PD10-SEC (eluent: water) indicated a RCP of 94%.   
 
Loading capacity of Fe2O3@Au with 
68Ga-2 
[68Ga]Ga-2 was prepared as described above and then neutralised with NaOH (1M, approx. 25 µL).  A dilution 
series was then performed (0.6-23.3 µM) and 20 µL of each 68Ga-2 sample was added to 20 µL Fe2O3@Au (0.54 
mM). Radio-iTLC was then used to determine the RCC. It was found that concentrations of [68Ga]Ga-2 > 2.33 
µM saturated the nanoparticle surface and led to free [68Ga]Ga-2 in solution.  
 































































































Kinetic study of the functionalisation of nanoparticles with 68Ga-2 
[68Ga]Fe2O3@Au-(Ga-2) reactions were prepared as described above by using the maximum concentration of 
chelate (2.33 µM) and cooled to 4 oC.  On addition of [68Ga]Ga-2, aliquots were taken at time intervals (5-90 s) 
and the RCC determined. The rate constant was determined by fitting the data to second-order rate kinetics.  
 
Control studies 
Scheme 6.2. Chemical synthesis of [68Ga]Ga-DOTAGA-PEG4-NH2 ([68Ga]Ga-3) and the control reaction with 
Fe2O3@Au. 
 
Preparation of 68Ga-3 
Radiolabeling reactions to prepare [68Ga]DOTAGA-Ga-(PEG)4-NH2 ([68Ga]Ga-3) were accomplished by addition 
of an aliquot of [68Ga][Ga(H2O)6]Cl3(aq.) stock solution (10.7 MBq) to an aqueous solution of 3 (8.90 µg, 12.8 
nmol) buffered with NaOAc (0.2 M, pH 4.4). The reaction was monitored by using radio-iTLC and was found to 
be complete after 10 min. at 70 oC giving a radiochemical conversion (RCC) = 98% (Rf = 0.00 – 0.32, eluent: 0.2 
M citrate buffer, pH4.5).  
 
Incubation of 68Ga-3 with NP 
68Ga-3 was prepared as described above and then neutralised with NaOH (1M, approx. 25 µL). An aliquot of 
68Ga-3 (10 µL, 0.47 nmol) was added to Fe2O3@Au (190 µL, 102.03 nmol of Au) and reaction vortexed. After 5 






























































Figure 6.11. (A) Radio-iTLC data irradiated for [68Ga]Ga-3 with silica as stationary phase and 0.2 M citrate 




Photoconjugation of radiolabelled photo-activatable chelate to nanoparticle surface 
Radiolabelling of photoactivatable chelate  






High chelate concentration synthesis of [68Ga]Ga-4 
Radiolabelling reaction to prepare [68Ga]GaDOTA-PEG4-ArN3 ([68Ga]Ga-4) was accomplished by addition of an 
aliquot of [68Ga][Ga(H2O)6]Cl3(aq.) stock solution (54.38 MBq) to an aqueous solution of DOTA-PEG4-ArN3 (50 
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0.2 M NaOAc, 70 oC, 10 min
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and was found to be complete after 10 min. at 70 oC. Characterisation data analogous to that of the chelate 
at lower concentration below. 
 
Low chelate concentration synthesis of [68Ga]Ga-4 
Radiolabelling reaction to prepare [68Ga]GaDOTA-PEG4-ArN3 was accomplished by addition of an aliquot of 
[68Ga][Ga(H2O)6]Cl3(aq.) stock solution (28.4 MBq) to an aqueous solution of DOTA-PEG4-ArN3 (0.5 mM, 20 µL, 
10 nmol) buffered with NaOAc (0.2 M, pH 4.4). The reaction was monitored by using radio-iTLC and was found 
to be complete after 10 min. at 70 oC giving a radiochemical conversion (RCC) >99% (Rf = 0.08 – 0.21). RP-
UHPLC: tR(radioactive trace) = 8.60 min (RCP 98%). RP-UHPLC method: Nucleodur EC 250/4, 4 mm ID x 250 
mm (C18 HTec, 5 μm) at a flow rate of 1 mL min-1 with a linear gradient of A (H2O containing 0.1% TFA) and B 
(MeOH): t = 0-2 min., 80% A; t = 12 min., 5% A; t = 14 min., 5% A; t = 16 min., 80% A; t = 18 min., 80% A. 
 
Control - Irradiation of chelate 
Following the synthesis of [68Ga]GaDOTA-PEG4-ArN3, an aliquot (100 µL) of the reaction was placed in a glass 
vial and the pH adjusted to pH8 with the addition of NaHCO3 (1 M, 20 µL). The sample was then irradiated for 
10 min at 365 nm and analysed via radio-iTLC and PD10-SEC where the ‘RCC’ was found to be 0.8%. 
 
Figure 6.12. Characterisation data for irradiated [68Ga]Ga-4 (A) Radio-iTLC data with silica as stationary phase 
and 0.2 M citrate buffer (pH4.5) as eluent. (B) PD10-SEC with PBS as eluent 
 
 
Functionalisation of FH with APTES 




To a solution of FH nanoparticles (1 mL, 3 mg mL-1), APTES (30 µL, 28.38 µg, 128.1 µmol) was added and the 
reaction was vortexed for 14 h. Purification was then carried out by using preparative PD10 with saline as the 
eluent and collecting the first 1.8 mL. Amine concentration was then determined by using the Kaiser assay and 
was found to be 31.47 µmol mg-1. Samples were diluted to 1 mg mL-1 (31.47 mM amine). 
 
Light mediated conjugation of [68Ga]GaDOTA-PEG4-ArN3 to FH-APTES – High concentration of chelate  
Following the synthesis of [68Ga]Ga-4, an aliquot (100 µL) of the reaction (high chelate concentration synthesis) 
was placed in a glass vial and the pH adjusted to pH8 with the addition of NaHCO3 (1 M, 20 µL). Following this 
an aliquot of FH-APTES (100 µL, 1 mg mL-1) was added and the sample was irradiated at 365 nm for 10 min. 
The crude product was then analysed by using PD10-SEC (saline as eluent) and the RCC was found to be 1.4%. 
 
Light mediated conjugation of [68Ga]GaDOTA-PEG4-ArN3 to FH-APTES – Low concentration of chelate  
Following the synthesis of [68Ga]Ga-4, an aliquot (100 µL) of the reaction was placed in a glass vial and the pH 
adjusted to pH8 with the addition of NaHCO3 (1 M, 20 µL). Following this an aliquot of FH-APTES (100 µL, 1 mg 
mL-1) was added and the sample was irradiated at 365 nm for 10 min. The crude product was then analysed 
using PD10-SEC (saline as eluent) and the RCC was found to be 4.1%. Purification of the sample could then be 
carried out using preparative PD10-SEC (saline as eluent) by collecting the first 1 mL eluted giving a RCY of 3.3 
%. A second analytical PD10-SEC (saline as eluent) determined the RCP to be 97%. 
 
Conjugation of [68Ga]GaDOTA-PEG4-ArN3 to FH-APTES – control studies  
 
No irradiation control 
Following the synthesis of [68Ga]Ga-4, an aliquot (100 µL) of the reaction was placed in a glass vial and the pH 
adjusted to pH8 with the addition of NaHCO3 (1 M, 20 µL).  Following this an aliquot of FH-APTES (100 µL, 1 
mg mL-1) was added and the sample was left in the dark for 10 min. The crude product was then analysed 














No amine control  
Following the synthesis of [68Ga]Ga-4, an aliquot (100 µL) of the reaction was placed in a glass vial and the pH 
adjusted to pH8 with the addition of NaHCO3 (1 M, 20 µL). Following this an aliquot of FH (100 µL, 1 mg mL-1) 
was added and the sample was irradiated at 365 nm for 10 min. The crude product was then analysed by using 
SEC-PD10 (saline as eluent) and the ‘RCC’ was found to be 1.3%. 
 
Functionalisation of Fe3O4 with alendronate  
Scheme 6.5. Functionalisation of Fe3O4 with alendronate  
 
 
A solution of sodium alendronate (3 mg, 9.22 µmol) in water (200 µL) was prepared and the pH was adjusted 
to pH8 by the addition of NaOH (2M, 4 µL). This was then added to a dispersion of Fe3O4 (200 µL, 18.76 mg 
mL-1) in water (2 mL). The reaction was mixed overnight by heavy agitation and then purified using PD10-SEC 
using water as the eluent and collecting the first 1.8 mL eluted. The amine content was then determined using 
the Kaiser assay and found to be 4.93 µmol mg-1 (7.05 mM). Samples were diluted to 1 mg mL-1 (4.93 mM 
amine). 
 
Photoconjugation of [68Ga]GaDOTA-PEG4-ArN3 to Fe3O4@Alendronate   
Following the synthesis of [68Ga]Ga-4 the pH was adjusted to pH8 with the addition of NaHCO3 (1 M, 35 µL). 
An aliquot (10 µL) was then added to Fe3O4@Alendronate (100 µL, 1 mg mL-1) was added and the sample was 
irradiated at 365 nm for 10 min. The crude product was then analysed using PD10-SEC (water as eluent) and 
the RCC was found to be 7.4 ± 0.3% (n = 3). Purification of the sample could then be carried out using 
preparative PD10-SEC (water as eluent) by collecting the first 1 mL eluted giving a RCY of 6.0 ± 0.2% (n = 3). A 
second analytical PD10-SEC (water as eluent) determined the RCP to be 91%. 
 
Photoconjugation of [68Ga]GaDOTA-PEG4-ArN3 to Fe3O4@Alendronate  - Control Studies  
No irradiation control 
Following the synthesis of [68Ga]Ga-4 the pH was adjusted to pH8 with the addition of NaHCO3 (1 M, 35 µL). 























was incubated in the dark for 10 min. The crude product was then analysed by using PD10-SEC (water as 
eluent) and the ‘RCC’ was found to be 1.7%.   
No amine control  
Following the synthesis of [68Ga]GaDOTA-PEG4-ArN3 the pH was adjusted to pH8 with the addition of NaHCO3 
(1 M, 35 µL). An aliquot (10 µL) was then added to Fe3O4 (100 µL, 1 mg mL-1) was added and the sample was 
irradiated at 365 nm for 10 min. The crude product was then analysed by using PD10-SEC (water as eluent) 
and the ‘RCC’ was found to be 1.6%.  
 
Chelate-free radiolabelling of iron oxide nanoparticles  
Chelate free radiolabeling of Fe3O4@Al(OH)3  
To Fe3O4@Al(OH)3 solutions (750 µL, 750 µg) buffered with NaOAc (0.2 M, pH 4.4) aliquots of 
[68Ga][Ga(H2O)6]Cl3(aq.) stock solution (~25.0 MBq) were added. Reactions were incubated at 21 oC and 70 
oC for 10 min. The RCC was determined by radio-iTLC (stationary phase: silica gel, mobile phase: 1 M citrate 
buffer, pH 4.5) to be 37.2% (@21 oC) and 96.1% (@70 oC). 
 
Chelate free radiolabeling of Fe3O4@ATPES 
To Fe3O4@ATPES solutions (750 µL, 750 µg) buffered with NaOAc (0.2 M, pH 4.4) aliquots of 
[68Ga][Ga(H2O)6]Cl3(aq.) stock solution (~25.0 MBq) were added. Reactions were incubated at 21 oC and 70 
oC for 10 min. The RCC was determined by radio-iTLC (stationary phase: silica gel, mobile phase: 1 M citrate 
buffer, pH 4.5) to be 98.2% (@21 oC) and 99.2% (@70 oC). 
 
Kinetic study of 68Ga radiolabeling of Fe3O4 
To Fe3O4 solutions (100 µL, 100 µg) aliquots of [68Ga][Ga(H2O)6]Cl3(aq.) stock solution (~0.40 MBq) were 
added. Reactions were incubated at 21 oC, 37 oC, 50 oC and 70 oC at pH2. Aliquots of the reactions were 
taken at various time point and the RCC was determined by radio-iTLC (stationary phase: silica gel, mobile 
phase: 1:1 MeOH:H2O with 1% HCl). Reactions were performed in triplicate and obtained RCCs are 
summarised in Table 6.1.  
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Table 6.1. Mean RCC and associated SEM for the 68Ga radiolabeling of Fe3O4 





SEM / % Mean RCC 
/ % 
SEM / % Mean RCC 
/ % 
SEM / % Mean RCC 
/ % 
SEM / % 
0.25 - - - - 14.8 2.8 60.2 3.0 
0.5 3.4 - 5.0 1.2 22.4 4.9 79.7 1.8 
1 5.9 0.1 5.8 0.1 35.9 4.3 87.3 2.2 
2 - - - - 58.8 8.0 93.9 0.6 
3 6.2 0.1 12.8 0.8 76.1 6.2 96.7 0.2 
5 - 0.4 - - 84.0 3.8 98.3 0.8 
6 8.9 0.5 14.1 0.1 - - - - 
10 - - - - 92.3 1.2 97.5 0.4 
12 13.7 0.5 30.7 4.5 - - - - 
15 - 3.7 - - 92.8 0.3 97.8 0.1 
20 20.2 0.6 55.2 3.3 - - - - 
-30 25.6 2.2 73.2 2.8 - - - - 
60 36.1 - 86.8 1.3 - - - - 
120 46.1 - 87.9 0.5 - - - - 
 
Kinetic study of 68Ga radiolabeling of FH 
To FH solutions (100 µL, 100 µg) aliquots of [68Ga][Ga(H2O)6]Cl3(aq.) stock solution (~0.40 MBq) were added. 
Reactions were incubated at 37 oC, 50 oC, 70 oC and 90 oC at pH3. Aliquots of the reactions were taken at 
various time point and the RCC was determined by radio-iTLC (stationary phase: silica gel, mobile phase: 100% 




Table 6.2.  Mean RCC and associated SEM for the 68Ga radiolabeling of FH 
 





SEM / % Mean RCC 
/ % 
SEM / % Mean RCC 
/ % 
SEM / % Mean RCC 
/ % 
SEM / % 
0.25 - - 1.8 0.5 14.6 2.3 44.5 7.6 
0.5 - - 4.9 0.8 34.0 2.1 73.9 3.4 
1 0.5 0.1 10.2 1.5 57.5 4.2 86.8 2.0 
2 - - 21.6 3.3 76.7 3.9 94.0 0.4 
3 1.5 0.1 30.6 4.3 82.3 3.4 93.5 1.2 
5 2.4 0.4 45.7 6.2 89.7 1.8 96.0 1.1 
10 6.7 0.5 59.1 4.6 92.0 1.8 97.4 0.4 
15 - - 67.8 4.9 95.4 2.2 96.8 0.5 
20 13.0 0.5 75.9 3.3 96.1 0.4 - - 
30 20.2 3.7 83.1 2.4 97.0 0.3 - - 
60 44.4 0.6 87.8 1.7 - - - - 
120 64.1 2.2 - - - - - - 
 
Kinetic study of 111In radiolabeling of Fe3O4 
To a portion of [111In]InCl3(aq.) (6.08 MBq) 1 M acetate buffer (20 µL, pH4.4) was added. This [111In]In(OAc)3 
stock was then used for the following reactions. To Fe3O4 solutions (50 µL, 50 µg) aliquots of 
[111In]In(OAc)3(aq.) stock solution (~0.21 MBq) were added. Reactions were incubated at 37 oC, 50 oC, 70 oC 
and 90 oC at pH3. Aliquots of the reactions were taken at various time point and the RCC was determined by 
radio-iTLC (stationary phase: silica gel, mobile phase: 50 mM DTPA, pH7.1). N.B. TLC were quantified by 
dividing the TLC in two and measuring the associated activity using the Hidex Gamma counter (as opposed to 
using the TLC plate reader). Reactions were performed in triplicate and obtained RCCs are summarised in 




Table 6.3. Mean RCC and associated SEM for the 111In radiolabeling of Fe3O4 
 





SEM / % Mean RCC 
/ % 
SEM / % Mean RCC 
/ % 
SEM / % Mean RCC 
/ % 
SEM / % 
0.25 - - - - 8.7 0.8 21.0 0.3 
0.5 - - - - 16.9 1.2 26.2 0.7 
1 - - 19.7 0.7 23.7 1.9 33.5 1.4 
2 6.4 1.0 22.8 2.2 26.4 1.5 36.8 1.0 
3 - - -  32.6 5.4 55.2 9.2 
5 11.7 0.5 28.8 5.5 46.0 6.3 66.3 7.7 
10 14.9 3.0 47.9 1.4 56.7 3.1 80.5 4.8 
15 - - 50.5 4.1 69.3 1.6 86.4 4.2 
20 24.7 4.1 54.7 4.9 71.3 3.7 89.9 5.0 
30 30.6 1.1 61.1 9.2 75.6 2.5 - - 
60 39.0 1.5 77.0 6.2 - - - - 
 
 
Kinetic study of 111In radiolabeling of FH 
To a portion of [111In]InCl3(aq.) (6.08 MBq) 1 M acetate buffer (20 µL, pH 4.4) was added. This [111In]In(OAc)3 
stock was then used for the following reactions. To FH solutions (50 µL, 50 µg) aliquots of [111In]In(OAc)3(aq.) 
stock solution (~0.21 MBq) were added and reactions were buffered with 0.2M NaOAc (pH 4.4). Reactions 
were incubated at 37 oC, 43 oC, 50 oC and 70 oC at pH4.4. Aliquots of the reactions were taken at various time 
point and the RCC was determined by radio-iTLC (stationary phase: silica gel, mobile phase: 100% H2O). N.B. 
TLC were quantified by dividing the TLC in two and measuring the associated activity using the Hidex Gamma 
counter (as opposed to using the TLC plate reader). Reactions were performed in triplicate and obtained RCCs 




Table 6.4.  Mean RCC and associated SEM for the 111In radiolabeling of FH 
 





SEM / % Mean RCC 
/ % 
SEM / % Mean RCC 
/ % 
SEM / % Mean RCC 
/ % 
SEM / % 
0.25 - - - - - - 47.0 4.3 
0.5 - - - - - - 61.8 2.9 
1 - - 14.5 2.3 35.3 2.1 76.7 0.7 
2 - - 38.2 1.7 50.4 2.5 88.6 0.4 
3 - - - - - - 90.2 0.2 
5 19.2 1.8 64.4 6.5 81.3 1.2 90.2 0.3 
10 28.6 0.8 74.7 2.8 90.2 0.2 89.7 0.3 
15 - - 76.9 6.1 90.4 0.3 - - 
20 41.3 3.5 82.5 3.3 90.2 0.2 89.6 0.3 
30 44.9 1.1 85.2 0.5 90.3 0.3 88.7 0.5 
60 52.6 2.1 88.6 1.1 - - 47.0 4.3 
 
Thiol mediated radiolabelling of Fe2O3@Au 
Neutralisation of 64Cu stock 
The pH of a portion of the 64Cu stock solution (50 µL, 2.85 MBq) was adjusted to pH7 via the addition of 
NH4OAc (1 M, 7 µL) and Na2CO3 (1 M, 35 µL). 
 
Functionalisation of Fe2O3@Au with CH3-PEGn-SH to produce Fe2O3@Au(-S-PEGn-CH3)x 
CH3-PEGn-SH - Average Mn = 800 - Estimated Mw » 35310 g mol-1 
Using the approximate molecular weight a stock solution of CH3-PEGn-SH was prepared in H2O with the 
concentration of ~ 1 mM. This was then diluted to ~ 46.54 µM. An aliquot of CH3-PEGn-SH (~ 46.54 µM, 10.5 
µL) was added to Au@Fe2O3 NP (490 µL). The sample was incubated for 1 h at 21 oC and then used without 
further purification.  
 
Radiolabelling of Au@Fe2O3(-S-PEGn-CH3)x 
To test varying temperatures parallel reactions were prepared. To a Au@Fe2O3(-S-PEGn-CH3)x solution (48 µL) 
an aliquot of neutralised 64Cu stock (2 µL, ~0.2 MBq) was added. The reaction was left at 4 oC, 21 oC, 37 oC or 
50 oC. Aliquots of the reaction were taken for TLC analysis at time points between 0-60 min.  
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Reaction conditions - 20 min at 50 oC 
To a Au@Fe2O3(-S-PEGn-CH3)x solution (48 µL) an aliquot of neutralised 64Cu stock (3.5 µL, ~0.2 MBq) was 
added. The reaction was incubated at 50 oC for 20 min. The RCC was determined to be 88.1 ± 1.6% (n = 2) 
using radio-iTLC.  The RCP was determined to be 93.3 ± 1.2 % (n = 2) using PD-10 SEC with water as the eluent. 
The reaction was purified by PD10-SEC taking the first 1.8 mL to give a RCY of 74.8% and RCP of 99.6%. 
 
Reaction conditions - 1 h at 37 oC 
To a Au@Fe2O3(-S-PEGn-CH3)x solution (48 µL) an aliquot of neutralised 64Cu stock (3.5 µL, ~0.2 MBq) was 
added. The reaction was incubated at 37 oC for 1 h. The RCC was determined to be 91.1 ± 1.8% (n = 3) using 
radio-iTLC.  The RCP was determined to be 85.3 ± 8.6% (n = 2) using PD-10 SEC with water as the eluent. 
 
Control studies  
Control 1 – radiolabelling of non-functionalised nanoparticles (bare Fe2O3@Au NP) 
To test varying temperatures three reactions were prepared. To a NP solution (190 µL) an aliquot of 
neutralised 64Cu stock (3.5 µL, ~95 kBq) was added. The reaction was left at 21 oC, 37 oC or 70 oC. Aliquots of 
the reaction for were taken for TLC analysis after 1 h.  
 
Control 2 – radiolabelling of CH3-PEGn-SH 
Preparation of CH3-PEGn-SH solution.  An aliquot of CH3-PEGn-SH (~ 46.54 µM, 10.5 µL) was added to H2O (490 
µL). The sample was incubated for 1 h at 21 oC and then used without further purification. To test varying 
temperatures three reactions were prepared. To the CH3-PEGn-SH solution (48 µL) an aliquot of neutralised 
64Cu stock (2 µL, ~0.2 MBq) was added. The reaction was left at room temperature, 37 oC or 70 oC. Aliquots of 
the reaction were taken for TLC analysis at 60 min.  
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6.3 Experimental methods associated with Chapter 3  
6.3.1 PSMA targeting  
Synthesis and characterisation 





Synthesis of compound 5 
To a solution of N-CBz-L-Lysin (2.0 g, 7.1 mmol) in t-butyl acetate (20 mL), 70% perchloric acid (1.0 mL) was 
added and the mixture stirred at 21 oC for 20 h. Ethyl acetate (50 mL) was added and mixture extracted with 
water (50 mL), 0.5 M HCl (50 mL), then water (50 mL). Aqueous layers were combined followed by addition of 
30% NaOH (aq.) until pH11. Product was extracted with ethyl acetate (3 x 100 mL), organic layer washed with 
brine, dried over anhydrous MgSO4, and solvent removed under reduced pressure. The crude product was 
purified on silica gel (50-75% EtOAC/Hexane) to isolate compound 5 as a clear oil (1.3 g, 4.0 mmol, 56%). 1H 
NMR (400 MHz, CDCl3) δ (ppm) 7.37 – 7.27 (m, 5H), 5.09 (s, 2H), 4.83 (s, 1H), 3.31 (dd, J = 7.3, 5.5 Hz, 1H), 3.20 
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13C{1H} NMR (101 MHz, CDCl3) δ (ppm) 175.35, 156.47, 136.70, 128.51, 128.10, 80.99, 66.55, 54.84, 40.85, 
34.50, 29.71, 28.07, 22.81. Rf (silica gel, EtOAc:Hexane 3:1) = 0.43. HRMS (ESI+) (m/z): calculated for 
C18H29N2O4+ ([M+H]+): 337.4395; found: 337.2120 (100%). 
 









Synthesis of compound 6 
To a solution of L-glutamic acid (1.0 g, 7 mmol) in t-butyl acetate (20 mL), 70% perchloric acid (1.0 mL) was 
added and the mixture stirred at 21 oC for 20 h. Ethyl acetate (50 mL) was added and mixture extracted with 












































































saturated NaHCO3 (aq.) and extracted with ethyl acetate (3 x 100 mL). The organic layer was washed with 
brine, dried over anhydrous MgSO4, and solvent removed under reduced pressure. The crude product was 
purified on silica gel (20-50% EtOAC/Hexane) to isolate compound 6 as a clear oil (350 mg, 2.3 mmol, 20%). 1H 
NMR (400 MHz, CDCl3) δ (ppm) 3.36 (dd, J = 8.2, 5.2 Hz, 1H), 2.35 (t, J = 7.6 Hz, 2H), 2.05 – 1.94 (m, 1H), 1.82 
(s, 2H), 1.80 – 1.71 (m, 1H), 1.46 (s, 9H), 1.44 (s, 9H). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm) 174.84, 172.71, 
81.44, 80.55, 54.43, 32.06, 30.07, 28.24, 28.19. Rf (silica gel, EtOAc:Hexane 1:1) = 0.40. HRMS (ESI+) (m/z): 
calculated for C13H26NO4+ ([M+H]+): 260.1817; found: 260.1854 (100%). 
 
Figure 6.15. 1H NMR spectrum (CDCl3, 400 MHz) of compound 6. 
 
 























































Synthesis of compound 7 
Under an N2 atmosphere, a solution of triphosgene (0.2 g, 0.7 mmol) in DCM (20 mL) was cooled to 0 oC and a 
solution of 6 (0.7 g, 2.0 mmol) in DCM (1 mL) and DIPEA (1 mL) was added dropwise over 2 h. The reaction 
reached room temperature and a solution of 5 (0.5 g, 2.0 mmol) in DCM (1 mL) and DIPEA (1 mL) was added 
in one portion then stirred for 1 h. The mixture was concentrated to dryness, dissolved in EtOAc (50 mL) then 
washed with 2 M NaHSO4 (2 x 40 mL) and sat. NaCl (aq.). Organic phase was dried over anhydrous MgSO4 and 
solvent removed under reduced pressure. The crude product was purified on silica gel (20-50% EtOAC/Hexane) 
to isolate compound 7 as a clear oil (0.2 g, 0.3 mmol, 28%). 1H NMR (ppm) (400 MHz, CDCl3) 1H NMR (400 MHz, 
CDCl3) δ 7.44 – 7.29 (m, 5H), 5.26 – 4.92 (m, 5H), 4.32 (m, 2H), 3.25 – 3.11 (m, 2H), 2.41 – 2.19 (m, 2H), 2.16 – 
1.96 (m, 1H), 1.91 – 1.71 (m, 2H), 1.60-1.71 (m, 3H), 1.51-1.59 (m, 3H), 1.45 – 1.43 (m, 27H), 1.40 – 1.24 (m, 
2H). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm) 172.56, 172.19, 171.97, 156.98, 156.57, 136.66, 128.47, 128.05, 
128.02, 82.25, 81.88, 80.66, 66.58, 53.38, 53.08, 40.61, 32.54, 31.53, 29.35, 28.29, 28.07, 28.01, 27.99, 22.21. 
Rf (silica gel, EtOAc:Hexane 1:1) = 0.58. HRMS (ESI+) (m/z): calculated for C32H52N3O9+ ([M+H]+): 622.2698; 
found: 622.3704 (100%). 
 



































































Synthesis of compound 8 
To a solution of 7 (190 mg, 0.30 mmol) in EtOH (10 mL) and Pd/C (20 mg) was added. The mixture was 
degassed with N2, system flushed with H2, and then reaction stirred for 20 h under an H2 atmosphere. The 
mixture was passed through Celite® using EtOH (20 mL) and the solvent was removed under reduced 
pressure to yield compound 8 as a yellow oil (100 mg, 0.21 mmol, 70%). 1H NMR (400 MHz, CDCl3):  δ 5.36 (s, 
1H), 5.34 (s, 1H), 4.36 – 4.27 (m, 2H), 2.71 (t, J = 6.7 Hz, 2H), 2.51 (s, 2H), 2.39 – 2.19 (m, 2H), 2.11–2.00 (m, 
1H), 1.91 – 1.69 (m, 2H), 1.66 – 1.53 (m, 1H), 1.53 – 1.45 (m, 2H), 1.45–1.38 (m, 27H), 1.38 – 1.26 (m, 2H). 
13C{1H} NMR (101 MHz, CDCl3) δ 172.76, 172.58, 157.12, 82.14, 81.78, 80.63, 53.56, 53.13, 41.56, 32.78, 
32.37, 31.76, 28.45, 28.20, 28.14, 28.13, 22.44. HRMS (ESI+) (m/z): calculated for C24H46N3O7+ ([M+H]+): 









































































Synthesis of compound 9 
Compound 8 (200 mg, 0.41 mmol) was stirred in 1:1 TFA/DCM (2 mL) for 1 h. Cold diethyl ether (15 mL) was 
added, the formed precipitate was collected, washed with cold ether (3 x 5 mL) and dried under reduced 
pressure. HCl (0.5 M, 1 mL) was added and then lyophilised to yield 9 as a white solid (128 mg, 0.40 mmol, 
98%). 1H NMR (400 MHz, MeOD) δ 4.36 – 4.25 (m, 2H), 2.98 – 2.85 (m, 2H), 2.51 – 2.34 (m, 2H), 2.22 – 2.09 
(m, 1H), 1.99 – 1.81 (m, 2H), 1.79 – 1.61 (m, 3H), 1.57 – 1.40 (m, 2H). 13C NMR (101 MHz, D2O) δ 177.27, 176.91, 
176.35, 159.35, 52.89, 52.57, 39.21, 30.40, 30.05, 26.12, 21.96. HRMS (ESI+) (m/z): calculated for C12H22N3O7+ 

















































































































































6.3.2 Chelate conjugated, 68Ga radiolabeled, PSMA targeted gold coated iron oxide nanoparticles 
for PET/MR imaging 
Synthesis and characterisation 




Synthesis of compound 10 
To a solution of compound 1 (42.2 mg, 0.14 mmol) in DMF (1 mL) and TEA (40 µL), compound 9 (44.3 mg, 0.14 
mmol) was added. The solution was stirred for 24 h at 21 oC before further addition of compound 9 (17.9 mg, 
59 µmol). The reaction was then stirred for a further 24 h and then the solvent was removed under reduced 
under reduced pressure.  The solid was washed with DCM (3 x 5 mL) and cold water (1 x 5 mL) to yield 10 as a 
white solid (12.7 mg, 25 µmol, 18%). 1H NMR (400 MHz, D2O/MeCN-d3) δ 4.74 (dd, J = 8.8, 5.3 Hz, 1H), 4.68 
(dd, J = 8.5, 5.0 Hz, 1H), 4.21 – 4.12 (m, 1H), 3.78 – 3.69 (m, 2H), 3.66 (t, J = 6.8 Hz, 2H), 3.05 – 2.98 (m, 1H), 
2.96 (t, J = 7.6 Hz, 2H), 2.70 (t, J = 7.4 Hz, 2H), 2.67 – 2.58 (m, 1H), 2.51 – 2.39 (m, 2H), 2.36 – 2.07 (m, 6H), 2.07 
– 1.86 (m, 6H). 13C NMR (126 MHz, D2O/MeCN-d3) δ 179.09, 178.36, 178.08, 161.38, 59.27, 55.91, 55.34, 42.92, 
41.58, 41.01, 38.42, 36.83, 33.93, 32.86, 31.02, 29.69, 28.05, 25.27. HRMS (ESI+) (m/z): calculated for 































































































Radiochemistry   
Synthesis of [68Ga]Fe2O3@Au-(Ga-2)-10 
A solution of 10 was prepared in 1:4 MeCN:H2O (3.81 mM), this was then further diluted in H2O (48.6 µM). 













































68Ga-2 (3.5 µL, 0.17 nmol) and compound 10 (3.5 µL, 48.6 µM, 0.17 nmol) was added to Fe2O3@Au (190 µL, 
102.03 nmol of Au) and reaction vortexed. After 5 mins radio-iTLC (stationary phase: silica gel, mobile phase: 
MeOH/H2O 1:1 with 0.5% HCl) gave a RCC>94% (n = 3, Rf = 0.0 – 0.23). PD10-SEC (eluent: saline) gave a RCP of 
95%.   
Stability studies 
[68Ga]Fe2O3@Au-(Ga-2)-10  and [68Ga]Fe2O3@Au-(Ga-2) were prepared as previously described.  To 100 µL of 
the reaction, 100 µL of either saline +1% FBS, 50 mM EDTA, PBS 1% FBS or 50 mM cysteine was added. The 
samples were incubated at 37 oC. RCP was monitored via radio-TLC at time points up to 2 h. 
Cellular studies  
Cells were harvested and distributed in Eppendorf tubes (3 x 106 / vial) in media (270 µL) or media with sodium 
azide (270 µL, 0.1%), or in media containing free PSMA ligand (20 µM). Reactions were prepared as previously 
described and diluted (3-fold) in cell media and then added (30 µl, 8 kBq) to the prepared cells. After mixing 
for 1.5 h at 37 oC, the samples were centrifuged (2000 rpm, 3 min) and the cell pellet washed with ice-cold 
PBS (2 x 1 mL) keeping the samples on ice between washes. The radioactivity associated with each sample was 
quantified using the gamma counter. A BCA assay was then used to quantify the protein content of cell 
samples and this was used to normalise data. Experiments were performed in triplicate. 
Small-animal PET imaging  
[68Ga]Fe2O3@Au-(Ga-2)-10 was prepared as stated above and diluted 2-fold with PBS+1% FBS. 200 µL (0.4 
MBq) was injected i.v. via the tail vein of a mouse (n=1) bearing an LNCaP tumour. Images were then 
acquired at 10 mins, 30 mins, 1 h and 3 h (10 min scan). Prior to image acquisition the mouse anaesthetised 
using an isoflurane dose between 3.0 – 4.0%. During image acquisition, the respiration rate of the animal 
was monitored via live video feed and anaesthesia was maintained by an experience animal experimenter by 
controlling the isoflurane dose between 1.5 – 2.0%. Images were reconstructed and analysed using 
VivoQuantTM 3.5 patch 2 software (InviCRO, Boston, MA). 
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6.3.3 Chelate free, 68Ga radiolabelled, PSMA targeted Feraheme® nanoparticles for PET/MR 
imaging 
Synthesis of small molecules 




Synthesis of compound 11 
Synthesis of compound 11 uses modified literature procedures.337 
To a solution of formamide (192 µL, 4.82 mmol) and triethyphosphite (1.67 mL, 9.64 mmol) cooled to -7.5 oC, 
phosphorus oxychloride (896 µL, 9.64 mmol) was added dropwise over 1 h. Reaction the allowed to come to 
21 oC and stirred for 1 h. Reaction mixture was poured over 30% ammonia solution (9 mL) on ice (30 g), and 
extracted with DCM (3 x 40 mL). The solvent was removed under reduced pressure and crude product re-
dissolved in DCM (60 mL). Product was extracted with 0.5 M HCl (60 mL), and then the aqueous phase was 
washed with DCM (3 x 40 mL). 1 M NaOH was added to aqueous phase until pH10 reached, and product 
extracted with DCM (5 x 40 mL), dried over anhydrous Na2SO4, and the solvent was removed under reduced 
pressure to isolate 11 as a clear oil (518 mg, 1.71 mmol, 35%) 1H NMR (400 MHz, CDCl3) δ 4.33 – 4.10 (m, 8H), 
3.44 (t, J = 20.6 Hz, 1H), 2.15 (d, J = 1.8 Hz, 2H, -NH2), 1.34 (t, J = 7.1 Hz, 12H). 13C{1H}  NMR (101 MHz, CDCl3) 
δ 63.35 (dd, J = 7.8, 3.3 Hz), 47.76 (t, J = 144.6 Hz), 16.56 (t, J = 2.8 Hz). 31P{1H} NMR (162 MHz, CDCl3) δ 19.85 





















































































































Synthesis of compound 12 
To a solution of Boc-NH-(PEG)4-COOH (100 mg, 0.27 mmol) and dicyclohexylcarbodiimide (54 mg, 0.27 mmol) 
in DCM (5 mL), compound 11 (83 mg, 0.27 mmol) was added. The reaction was stirred for 16 h before being 
chilled at -18 oC and filtered.  Solvent from the filtrate was removed under reduced pressure to yield the crude 
product which was purified on silica gel (4-10% MeOH/DCM) to isolate compound 12 as a clear oil (98 mg, 
0.15 mmol, 53%). 1H NMR (400 MHz, CDCl3) δ 7.01 (d, J = 9.1 Hz, 1H), 5.09 – 4.95 (m, 2H), 4.23 – 4.07 (m, 8H), 
3.71 (t, J = 5.9 Hz, 2H), 3.65 – 3.54 (m, 12H), 3.49 (t, J = 5.2 Hz, 2H), 3.26 (q, J = 4.9 Hz, 2H), 2.53 (t, J = 5.9 Hz, 
2H), 1.40 (s, 9H), 1.29 (td, J = 7.1, 3.4 Hz, 12H). 13C{1H} NMR (101 MHz, CDCl3) δ 170.67 (t, J = 4.1 Hz), 156.05, 
79.17, 70.65, 70.61, 70.55, 70.53, 70.47, 70.28, 67.07, 63.60 (q, J = 2.9 Hz), 43.46 (t, J = 147.1 Hz), 40.40, 36.65, 
29.73, 28.47, 16.43 (dt, J = 9.5, 2.9 Hz). 31P NMR (162 MHz, CDCl3) δ 16.41 (d, J = 20.9 Hz, 2P). 31P {1H} NMR 
(162 MHz, CDCl3) δ 16.41 (s, 2P). Rf (silica gel, MeOH:DCM 1:9) = 0.53. HRMS (ESI+) (m/z): calculated for 





































































































































Figure 6.32. 31P{1H} NMR spectrum (CDCl3, 162 MHz) of compound 12. 
 
 
Synthesis of compound 13 
A solution of compound 12 (80 mg, 0.12 mmol) in DCM (0.5 mL) was cooled to cooled to 0 oC. TFA (0.5 mL) 
was added and reaction stirred at room temperature for 2 h. Toluene (10 mL) was added and the solvent was 
removed under reduced pressure. This last step was repeated three times to obtain the crude product which 
was purified on silica gel (5-10% MeOH/DCM with 1% TEA) to yield compound 13 as a yellow oil (56 mg, 0.10 
mmol, 81%). 1H NMR (400 MHz, CDCl3) δ 5.68 (br s, 1H), 5.05 (td, J = 22.3, 9.9 Hz, 1H), 4.18 – 4.05 (m, 8H), 3.73 
(m, J = 7.8, 5.0 Hz, 4H), 3.68 – 3.50 (m, 12H), 3.13 (br, 2H), 3.06 (m, 2H), 2.62 (t, J = 5.5 Hz, 2H), 1.26 (m, 12H). 
13C NMR (101 MHz, CDCl3) δ 171.29, 70.10, 70.05, 70.01, 69.98, 69.94, 67.19, 67.07, 63.81 (dt, J = 24.4, 3.3 Hz), 
43.46 (t, J = 148.1 Hz), 39.65, 35.68, 16.29 (dt, J = 6.1, 3.0 Hz). 31P {1H} NMR (162 MHz, CDCl3) δ 16.59. Rf (silica 




















































































































































































Scheme 6.9. Chemical synthesis of the functionalization of the PEGylated bisphosphonate with the PSMA 





Synthesis of compound 14 
A solution of triphosgene (16 mg, 0.05 mmol) in dry DCM (2 mL) was cooled to 0 oC. A solution of 9 (80 mg, 
0.16 mmol) in dry DCM (0.5 mL) and DIPEA (70 µL) was added dropwise over 2 h. Compound 13 in DCM (2 mL) 
and DIPEA (70 µL) then added in one portion and stirred for 1 h at room temperature. Reaction was then 
washed with water (2 x 5 mL) and brine (5 mL), dried with anhydrous MgSO4 and solvent removed under 
reduced pressure. The crude product was purified on silica gel (5-10% MeOH/DCM) to isolate compound 14 










































































































21 oC, 1 h
 189 
10.1 Hz, 1H), 4.35 – 4.20 (m, 2H), 4.18 – 4.07 (m, 8H), 3.69 (t, J = 6.0 Hz, 2H), 3.61 – 3.54 (m, 12H), 3.53 – 3.46 
(m, 2H), 3.33 – 3.27 (m, 2H), 3.19 – 3.00 (m, 2H), 2.51 (t, J = 6.0 Hz, 2H), 2.34 – 2.16 (m, 2H), 1.81 – 1.49 (m, 
4H), 1.50 – 1.40 (m, 4H), 1.40 – 1.34 (m, 27H), 1.26 (dt, J = 8.0, 6.4 Hz, 12H). 13C NMR (101 MHz, CDCl3) δ 
172.89, 172.67, 172.34, 170.77 (t, J = 4.2 Hz), 159.19, 157.51, 81.75, 81.24, 80.34, 70.71, 70.61, 70.40, 70.34, 
70.31, 70.24, 70.12, 67.00, 63.72 – 63.54 (m), 53.40, 52.78, 43.36 (t, J = 147.4 Hz), 40.29, 39.58, 36.46, 32.26, 
31.66, 29.64, 28.50, 28.07, 28.01, 22.34, 16.36 (dt, J = 6.4, 3.0 Hz).31P NMR (162 MHz, CDCl3) δ 16.49 (d, J = 
21.8 Hz). HRMS (ESI+) (m/z): calculated for C45H88N5O19P2+ ([M+H]+): 1064.5543; found: 1064.5540) (100%). 
 

























































































































































































Synthesis of compound 15 
Compound 14 (70 mg, 0.07 mmol) was stirred in TFA (0.5 mL) for 60 min. Et2O was added (6 mL) and precipitate 
collected and washed with ice cold Et2O (3 x 5 mL) to yield 15 as a white solid (53 mg, 0.06 mmol, 90 %). 1H 
NMR (400 MHz, MeOH) δ 5.12 (t, J = 22.9 Hz, 1H), 4.38 – 4.26 (m, 2H), 4.27 – 4.16 (m, 8H), 3.78 (t, J = 6.1 Hz, 
2H), 3.69 – 3.59 (m, 12H), 3.54 (t, J = 5.3 Hz, 2H), 3.14 (s, 4H), 2.61 (t, J = 6.1 Hz, 2H), 2.49 – 2.39 (m, 2H), 2.24 
– 2.09 (m, 1H), 1.99 – 1.80 (m, 2H), 1.75 – 1.63 (m, 1H), 1.59 – 1.49 (m, 2H), 1.47 – 1.42 (m, 2H), 1.36 (td, J = 
7.1, 2.7 Hz, 12H). 31P NMR (162 MHz, MeOD) δ 16.41. HRMS (ESI+) (m/z): calculated for C33H64N5O19P2+ 

















































































Synthesis of compound 16 
Under an N2 atmosphere, compound 15 was dissolved in dry MeCN (4 mL) and cooled to 0 oC.  
Trimethylsiylbromide (0.67 mmol, 89 µL) was added dropwise then the reaction was allowed to reach room 
temperature and stirred for 12 h. Water (3 mL) was added and reaction and stirred for a further 1 h. The 
reaction was then filtered, wash with DCM (2 x 4 mL) and lyophilised to yield product as a white solid (30 mg, 
38.3 µmol, 86%). 1H NMR (400 MHz, D2O) δ 4.53 (t, J = 21.1 Hz, 1H), 4.19 (dd, J = 9.1, 5.1 Hz, 1H), 4.12 (dd, J = 



































































































































Hz, 2H), 3.03 (t, J = 5.1 Hz, 2H), 2.58 (t, J = 5.8 Hz, 2H), 2.44 (t, J = 7.3 Hz, 2H), 2.20 – 2.05 (m, 1H), 1.97 – 1.83 
(m, 1H), 1.83 – 1.71 (m, 1H), 1.71 – 1.60 (m, 1H), 1.50 – 1.37 (m, 2H), 1.38 – 1.28 (m, 2H). 13C NMR (126 MHz, 
D2O) δ 177.23, 177.16, 176.24, 172.94, 160.56, 159.32, 69.78, 69.57, 69.54, 69.49, 69.46, 69.41, 66.53, 58.48, 
53.19, 52.53, 39.50, 39.46, 35.71, 30.57, 30.02, 28.63, 26.17, 22.19. 31P NMR (203 MHz, D2O) δ 13.30. 
 






































































































































































































Synthesis of compound 17 
Under an inert atmosphere, a solution of triphosgene (0.61 g, 2.07 mmol) in DCM (50 mL) was cooled to 0 oC 
and a solution of H-D-Lys(Z)-OtBu (2.11 g, 6.28 mmol) in DCM (10 mL) and DIPEA (1.25 mL) was added dropwise 
over 2 h. The reaction reached room temperature and a solution of H-D-Glu(OtBu)OtBu.HCl (1.85 g, 6.28 mmol) 
in DCM (15 mL) and DIPEA (1.25 mL) was added in one portion then stirred for 1 h. The mixture was 
concentrated to dryness, dissolved in 100 mL EtOAc then washed with 2 M NaHSO4 (2 x 100 mL) and sat. NaCl 
(aq.). Organic phase was dried over anhydrous MgSO4 and the solvent was removed under reduced pressure. 
The crude product was purified on silica gel (20-50% EtOAC/Hexane) to isolate compound 17 as a clear oil (438 
mg, 0.70 mmol, 11%). 1H NMR (400 MHz, CDCl3) δ 7.41 – 7.29 (m, 5H), 5.20 – 4.97 (m, 5H), 4.38 – 4.29 (m, 2H), 
3.20 (q, J = 6.8, 5.9 Hz, 2H), 2.41 – 2.18 (m, 2H), 2.14 – 2.00 (m, 1H), 1.97 – 1.71 (m, 2H), 1.70 – 1.57 (m, 3H), 
1.57 – 1.50 (m, 2H), 1.47 – 1.43 (m, 27H), 1.43 – 1.34 (m, 2H). Rf (silica gel, EtOAc:Hexane 1:1) = 0.58. HRMS 























































EtOH, 21 oC, 12 h
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Figure 6.45. 1H NMR spectrum (CDCl3, 400 MHz) of compound 17. 
 
 
Synthesis of compound 18 
To a solution of 17 (430 mg, 0.69 mmol) in EtOH (30 mL), Pd/C (30 mg) was added. The mixture was degassed 
with N2, and the system flushed with H2. The reaction was then stirred for 20 h under an H2 atmosphere before 
it was passed through Celite® with excess EtOH. The solvent removed under reduced pressure to yield 
compound 18 as a yellow oil (318 mg, 0.65 mmol, 94%). 1H NMR (400 MHz,CDCl3) δ 5.22 (s, 1H), 5.20 (s, 1H), 
4.39 – 4.31 (m, 2H), 2.73 (t, J = 6.7 Hz, 2H), 2.43 – 2.24 (m, 4H), 2.15 – 2.03 (m, 1H), 1.94 – 1.73 (m, 2H), 1.72 
– 1.59 (m, 1H), 1.56 – 1.49 (m, 2H), 1.49 (s, 27H), 1.40 – 1.29 (m, 2H).  HRMS (ESI+) (m/z): calculated for 







































































































Scheme 6.11. Chemical synthesis of the functionalization of the PEGylated bisphosphonate with the inactive 




Synthesis of compound 19 
A solution of triphosgene (10 mg, 0.04 mmol) in dry DCM (1.5 mL) was cooled to 0 oC. A solution of 18 (50 mg, 
0.11 mmol) in dry DCM (0.5 mL) and DIPEA (50 µL) was added dropwise over 2 h. Compound 13 (58 mg, 0.11 
mmol) in DCM (2 mL) and DIPEA (50 µL) then added in one portion and stirred for 1 h at room temperature. 
Reaction was then washed with water (2 x 5 mL) and brine (5 mL), dried with anhydrous MgSO4 and solvent 
removed under reduced pressure. The crude product which was purified on silica gel (5-10% MeOH/DCM) to 
isolate compound 19 as a yellow oil (49 mg, 0.05 mmol, 43%).









































































































21 oC, 1 h
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(td, J = 21.9, 10.1 Hz, 1H), 4.30 (br s, 2H), 4.08-4.21 (m, 8H), 3.72 (t, J = 6.0 Hz, 2H), 3.65 – 3.56 (m, 12H), 3.53 
(td, J = 5.2, 2.1 Hz, 2H), 3.38 – 3.30 (m, 2H), 2.56 (t, J = 5.8 Hz, 2H), 2.39 – 2.20 (m, 2H), 1.97-2.06 (m, 1H), 1.88 
– 1.65 (m, 3H), 1.64 – 1.47 (m, 4H), 1.43 – 1.38 (m, 27H), 1.29 (q, J = 7.1 Hz, 12H). 31P {1H} NMR (162 MHz, 
CDCl3) δ 16.50. 
 





























































































































































Synthesis of compound 20 
Compound 19 (45 mg, 0.04 mmol) was stirred in TFA (0.5 mL) for 1 h. Et2O was added (6 mL) and precipitate 
collect and washed with cold Et2O (3 x 5 mL) to yield 20 as a white solid (33 mg, 0.04 mmol, 88%). 1H NMR 
(300 MHz, MeOD) δ 4.37 – 4.27 (m, 2H), 4.27 – 4.14 (m, 8H), 3.77 (t, J = 6.1 Hz, 2H), 3.71 – 3.56 (m, 12H), 3.53 
(t, 2H), 3.19 – 3.04 (m, 4H), 2.60 (t, J = 5.9 Hz, 2H), 2.42 (t, J = 8.1 Hz, 1H), 2.25 – 2.04 (m, 1H), 2.00 – 1.79 (m, 
2H), 1.74 – 1.59 (m, 1H), 1.59 – 1.41 (m, 4H), 1.35 (td, J = 7.0, 3.7 Hz, 12H). 31P NMR (162 MHz, MeOD) δ 16.51. 
HRMS (ESI+) (m/z): calculated for C33H63N5O19P2Na+ ([M+Na]+): 918.3485; found: 918.3487 (100%). 
 






























































































































Synthesis of compound 21 
Under an N2 atmosphere, compound 20 (25 mg, 27.9 µmol) was dissolved in dry MeCN (4 mL) and cooled to 
0 oC. Trimethylsilylbromide (0.67 mmol, 89 µL) was added dropwise then the reaction was allowed to reach 
room temperature and stirred for 12 h. Water (3 mL) was added and reaction and stirred for a further 1 h. The 
reaction was then filtered, wash with DCM (2 x 4 mL) and lyophilised to yield 21 as a white solid (18 mg, 23.0 
µmol, 82%). 1H NMR (500 MHz, D2O) δ 4.62 (t, J = 20.9 Hz, 1H), 4.26 (dd, J = 9.2, 5.1 Hz, 1H), 4.20 – 4.16 (m, 
1H), 3.82 (t, J = 6.0 Hz, 2H), 3.71 – 3.66 (m, 12H), 3.58 (t, J = 5.3 Hz, 2H), 3.29 (t, J = 5.3 Hz, 2H), 3.10 (t, J = 6.7 
Hz, 2H), 2.65 (t, J = 6.2 Hz, 2H), 2.51 (t, J = 7.2 Hz, 2H), 2.24 – 2.13 (m, 1H), 2.03 – 1.92 (m, 1H), 1.90 – 1.80 (m, 
1H), 1.77 – 1.67 (m, 1H), 1.55 – 1.46 (m, 2H), 1.44 – 1.36 (m, 2H). 13C NMR (126 MHz, D2O) δ 177.83, 177.75, 
176.82, 161.14, 70.35, 70.15, 70.12, 70.07, 70.05, 69.99, 67.10, 53.76, 53.10, 40.10, 40.05, 36.27, 31.14, 30.60, 
29.20, 26.74, 22.78.  31P NMR {1H} (162 MHz, D2O) δ 13.79. 
 








































































Functionalisation of Feraheme 
Determination of concentration of Feraheme particles 
The absorbance of known concentrations of FerahemeTM particles was measured at 468 nm. The plot was then 














































































































Functionalisation of particles with compound 16 
A solution of FerahemeTM particles (10 µL, 30 mg ml-1) and compound 6 (10 µL, 11.2 µM) were vortexed for 12 
h. The mixture was then loaded onto a PD10-SEC (stationary phase: Sephadex G-25, mobile phase: saline) and 
the first 2.0 mL was collected and diluted to give a final concentration of 0.13 mg ml-1. 
Functionalisation of particles with compound 21 
Analogous to functionalisation with compound 16. 
 
ICP-MS measurement of FH-16 
Samples measured by UZH ICP-MS service. Nitric acid (3 mL, 2%) was added to samples (0.3 mL, 0.21 mg mL-
1) and then a 1:10 dilution was performed before measurements were carried out on an Agilent 8800 ICP-MS. 
Data was then compared to a phosphorous calibration plot. The phosphorous content was determined to be 
2.99 ± 0.11 µg of phosphorous per 1 mg of iron. This was compared to the bare FerahemeTM particles which 
contain 0.049 ± 0.001 µg of phosphorous per 1 mg of iron.   
 
Radiochemistry 
Synthesis of [68Ga]FH-16-Ga and [68Ga]FH-21-Ga 
Radiolabelling reactions to prepare [68Ga]FH-16-Ga and [68Ga]FH-21-Ga were accomplished by addition of an 
aliquot of [68Ga][Ga(H2O)6]Cl3(aq.) stock solution (ca. 15 MBq) to an aqueous solution of FH-16 and FH-21 (13.0 
µg) buffered with NaOAc (0.2 M, pH 4.4). After 20 min. at 70 oC a radiochemical conversion (RCC) >98% was 
found by radio-TLC (Rf [silica gel, 0.1 M citrate buffer] = 0.0-0.2) and >94% for PD10 SEC (saline as eluent).  
 
Stability studies  
Reactions were prepared as previously described and then 25 µL was added to PBS, saline or 25 mM EDTA 
(300 µL) and the samples were incubated (37 oC). RCP was monitored via radio-TLC at time points up to 2 h. 



















Binding assay  
LNCaP cells were plated in 6-well plates with a density of 5 x 105 cells/well in 2 mL media. After 24 h, reactions 
were prepared as described above and diluted in cell media (210-fold). The cell media was removed from the 
6-well plates and replaced with the diluted reaction mixture (2 mL, 43 kBq) before incubation (37 oC) for 1.5 
h. The plates were then placed on ice and each well washed with ice-cold PBS (2 x 1 mL), 1 M NaOH (1 mL) 
added and incubated for 10 min. Cells were then collected and their associated radioactivity quantified with 
the gamma counter. A BCA assay was then used to quantify the protein content of cell samples and this was 
used to normalise data. Experiments were performed in replicates (n=5).  
Blocking assay  
LNCaP cells were plated in 6-well plates with a density of 8 x 105 cells/well in 2 mL media. After 24 h cells, 
media was removed, cells washed with PBS (2 mL) and the media replaced with either media alone or media 
containing 0.1% azide (1.8 mL), with the media of blocked wells containing 10 µM 2-PMPA binding motif. Cells 
were then incubated for 1 h. [68Ga]FH-16 was prepared as described above, diluted in cell media (60-fold) and 
added to wells (200 µL, 0.17 MBq) then plates incubated for 1.5 h. Plates were then placed on ice and each 
well washed with ice-cold PBS (2 x 1 mL), 1 M NaOH (1 mL) added and plates incubated for 10 min. Cells were 
then collected and their associated radioactivity quantified with the gamma counter. A BCA assay was then 
used to quantify the protein content of cell samples and this was used to normalise data. Experiments were 
performed in replicates (n = 5). 
In vivo studies  
[68Ga]FH-16 was prepared as stated above and diluted with 6-fold with PBS. The tracer was (0.9-1.1 MBq) was 
injected i.v. via the tail vein of mice bearing an LNCaP tumours (168.7 ± 65.6 mm3; n=3). Images were then 
acquired at 30 mins, 1 h and 2 h (10 min scan). Prior to image acquisition the mouse anaesthetised using an 
isoflurane dose between 3.0-4.0%. During image acquisition, the respiration rate of the animal was monitored 
via live video feed and anaesthesia was maintained by an experience animal experimenter by controlling the 
isoflurane dose between 1.5-2.0%. Images were reconstructed and analysed using VivoQuantTM 3.5 patch 2 
software (InviCRO, Boston, MA). 
Biodistribution studies  
Following the final image at 2 h, the mouse was euthanised and biodistribution studies were performed. A 
total of 15 tissues (including the tumour) were removed, rinsed in water, dried in air for approx. 2 min., 
weighed and counted on a calibrated gamma counter for accumulation of activity. Count data were 
background- and decay-corrected, and the tissue uptake for each sample (determined in units of percentage 
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injected dose per gram [%ID g-1]) was calculated by normalisation to the total amount of activity injected into 
the animal.  
 
6.4 Experimental methods associated with Chapter 4   
6.4.1 Synthesis and characterisation  
Synthesis of small molecules for GNF functionalisation 





Synthesis of compound 22 
To (Boc-amino)-PEG4-carboxylic acid (80 mg, 0.21 mmol) in DCM (5 mL), was added NHS (29 mg, 0.25 mmol) 
and EDC (84 mg, 0.44 mmol) and mixture stirred until TLC showed consumption of product. The reaction 
mixture was washed with 2.5% NaHSO4 (aq.) (3x10 mL) and brine then the organic phase was dried over 
anhydrous MgSO4 and solvent removed under reduced pressure to yield compound 22 as a white solid (90 
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12H), 3.53 (t, J = 5.1 Hz, 2H), 3.35 – 3.26 (m, 2H), 2.90 (t, J = 6.5 Hz, 2H), 2.83 (s, 4H), 1.44 (s, 9H). Rf (silica gel, 
MeOH:DCM 1:20) = 0.4 
 





Synthesis of compound 23 
Compound 22 (35 mg, 0.07 mmol) and ammonium formate (45 mg, 0.72 mmol) were dissolved in MeOH (3 
mL), stirred for 30 min and the solvent was then removed under reduced pressure. Compound 9 (33 mg, 0.07 
mmol) was then added in DCM (8 mL) and TEA (80 µL, 0.57 mmol) and reaction stirred for 16 h. Organic layer 
was washed with water (3 x 10 mL) and brine (10 mL), then the organic phase was dried over anhydrous MgSO4 
and the solvent removed under reduced pressure. Crude product was purified on silica gel (7% MeOH/DCM) 
to isolate compound 23 as a clear oil (0.2 g, 0.3 mmol, 42%) 1H NMR (400 MHz, CDCl3) δ (ppm) 6.78 (s, 1H), 
6.56 (s, 1H), 5.47 (s, 1H), 5.20 (s, 1H), 4.38 – 4.15 (m, 2H), 3.79 – 3.72 (m, 2H), 3.70 – 3.62 (m, 12H), 3.60 – 3.52 
(m, 2H), 3.40 – 3.29 (m, 2H), 3.28 – 3.08 (m, 2H), 2.55 – 2.45 (m, 2H), 2.42 – 2.27 (m, 2H), 2.13 – 2.02 (m, 3H), 













































Synthesis of compound 24  
Compound 6 (20 mg, 0.02 mmol) was stirred in TFA (500 µL) for 1 h and then precipitated in Et2O (5 mL).  
Product was collected by centrifugation, washed with cold Et2O and dried under reduced pressure to yield 
compound 24 as a white solid (13.1 mg, 0.02 mmol, 95%) 1H NMR (400 MHz, MeOD) δ (ppm) 4.32 (dd, J = 8.6, 
5.1 Hz, 1H), 4.26 (dd, J = 8.5, 4.9 Hz, 1H), 3.79 – 3.59 (m, 16H), 3.19 (t, J = 6.8 Hz, 2H), 3.17 – 3.11 (m, 2H), 2.45 
(t, J = 6.0 Hz, 2H), 2.43 – 2.37 (m, 2H), 2.22 – 2.04 (m, 1H), 1.98 – 1.78 (m, 2H), 1.69 – 1.60 (m, 1H), 1.57 – 1.51 
(m, 2H), 1.46 – 1.41 (m, 2H). 13C NMR (101 MHz, MeOD) δ (ppm) 175.02, 174.96, 174.42, 172.64, 158.70, 70.01, 
69.93, 69.85, 69.82, 69.41, 66.93, 66.40, 52.54, 52.10, 39.11, 38.69, 35.98, 31.79, 29.66, 28.45, 27.51, 22.52. 







































































Figure 6.57. 1H NMR spectrum (MeOD, 400 MHz) of compound 24. 
 
 


















































































































Synthesis of compound 25 
4-(p-Iodophenyl)butyric acid (300 mg, 1.03 mmol) in DMF (10 mL) was activated with HBTU (430 mg, 1.12 
mmol). Following the addition of N-Boc-1,4-butanediamine (194 mg, 1.03 nmol) the reaction was stirred for 
20 h. The solvent was removed under reduced pressure and the product re-dissolved in DCM (20 ml) which 
was washed with 0.1 M NaOH (3 x 20 ml), 0.1 M HCl (3 x 20 mL), and brine (3 x 20 mL). The organic phase was 
dried over anhydrous MgSO4 and the solvent was removed under reduced pressure. The crude product was 
purified on silica gel (5-10% DCM/MeOH) to isolate compound 25 as a clear oil (230 mg, 0.49 mmol, 47%). 1H 
NMR (400 MHz, CDCl3) δ 7.58 (d, J = 8.2 Hz, 2H), 6.92 (d, J = 8.1 Hz, 2H), 5.76 (s, 1H), 4.62 (s, 1H), 3.30 – 3.21 
(m, 2H), 3.17 – 3.06 (m, 2H), 2.58 (t, J = 7.5 Hz, 2H), 2.15 (t, J = 7.5 Hz, 2H), 1.97 – 1.88 (m, 2H), 1.54 – 1.45 (m, 
4H), 1.43 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 172.82, 156.34, 141.29, 137.53, 130.74, 91.11, 79.48, 39.31, 
38.82, 35.80, 34.83, 28.54, 27.84, 27.04, 26.69. Rf (silica gel, MeOH:DCM 1:14) = 0.59.  HRMS (ESI+) (m/z): 
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Figure 6.59. 1H NMR spectrum (CDCl3, 400 MHz) of compound 25. 
 
 




Synthesis of compound 26 
Compound 25 (230 mg, 0.48 mmol) was stirred with TFA (0.5 mL) for 1 h. Toluene was added (10 mL) and 
solvent removed under reduced pressure. The crude product was then dissolved in DCM (10 mL) and washed 
with NaHCO3 (0.1 M, 10 mL) and brine (10 mL). The organic phase was dried over anhydrous MgSO4 and the 
solvent was removed under reduced pressure to yield compound 26 as a yellow solid (161 mg, 0.44 mmol, 
90%). 1H NMR (400 MHz, CDCl3) δ (ppm) 7.59 (d, J = 8.2 Hz, 2H), 6.93 (d, J = 8.1 Hz, 2H), 5.91 (s, 1H), 3.24 (m, 
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1.43 (m, 4H). 13C NMR (101 MHz, CDCl3) δ (ppm) 172.50, 141.21, 137.41, 130.63, 90.98, 41.45, 39.26, 35.74, 
34.68, 30.27, 27.04, 26.89. HRMS (ESI+) (m/z): calculated for C24H46N3O7+ ([M+Na]+): 361.0777; found: 
361.0772 (100%). 
 
Figure 6.61. 1H NMR spectrum (CDCl3, 400 MHz) of compound 26. 
 
 































































Chemical synthesis of the functionalised GNFs 
Synthesis of GNF-1 




GNFs (4.56 mg) in DMF (1 mL) and TEA (20 µL) were activated with HATU (8.24 mg, 0.02 mmol). Following the 
addition of DFO (0.40 mg, 0.61 µmol) reaction was vortexed for 24 h. The solvent was removed under reduced 
pressure and the product purified on silica gel (100% H2O), after lyophilisation, GNF-1 was obtained as a black 
solid (2.13 mg, 42%). 
 
Synthesis of GNF-2 
Scheme 6.15. Chemical synthesis of GNF-2. 
 
 
GNFs (4.10 mg) in DMF (1 mL) and TEA (20 µL) were activated with HATU (8.01 mg, 0.02 mmol). Following the 
addition of DFO (0.50 mg, 0.61 µmol), (R)-ispinesib (0.53 mg, 1.03 µmol), and 4 (0.50 mg, 1.03 µmol) reaction 
was vortexed for 24 h. TFA (0.5 mL) was added and after 1 h the solvent removed under reduced pressure and 
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Synthesis of GNF-3 
Scheme 6.16. Chemical synthesis of GNF-3. 
 
 
GNFs (4.27 mg) in DMF (1 mL) and TEA (20 µL) were activated with HATU (8.07 mg, 0.02 mmol). Following the 
addition of DFO (0.47 mg, 0.72 µmol), (R)-ispinesib (0.60 mg, 1.16 µmol), and 7 (0.53 mg, 0.93 µmol) reaction 
was vortexed for 24 h. Solvent was removed under reduced pressure and product purified on silica gel (100% 































    DMF, 21 oC, 30 min
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Synthesis of GNF-4 




GNFs (4.15 mg) in DMF (1 mL) and TEA (20 µL) were activated with HATU (8.06 mg, 0.02 mmol). Following the 
addition of DFO (0.47 mg, 0.72 µmol), (R)-ispinesib (0.54 mg, 1.04 µmol), 7 (0.56 mg, 0.99 µmol) and 9 (0.31 
mg, 0.86 µmol) reaction was vortexed for 24 h. Solvent was removed under reduced pressure and product 
purified on silica gel (100% H2O), after lyophilisation, GNF-4 was obtained as a black solid (1.81 mg, 30%). 
 
Purification of GNF constructs 
GNF constructs were purified on silica gel. All starting materials remained at the baseline (Rf = 0.0-0.1) whilst 
GNF-1, -2, -3 and -4 moved to the solvent from. Compounds which are UV active are visualised using 254 nm, 
















































    DMF, 21 oC, 30 min
2) x eq DFO, y eq 24, z eq (R)-Ispinesib, n eq 26




















Figure 6.63. TLC separation of GNF constructs and starting materials.  Silica gel as stationary phase and 100% 





General Radiolabeling Conditions  
Radiolabelling reactions to prepare [68Ga]GNF-1, -2, -3, and -4 were accomplished by addition of an aliquot of 
[68Ga][Ga(H2O)6]Cl3(aq.) stock solution (ca. 40 MBq) to an aqueous solution of GNF-1-4 (25 µg) buffered with 
NaOAc (0.2 M, pH 4.4). The reaction was monitored by using radio-iTLC and was found to be complete after 
10 min at 21 oC giving a radiochemical conversions (RCC) >97% (Rf [silica gel, H2O] = 0.90-1.00).  
Quantification of DFO content  
[68Ga]GNF-1, -2, -3, and -4 samples were prepared at a variety of concentrations and buffered with NaOAc (0.2 
M, pH 4.4). Aliquots of [68Ga][Ga(H2O)6]Cl3(aq.) stock solution (ca. 18 MBq) were added to each sample and 
after 10 min radio-iTLC was used to gain a RCC. Plots were used in conjunction with the known molar activity 
of the generator to calculate the amount of DFO (nmol) per mass of GNF (mg). 
Lipophilicity measurements 
n-Octanol was pre-saturated with PBS for 24 h. Reactions were prepared as described above. Reaction mixture 
(50 µL) was added to pre-saturated octanol (400 µL) and PBS (350 µL) and shaken for 1 h at 37 oC. Samples 
were then centrifuged (2000 RPM, 2 min), an aliquot of 50 µL was taken from each phase and the radioactivity 
































Stability Studies  
Stability in saline and PBS  
Reactions were prepared as previously described and then PBS or saline (300 µL) were added and samples 
incubated (37 oC). RCP was monitored via radio-TLC at time points up to 2 h (n = 3, Table 6.5, Table 6.6).  
 
Table 6.5. Percentage radiochemical purity (RCP) of [68Ga]GNF-1-4 determined from radio-iTLC following 
incubation with PBS up to 2 h at 37 oC.  
 RCP / % 
Time / min [68Ga]GNF-1 [68Ga]GNF-2 [68Ga]GNF-3 [68Ga]GNF-4 
0 99.1 ± 0.7 98.6 ± 0.2 97.4 ± 0.6 97.3 ± 0.4 
10 95.2 ± 0.3 97.0 ± 0.3 96.8 ± 0.4 88.1 ± 1.1 
20 95.1 ± 1.5 95.3 ± 1.0 90.4 ± 3.5 85.8 ± 2.4 
30 96.5 ± 0.6 93.0 ± 0.9 94.5 ± 0.4 88.7 ± 2.3 
60 96.5 ± 0.9 92.8 ± 0.3 93.5 ± 0.4 90.7 ± 1.4 
120 95.0 ± 0.4 89.3 ± 1.6 93.7 ± 0.5 89.0 ± 0.8 
 
Table 6.6. Percentage radiochemical purity (RCP) of [68Ga]GNF-1-4 determined from radio-iTLC following 
incubation with saline up to 2 h at 37 oC.  
 RCP / % 
Time / min [68Ga]GNF-1 [68Ga]GNF-2 [68Ga]GNF-3 [68Ga]GNF-4 
0 96.6 ± 0.8 98.6 ± 0.2  97.4 ± 0.6  97.3 ± 0.4 
10 96.0 ± 2.9 96.6 ± 0.2 93.8 ± 1.0  92.9 ± 0.6  
20 91.8 ± 1.5 94.1 ± 1.1  91.5 ± 1.2  89.2 ± 2.8  
30 94.7 ± 5.7 89.9 ± 2.4 92.6 ± 2.2  85.0 ± 1.9 
60 95.4 ± 1.2 92.1 ± 0.5  88.6 ± 2.2 82.1 ± 1.2  
120 95.1 ± 1.0 90.1 ± 0.8  87.6 ± 1.9 83.2 ± 2.2  
 
Stability in human serum albumin  
Reactions were prepared as described previously, human serum albumin (300 µL) was added and samples 
incubated (37 oC). Stability in human serum was monitored via radio-SEC (mobile phase: 200 mM arginine in 
PBS) for time points up to 2.5 h ([68Ga]GNF-1: n = 3, [68Ga]GNF-2, -3 and -4: n = 1, Table 6.7). 
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Table 6.7. Percentage radiochemical purity (RCP) of [68Ga]GNF-1-4 determined from radio-SEC-HPLC 
following incubation with human serum for up to 2.5 h at 37 oC.  
 
 RCP / % 
Time / min [68Ga]GNF-1 [68Ga]GNF-2 [68Ga]GNF-3 [68Ga]GNF-4 
0 95.9 ± 1.6 97.1  98.6  97.3 
10 90.7 ± 2.3 95.4 97.5  97.0 
80 88.1 ± 2.4 91.3  94.9  95.5  
150 84.4 ± 3.6 88.7 93.9  94.4  
 
 
6.4.3 Cellular assays 
In vitro cell proliferation assays 
Treatment with GNF-2-4 
Cells were plated in 96-well plates with a density of 3000 cells/well in 150 µL media. After 24 h cells were 
treated with 50 µL compound (1:2 or 1:3 dilution in cell media, 0.25 mg mL-1 to 1 pg mL-1) and plates incubated 
for 48 h then treated with thiazolyl blue tetrazolium bromide (50 µL, 5.0 mg mL-1 solution in PBS). Following 3 
h incubation in darkness, media was removed, DMSO (100 µL/well) added and after 30 min absorbance was 
measured at 570 nm (Hidex Sense plate reader). Experiments were performed in triplicate. 
Treatment with (R)-ispinesib 
Experimental procedure was similar to the above with the addition of 0.2% DMSO in cell media during the 
treatment period. 
 
Cell Binding Assay 
Cells were harvested and distributed in Eppendorf tubes (3 x 106 cells / vial) in media (270 µL) or media with 
sodium azide (270 µL, 0.1%). Reactions were prepared as previously described and diluted (40-fold) in cell 
media and then added (30 µl, 75 kBq) to the prepared cells. After mixing for 1.5 h at 37 oC, the samples were 
centrifuged (2000 rpm, 3 min) and the cell pellet washed with ice-cold PBS (2 x 1 mL) keeping the samples on 
ice between washes. The radioactivity associated with each sample was quantified using the gamma counter. 
Experiments were performed in triplicate. 
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Blocking Assay  
LNCaP cells were plated in 6-well plates with a density of 8 x 105 cells / well in 2 mL media. After 24 h cells, 
media was removed, cells washed with PBS (2 mL) and the media replaced (1.8 mL), with the blocked wells 
containing media with 5 µM PSMA binding motif. Cells were then incubated for 1 h. Reactions were prepared 
as described above, diluted in cell media (55-fold) and added to wells (200 µL, 1.4 MBq) then plates incubated 
for 1.5 h. Plates were then placed on ice and each well washed with ice-cold PBS (2 x 1 mL), 1 M NaOH (1 mL) 
added and plates incubated for 10 min. Cells were then collected and their associated radioactivity quantified 
with the gamma counter. Experiments were performed in triplicate. 
 
Confocal Microscopy  
Cells were plated in 4 well plates with a density of 8000 cells/well. After 24 h, cells were treated with 1 µg  
mL-1 GNF (GNF, GNF-2, -3 or -4) and left for 24 h. The media was then removed, wells washed with PBS (3 x 
600 µL) and incubated with fixative solution (600 µL, 4% formaldehyde in PBS) for 15 min. Wells were then 
washed with PBS (3 x 600 µL), incubated with permeabilisation buffer (500 µL, x0.2) for 15 min, washed with 
PBS (3 x 600 µL) then incubated with 2 drops of Imageit FX. After 30 min, wells washed with PBS (3 x 600 µL), 
incubated with primary antibody (400 µL, mouse a-tubulin, 1:1000 dilution in blocking buffer) for 2 h, washed 
with PBS (3 x 600 µL) and incubated with secondary antibody (400 µL, Goat a-mouse Alexa Flour 568 a-tubulin 
staining, 1:2000 dilution in blocking buffer) for 1.5 h. Following washing with PBS (3 x 600 µL) cells were 
incubated with Hoeschst 33342 (600 µL, 1:100,000 dilution in H2O) for 10 min followed by a final washing with 
H2O (3 x 600 µL). Slides were drained, dried and wells removed, 1 drop Prolong Gold added and cover slips 
held in place with nail polish.  
 
Preparation of blocking buffer  
A solution of PBS containing 1% BSA and 0.3% Tween-20 was prepared. 
Preparation of permeabilisation buffer  
A 10x permeabilisation buffer was prepared from 1.54 M NaCl, 15.44 mM KH2PO4, 28.58 mM Na2HPO4.7H2O 
and 5% Triton X-100 in 5 mL H2O. 40 mL of H2O added, followed by adjustment of pH to 7.2 before making up 
to 50 mL creating the 1x permeabilisation buffer. This was stored in the fridge and diluted when needed. 
 
Flow Cytometry  
Cells were plated onto 100 mm2 petri dishes at a cell density of 1.0 x 106 cells/dish. After 24 h cells were treated 
with 12 ng mL-1 and 120 ng mL-1 of the compounds (GNF, GNF-2, -3 or -4) for 36 h, then washed with ice-cold 
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PBS (4 mL), detached with trypsin-EDTA (2 mL, 0.25%) and collected via centrifugation (100 g, 10 min) with 
ice-cold PBS (10 mL). Cell pellet was washed with ice-cold PBS (5 mL) then re-suspended in fixation solution (4 
mL, 70 vol% EtOH, 30 vol% H2O) and stored at -20oC for 24 h. Subsequently, ice-cold PBS was added and cells 
centrifuged (100 xg, 10 min), washed with PBS (10 mL) and re-suspended in staining solution (1 mL) consisting 
of 0.1 mg/mL RNAse A (Sigma Aldrich), 50 μg/mL propidium iodide (PI) from 2.5 mg/mL stock solution and 
0.05% Triton X-100 (Sigma Aldrich) in PBS. After incubation at 37 oC for 40 min the cells were collected by 
centrifugation (100 xg, 10 min), washed with PBS (10 mL), re-suspended in PBS (2 mL) and samples then 
analysed on a BD LSR Fortessa cytometry system. Data were analysed by cell-cycle analysis software (FlowJo, 
TreeStar Inc.). 
 
6.4.4 In vivo studies 
Small animal PET imaging 
The dynamic scan PET scan (15x2 min scans) was commenced and at t=2 min [68Ga]GNF-3 or [68Ga]GNF-4 (~1 
MBq, [~27 µCi], in 200 µL sterile PBS) was injected intravenous (i.v.) via the tail vein catheter. During image 
acquisition, the respiration rate of the animal was monitored via live video feed and anaesthesia was 
maintained by an experience animal experimenter by controlling the isoflurane dose between 1.5 – 2.0%. List-
mode data were acquired for 15x2 min and 1x5 min. 
 
Figure 6.64. TACs plotted for the liver, bladder and brain with data extracted from 30 min dynamic PET analysis 
(15x2min scans) with injection of (A) [68Ga]GNF-3 (n = 3) and (B) [68Ga]GNF-4 (n = 4) at t = 2 min. VOIs were 
defined and data extracted using the VivoQuant™ software. See main text (Figure 4.11) for kidney, tumour, 





6.5 Experimental methods associated with Chapter 5  
 
6.5.1 Functionalisation of GNFs with a fluorescent BODIPY derivative  
Synthesis of small molecules  
Scheme 6.18. Chemical synthesis of boron-dipyrromethene (BODIPY) dyes 27 and 28.  
 
 
Compounds 27 and 28 were synthesised by using previously published procedures.382 
 
Synthesis of compound 27 
Under an N2 atmosphere, a solution of 2,4-dimethylpyrrole (0.46 mL, 4.50 mmol) and 4-nitrobenzaldehyde 
(302 mg, 2.00 mmol) in dry DCM (150 mL) is stirred at 21 oC. The reaction was monitored by TLC and once the 
consumption of 4-nitrobenzaldehyde was confirmed a solution of DDQ (454 mg, 2.00 mmol) in DCM was 
added. After 10 min TEA (4 mL) and boron trifluoride diethyl etherate (4 mL) were added dropwise and 
simultaneously and the reaction was stirred for 2 h at room temperature. The reaction was quenched with 
water (100 mL) and the product was extracted with DCM (3 x 100 mL), dried over anhydrous MgSO4 and the 
solvent removed under reduced pressure. The crude product was then recrystallized. Briefly, the crude 
product was dissolved in hot 1:1 ethyl acetate/hexane (25 mL) and the hot solution was filtered. The volume 
of the filtrate was reduced (15 mL) and left to cool gradually. The resulting crystals were washed with ice cold 
hexane and dried under vacuum to yield 27 as green crystals (130 mg, 0.35 mmol, 18%). 1H NMR (400 MHz, 
CDCl3) δ 8.39 (d, J = 8.8 Hz, 1H), 7.54 (d, J = 8.8 Hz, 1H), 6.02 (s, 1H), 2.57 (s, 3H), 1.37 (s, 3H). HRMS (ESI-) (m/z): 












































Synthesis of compound 28 
To a solution of compound 27 (15 mg, 40.6 µmol) in dry ethanol (2 mL) palladium on carbon (5 mg) and 
hydrazine monohydrate (35 µL, 0.71 mmol) were added. The reaction was refluxed for 30 min and then cooled 
to room temperature. After removing the solids via Celite® filtration the solvent was removed under reduced 
pressure to yield 28 as an orange solid (10 mg, 28.9 µmol, 71%) 1H NMR (400 MHz, CDCl3) δ 7.03 (d, J = 8.4 Hz, 


































Functionalisation of GNFs with 28 




GNFs (1.94 mg) in DMF (1 mL) and TEA (10 µL) were activated with HATU (4.01 mg, 0.01 mmol). Following the 
addition of 28 (1.19 mg, 3.51 µmol) the reaction was vortexed for 24 h. Solvent was removed under reduced 
pressure to obtain the crude product which was re-dissolved in water. Non-soluble starting materials were 
removed and the product was purified on silica gel (100% H2O). After lyophilisation, BODIPY-GNF was obtained 































    DMF, 30 min.
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Figure 6.67. TLC separation of GNF constructs and compound 28 (BODIPY). Silica gel as stationary phase and 
100% H2O as mobile phase (Visualisation of plates: V = visual observation, N = ninhydrin stain, UV = 254 nm). 
 
Characterisation of BODIPY-GNF 
Absorption/Emission Spectra of BODIPY-GNF 
Absorption measurements 
Absorption spectra were measure on a NanodropTM OneC UV-Vis Spectrophotometer using a 50 µg mL-1 
solution of BODIPY-GNF.  
 
Emission measurements 
Emission spectra were measured on a Perkin Elmer LS-50B Luminescence Spectrophotometer with 0.5 µg/mL 
aqueous solutions of BODIPY-GNF. Excitation at 475 nm, slit width 10 nm.  
To measure emission with differing concentrations a Hidex Sense Plate Reader was used. A dilution series was 
performed and emission was measured at 520 nm was measured following excitation at 475 nm.  
 
Conjugation of BODIPY-GNF to Trastuzumab and Onartuzumab   
Synthesis of BODIPY-GNF-trastuzumab 
To a solution of BODIPY-GNF (0.1 mg) in MES buffer (200 µL, 50 mM, pH6), EDC (0.6 mg, 1.93 µmol) and NHS 
(1.2 mg, 10.4 µmol) were added and the solution was mixed for 1.5 h. Pre-purified trastuzumab (0.6 mg) in 
PBS (800 µL) was added and the solution was mixed for 2.5 h at pH7. The was then purified using PD10-SEC 
(PBS as eluent) by collecting the first 1.8 mL. The construct was further purified using 100 kDa spin filters 
(washing with 5 x H2O, 14,000 g, 2 min). The protein content was determined via BCA assay to be 12.97 ± 0.55 
mg mL-1. Following a 1:500 dilution emission was measured on the Hidex Sense Plate Reader and found to be 
6811 ± 195. 
 
Synthesis of BODIPY-GNF-onartuzumab 
To a solution of BODIPY-GNF (0.1 mg) in MES buffer (200 µL, 50 mM, pH6), EDC (0.6 mg, 3.86 µmol) and NHS 
(1.2 mg, 10.4 µmol) and were added and the solution mixed for 1.5 h. Pre-purified onartuzumab (0.6 mg) in 









using PD10-SEC (PBS as eluent) by collecting the first 1.8 mL.  The construct was further purified using 100 kDa 
spin filters (washing with 5 x H2O, 14,000 g, 2 min).  The protein content was determined via BCA assay to be 
6.02 ± 0.06 mg mL-1. Following a 1:25 dilution emission was measured on the Hidex Sense Plate Reader and 
found to be 1997 ± 128.6. 
 
FACS analysis of BODIPY-GNF-trastuzumab  
Preparation of FACS buffer 
FACS buffer was prepared with the addition of 0.5% BSA and 0.05% sodium azide in PBS. 
FACs analysis using BODIPY-GNF-trastuzumab  
SK-OV-3 cells were harvested, washed with PBS and distributed in Eppendorf tubes (3 x 106 cells / vial) in FACS 
buffer (270 µL). For treatment of cells a solution of BODIPY-GNF-trastuzumab was prepared in FACS buffer 
with a protein concentration of 0.1 mg mL-1 (BODIPY-GNF concentration of 1.26 µg mL-1). A solution of BODIPY-
GNF was prepared in FACS buffer with a concentration of 1.26 µg mL-1. For blocking cells were pre-treated 
with 1 mg of trastuzumab and incubated at 0 oC for 30 mins before the addition of further solutions. To the 
prepared cells BODIPY-GNF-trastuzumab solution (30 µL), BODIPY-GNF solution (30 µL) or the control FACS 
buffer (30 µL) was added. Cells were incubated with gentle agitation for 30 min, washed with ice-cold PBS (2 
x 1 mL) and re-suspended in 1.5 mL FACS buffer. The samples were analysed on a BD LSRFortessa cytometry 
system (excitation laser: 488 nm, fluorescence detection: 519 nm) and data were analysed using FlowJo, 
TreeStar Inc. 
FACS analysis of BODIPY-GNF-onartuzumab 
MKN-45 cells were harvested, washed with PBS and distributed in Eppendorf tubes (3 x 106 cells / vial) in FACS 
buffer (270 µL). For treatment of cells a solution of BODIPY-GNF-onartuzumab was prepared in FACS buffer 
with a protein concentration of 0.1 mg mL-1 (BODIPY-GNF concentration of 0.70 µg mL-1).  A solution of 
BODIPY-GNF was prepared in FACS buffer with a concentration of 0.70 µg mL-1.  For blocking cells were treated 
with pre-treated with 1 mg of onartuzumab and incubated at 0 oC for 30 mins before the addition of further 
solutions. To the prepared cells BODIPY-GNF-onartuzumab solution (30 µL), BODIPY-GNF solution (30 µL) or 
the control FACS buffer (30 µL) was added.  Cells were incubated with gentle agitation for 30 min, washed 
with ice-cold PBS (2 x 1 mL) and re-suspended in 1.5 mL FACS buffer. The samples were analysed on a BD 
LSRFortessa cytometry system (excitation laser: 488 nm, fluorescence detection: 519 nm) and data were 
analysed using Flowjo, TreeStar Inc. 
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6.5.2 Conjugation of DFO-GNF (GNF-1) to trastuzumab 
Synthesis of DFO-GNF-trastuzumab 
To a solution of DFO-GNF (0.1 mg) in MES buffer (100 µL, 50 mM, pH6), EDC (0.60 mg, 1.93 µmol) and NHS 
(1.20 mg, 10.40 µmol) were added and the solution was mixed for 1.5 h. Pre-purified trastuzumab (0.60 mg) 
in PBS (800 µL) was added and the solution was mixed for 2.5 h. The reaction was then purified using PD10-
SEC (PBS as eluent) by collecting the first 1.8 mL. The construct was further purified using 100 kDa spin filters 
(washing with 5 x H2O, 14,000 g, 2 min).  
 
Radiolabelling of DFO-GNF-trastuzumab with 89Zr  
To a solution of DFO-GNF-trastuzumab (0.50 mg, 180 µL), Zr4+ stock (10 µL, 4.94 MBq) was added and the 
reaction was incubated at 21 oC for 45 min at pH7. The sample was then purified using 100 kDa spin filters, a 
portion of the sample (3.99 MBq) was loaded onto the filter and washed with saline (5 x 400 µL, 3 min, 5500 
RPM). The purified sample was then recovered (1.10 MBq) giving a RCY of 27.6 %, a RCP of 82% and a protein 
content (determined by BSA assay) of 0.46 ± 0 .02 mg mL-1. 
 
Lindmo assay using [89Zr]ZrDFO-GNF-trastuzumab 
SK-OV-3 cells were harvested and a 1:2 dilution series was performed (in triplicate) in DMEM media. The 
purified [89Zr]ZrDFO-GNF-trastuzumab (100 ng of protein, 40 Bq) in PBS (100 µL) was added to each cell 
sample. To determine the non-specific binding, a fourth dilution series was prepared and a 1000-fold excess 
of cold trastuzumab (100 µg) was added 1 h prior to the addition of the radiotracer. Three samples of 
radiotracer were prepared to act as standards for the total activity added. Samples were incubated at 37 oC 
with gentle agitation for 2 h. The cells were then pelleted by centrifugation (2000 RPM, 3 min) and washed 
with ice-cold PBS (2 x 0.5 mL) whilst on ice. The radioactivity of the cell pellet was measured and the 
immunoreactive fraction was determined as the reciprocal y-intercept from the Lindmo transformation.   
 
In vivo testing of [89Zr]ZrDFO-GNF-trastuzumab 
Small-animal PET imaging 
As a pilot study, tumour uptake was investigated in a single mouse. A mouse was injected with cancer cells (2 
x 106 SK-OV-3 cells) causing the development of a SK-OV-3 tumour with the volume of 113 mm3 (n = 1 mouse). 
The tail of the mouse was warmed gently using a warm water bath immediately before administering 
[89Zr]ZrDFO-GNF-trastuzumab (0.17 MBq, 140 μg of protein, in 200 μL sterile PBS) via intravenous (i.v.) tail-
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vein injection (t = 0 h). Images were obtained at 1 h, 6 h and 24 h before the animal was euthanised via 
isoflurane asphyxiation followed by terminal exsanguination.  
Biodistribution studies  
Following the final image at 24 h, the mouse was euthanised and biodistribution studies were performed. A 
total of 15 tissues (including the tumour) were removed, rinsed in water, dried in air for approx. 2 min., 
weighed and counted on a calibrated gamma counter for accumulation of activity. Count data were 
background- and decay-corrected, and the tissue uptake for each sample (determined in units of percentage 
injected dose per gram [%ID g-1]) was calculated by normalisation to the total amount of activity injected into 
the animal.  
 
6.5.3 Functionalisation of GNFs with DOTAGA(Gd) and DFO 
Synthesis and characterization of GdDOTAGA-DFO-GNF 
Scheme 6.20. Chemical synthesis of GdDOTAGA-PEG4-NH2, 29. 
 
Synthesis of compound 29 
DOTAGA-PEG4-NH2 (30 mg, 43 µmol) and GdCl3 (28 mg, 75 µmol) were dissolved in water (1 mL) and heated 
at 70 oC for 12 h. The solvent was then removed via lyophilisation and the crude product was purified using 
semi-preparative HPLC (5-95% MeOH/H2O) to obtain 29 as a white solid (61%, 22 mg, 26 µmol). HRMS (ESI+) 
(m/z): calculated for C29H52GdN6O132+ ([M+2H]2+): 425.1411; found: 425.6454) (100%). RP-HPLC method: A flow 
rate of 1.0 mL min-1 with a linear gradient of A (distilled H2O containing 0.1% TFA) and B (acetonitrile): t = 0 












































Figure 6.68. Characterisation data for compound 29. (A) HR-ESI-MS data. (B) HPLC chromatogram at 220 nm. 
 
 
Synthesis of GdDOTAGA-DFO-GNF 
GNFs (4 mg) in DMF (1 mL) and TEA (10 µL) were activated with HATU (8 mg, 0.01 mmol). Following the 
addition of 29 (1.30 mg, 1.52 µmol) and DFO mesylate (0.30 mg, 0.76 µmol) and the reaction was vortexed for 
24 h. Solvent was removed under reduced pressure to obtain the crude product which was re-dissolved in 
water and the product was purified on silica gel (100% H2O). After lyophilisation, GdDOTAGA-DFO-GNF was 
obtained as a brown solid (1.37 mg, 34% (mass yield)). 
 
Figure 6.69. TLC separation of GNF constructs and starting materials.  Silica gel as stationary phase and 100% 
H2O as mobile phase (Visualisation of plates: V = visual observation, N = ninhydrin stain, UV = 254 nm). 
 
 
Quantification of DFO content 
To a quantify the amount of DFO present on GNF flakes [68Ga]GdDOTAGA-GaDFO-GNF was prepared. GNF-
DOTAGA(Gd)-DFO samples were prepared at a variety of concentrations and buffered with NaOAc (0.2 M, pH 
4.4). Aliquots of [68Ga][Ga(H2O)6]Cl3(aq.) stock solution (ca. 1.2 MBq) were added to each sample after 10 min 
radio-iTLC was used to determine a RCC. Plots were used in conjunction with the known molar activity of the 




















T1 measurements  
T1 relaxation times for 29, GdDOTAGA-GaDFO-GNF and GdDOTAGA-DFO-GNF-trastuzumab were 
measuredusing a Bruker AV-III 11.74 T 500 MHz NMR. By varying concentrations, the r1 value could be 
obtained by calculating the gradient of the line when plotting concentration vs. 1/T1. 
 




Radiolabelling of GdDOTAGA-DFO-GNF with 89Zr  
To a solution of GdDOTAGA-DFO-GNF (40 µg,40 µL), Zr4+ stock (10 µL, 6.16 MBq) was added and the reaction 
is incubated at 21 oC, pH7.9 for 10 min. The product ([89Zr]GdDOTAGA-ZrDFO-GNF) was then characterised 
using radio-iTLC, PD10-SEC (PBS as eluent) and SEC-HPLC (PBS as eluent) to find a RCC of 97% and a RCP of 
98%. 
 
Synthesis of GdDOTAGA-DFO-GNF-trastuzumab 
To a solution of GdDOTAGA-DFO-GNF (0.1 mg) in MES buffer (100 µL, 50 mM, pH6), EDC (0.6 mg, 1.93 µmol) 
and NHS (1.2 mg, 10.4 µmol) were added and the solution was mixed for 1.5 h. Trastuzumab (0.6 mg) in PBS 
(800 µL) was added and the solution was mixed for 2.5 h. The was then purified using PD10-SEC (PBS as eluent) 
by collecting the first 1.8 mL. The construct was further purified using 100 kDa spin filters (washing with 5 x 




Radiolabelling of GNF-DOTAGA(Gd)-DFO-trastuzumab 
To a solution of GdDOTAGA-DFO-GNF-trastuzumab (,200 µL), 89Zr4+ stock (50 µL, 31 MBq) was added and the 
reaction is incubated at r.t for 2 h at pH7.9. PD10-SEC analysis of the crude product indicated a RCP of 6.3 ± 
2.2 % (n = 3). Reactions were purified using 100 kDa spin filters and washing with PBS (8 x 400 µL, 3 min, 14000 
RPM). The purified sample was then recovered giving [89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab in a RCY of 
9.4 ± 4.5 % (n = 3) a RCP of 91.4 ± 1.4 % (n = 3). Following combination of reactions, the protein content was 
determined to be 8.36 ± 0.44 mg mL-1. 
 
Stability study 
The stability of [89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab a with respect to change in radiochemical purity 
due to loss of radioactivity from the protein fraction was investigated in vitro. An aliquot (5 μL) of the purified 
and formulated radiotracer was added to a solution of DTPA (pH7.1, 50 mM) giving a total reaction volume of 
100 μL. The solution was incubated at 37 oC for 24 h and then analysed by radio-iTLC. The stability was 
monitored by quantifying the radioactivity associated with [89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab (Elution 
volume: 0.0-2.0 mL) versus the amount bound to DTPA ([89Zr]Zr-DTPA) (Elution volume 2.0 -8.0 mL). The RCP 
was found to be 84%. 
 
Figure 6.72. Radioactive PD10-SEC profile of [89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab following incubation 
with DTPA (50 mM, pH7.1, 24 h, 37 oC) 
 
 
Lindmo assay with [89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab 
SK-OV-3 cells were harvested and a 1:2 dilution series was performed (in triplicate) in DMEM media. The 
purified [89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab (100 ng of protein, 200 Bq) in PBS (100 µL) was added to 
each cell sample. To determine the non-specific binding, a fourth dilution series was prepared and a 1000-fold 
excess of cold trastuzumab (100 µg) was added 1 h prior to the addition of the radiotracer. Three samples of 
radiotracer alone were prepared to act as standards for the total activity added. Samples were incubated at 
37 oC with gentle agitation for 3 h. The cells were then pelleted by centrifugation (2000 RPM, 3 min) and 
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washed with ice-cold PBS (2 x 0.5 mL) whilst on ice. The radioactivity of the cell pellet was measured and the 
immunoreactive fraction was determined as the reciprocal y-intercept from the Lindmo transformation.   
 
In vivo testing of [89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab 
Small-animal PET imaging 
Mice were injected with cancer cells (2 x 106 SK-OV-3 cells) causing the development of a SK-OV-3 tumour with 
the volume of 192.5 ± 21.7 (n = 6 mouse). The tail of the mouse was warmed gently using a warm water bath 
immediately before administering [89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab (0.11-0.14 MBq, 65-82 µg of 
mAb in 200 µL PBS) via intravenous (i.v.) tail-vein injection (t = 0 h). The blocking formulation contained an 
additional 15.4-fold (1 mg) of mAb. Images were obtained at 1, 14, 24, 48, 72 and 90 h before the animal was 
euthanised via isoflurane asphyxiation followed by terminal exsanguination.  
 
Figure 6.73. PET images recorded following administration of [89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab 
blocking formulation. Study performed in mice bearing SK-OV-3 tumours on the right flank. 
 
Biodistribution studies  
Following the final image at 90 h, the mouse was euthanised and biodistribution studies were performed. A 
total of 15 tissues (including the tumour) were removed, rinsed in water, dried in air for approx. 2 min., 
weighed and counted on a calibrated gamma counter for accumulation of activity. Count data were 
background- and decay-corrected, and the tissue uptake for each sample (determined in units of percentage 
injected dose per gram [%ID g-1]) was calculated by normalisation to the total amount of activity injected into 
the animal.  
 
Table 6.8. Ex vivo biodistribution tissue uptake data measured at 90 h after i.v. administration of 
[89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab (normal (n = 4) and blocking (n = 4)  groups) in female athymic nude 




















uptake normal group / %ID g-1 ± SEM 
[89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab  
uptake block group / %ID g-1 ± SEM 
Blood 0.84 ± 0.12 0.89 ± 0.07 
Tumour 7.53 ± 0.83 4.21 ± 0.74 
Heart 1.61 ± 0.41 1.44 ± 0.23 
Lungs 1.36 ± 0.12 1.73 ± 0.13 
Liver 20.87 ± 1.98 22.95 ± 1.90 
Spleen 6.71 ± 1.34 11.89 ± 1.87 
Stomach 0.56 ± 0.12 0.87 ± 0.13 
Pancreas 1.07 ± 0.15 0.95 ± 0.12 
Kidney 6.68 ± 0.60 8.18 ± 1.01 
Sm. Int. 1.06 ± 0.19 1.34 ± 0.12 
Large Int. 0.34 ± 0.05 0.61 ± 0.10 
Fat 0.39 ± 0.15 0.41 ± 0.09 
Muscle 0.56 ± 0.11 0.40 ± 0.05 
Bone 10.02 ± 1.73 7.75 ± 2.36 





Table 6.9. Tumour-to-tissue contrast ratio data extracted form biodistribution data following the 
administration of [89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab (normal (n = 4) and blocking (n = 4)  groups) in 
female athymic nude mice bearing subcutaneous SK-OV-3 tumours. 
 
Tissue [89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab normal 
group, tumour-to-tissue contrast ratio ± SEM 
[89Zr]GdDOTAGA-ZrDFO-GNF-trastuzumab block 
group, tumour-to-tissue contrast ratio ± SEM 
Blood 9.68 ± 1.53 5.13 ± 1.01 
Tumour 1.00 1.00 
Heart 6.08 ± 1.40 3.53 ± 0.60 
Lungs 5.69 ± 0.70 2.62 ± 0.58 
Liver 0.38 ± 0.06 0.19 ± 0.03 
Spleen 1.32 ± 0.28 0.42 ± 0.17 
Stomach 15.52 ± 3.09 6.13 ± 1.78 
Pancreas 7.53 ± 1.00 5.14 ± 1.09 
Kidney 1.15 ± 0.13 0.58 ± 0.11 
Sm. Int. 8.22 ± 1.53 3.32 ± 0.53 
Large Int. 27.50 ± 1.57 8.24 ± 1.07 
Fat 34.28 ± 12.02 13.72 ± 2.25 
Muscle 15.47 ± 2.89 10.08 ± 1.46 
Bone 0.69 ± 0.18 0.75 ± 0.21 
Skin 2.85 ± 0.55 3.15 ± 0.16 
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